1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof

ABSTRACT

Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer&#39;s disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser.No. 16/032,905 filed Jul. 11, 2018, which is a continuation of U.S.application Ser. No. 15/420,398, filed Jan. 31, 2017, which iscontinuation application of U.S. application Ser. No. 14/962,681, filedDec. 8, 2015, which is a continuation application of U.S. applicationSer. No. 14/621,222, filed Feb. 12, 2015, which is a continuationapplication of U.S. application Ser. No. 14/454,279, filed Aug. 7, 2014,which is a continuation of U.S. application Ser. No. 13/887,177, filedMay 3, 2013, and claims the benefit of U.S. Provisional Application No.61/642,915, filed May 4, 2012, each of which is incorporated herein byreference in its entirety.

BACKGROUND OF THE INVENTION Field of the Invention

This invention relates to inhibitors of one or more proteins in the Wntpathway, including inhibitors of one or more Wnt proteins, andcompositions comprising the same. More particularly, it concerns the useof a 1H-pyrazolo[3,4-b]pyridine compound or salts or analogs thereof, inthe treatment of disorders characterized by the activation of Wntpathway signaling (e.g., cancer, abnormal cellular proliferation,angiogenesis, Alzheimer's disease, lung disease, osteoarthritis andidiopathic pulmonary fibrosis), the modulation of cellular eventsmediated by Wnt pathway signaling, as well as genetic diseases andneurological conditions/disorders/diseases. Also provided are methodsfor treating Wnt-related disease states.

Description of the Related Art

Pattern formation is the activity by which embryonic cells form orderedspatial arrangements of differentiated tissues. Speculation on themechanisms underlying these patterning effects usually centers on thesecretion of a signaling molecule that elicits an appropriate responsefrom the tissues being patterned. More recent work aimed at theidentification of such signaling molecules implicates secreted proteinsencoded by individual members of a small number of gene families.

A longstanding idea in cancer biology is that cancers arise and grow dueto the formation of cancer stem cells, which may constitute only aminority of the cells within a tumor but are nevertheless critical forits propagation. Stem cells are appealing as the cell of origin forcancer because of their pre-existing capacity for self-renewal and forunlimited replication. In addition, stem cells are relatively long-livedin comparison to other cells within tissues, providing a greateropportunity to accumulate the multiple additional mutations that may berequired to increase the rate of cell proliferation and produceclinically significant cancers. Of particular recent interest in theorigin of cancer is the observation that the Wnt signaling pathway,which has been implicated in stem cell self-renewal in normal tissues,upon continuous activation has also been associated with the initiationand growth of many types of cancer. This pathway thus provides apotential link between the normal self-renewal of stem cells and theaberrantly regulated proliferation of cancer stem cells.

The Wnt growth factor family includes more than 10 genes identified inthe mouse and at least 19 genes identified in the human. Members of theWnt family of signaling molecules mediate many important short- andlong-range patterning processes during invertebrate and vertebratedevelopment. The Wnt signaling pathway is known for its important rolein the inductive interactions that regulate growth and differentiation,and plays important roles in the homeostatic maintenance ofpost-embryonic tissue integrity. Wnt stabilizes cytoplasmic β-catenin,which stimulates the expression of genes including c-myc, c jun, fra-1,and cyclin D1. In addition, misregulation of Wnt signaling can causedevelopmental defects and is implicated in the genesis of several humancancers. More recently, the Wnt pathway has been implicated in themaintenance of stem or progenitor cells in a growing list of adulttissues that now includes skin, blood, gut, prostate, muscle and thenervous system.

Pathological activation of the Wnt pathway is also believed to be theinitial event leading to colorectal cancer in over 85% of all sporadiccases in the Western world. Activation of the Wnt pathway has also beenextensively reported for hepatocellular carcinoma, breast cancer,ovarian cancer, pancreatic cancer, melanomas, mesotheliomas, lymphomasand leukemias. In addition to cancer, inhibitors of the Wnt pathway canbe used for stem cell research or for the treatment of any diseasescharacterized by aberrant Wnt activation such as idiopathic pulmonaryfibrosis (IPF), diabetic retinopathy, neovascular glaucoma, rheumatoidarthritis, psoriasis as well as mycotic and viral infections and boneand cartilage diseases. As such, it is a therapeutic target that is ofgreat interest to the field.

Idiopathic pulmonary fibrosis (IPF) is a ravaging condition ofprogressive lung scarring and destruction. This is a chronic,progressive, usually fatal, lung disease characterized by excessivefibrosis which causes eventual deterioration of the lung's architecture[Nature Reviews Drug Discovery (2010), 9(2), 129-140]. Recently, theWnt/β-catenin pathway has become implicated in the etiology of thedisease [Annals of the Rheumatic Diseases (2012), 71(5), 761-767;Respiratory Research (2012), 13(3), pp. 9]. At the cellular level, it ishas been shown that β-catenin is overexpressed in bronchial epithelialcells which contributes to an epithelial to mesenchymal cell transition(EMT). This results in increased presence of proliferating fibroblastsand myofibroblasts which leads to excess collagen deposition in thelungs [Respiratory Research (2012), 13(3), pp. 9]. The formation ofthese fibroblastic foci and increased extracellular matrix depositionare pathological hallmarks of IPF.

There are also many cases of genetic diseases due to mutations in Wntsignaling components. Examples of some of the many diseases areAlzheimer's disease [Proc. Natl. Acad. Sci. USA (2007), 104(22),9434-9], osteoarthritis, polyposis coli [Science (1991), 253(5020),665-669], bone density and vascular defects in the eye(osteoporosis-pseudoglioma syndrome, OPPG) [N. Engl. J. Med. (2002),346(20), 1513-21], familial exudative vitreoretinopathy [Hum. Mutat.(2005), 26(2), 104-12], retinal angiogenesis [Nat. Genet. (2002), 32(2),326-30], early coronary disease [Science (2007), 315(5816), 1278-82],tetra-amelia syndrome [Am. J. Hum. Genet. (2004), 74(3), 558-63],Müllerian-duct regression and virilization [Engl. J. Med. (2004),351(8), 792-8], SERKAL syndrome [Am. J. Hum. Genet. (2008), 82(1),39-47], diabetes mellitus type 2 [Am. J. Hum. Genet. (2004), 75(5),832-43; N. Engl. J. Med. (2006), 355(3), 241-50], Fuhrmann syndrome [Am.J. Hum. Genet. (2006), 79(2), 402-8], Al-Awadi/Raas-Rothschild/Schinzelphocomelia syndrome [Am. J. Hum. Genet. (2006), 79(2), 402-8],odonto-onycho-dermal dysplasia [Am. J. Hum. Genet. (2007), 81(4),821-8], obesity [Diabetologia (2006), 49(4), 678-84], split-hand/footmalformation [Hum. Mol. Genet. (2008), 17(17), 2644-53], caudalduplication syndrome [Am. J. Hum. Genet. (2006), 79(1), 155-62], toothagenesis [Am. J. Hum. Genet. (2004), 74(5), 1043-50], Wilms tumor[Science (2007), 315(5812), 642-5], skeletal dysplasia [Nat. Genet.(2009), 41(1), 95-100], focal dermal hypoplasia [Nat. Genet. (2007),39(7), 836-8], autosomal recessive anonychia [Nat. Genet. (2006),38(11), 1245-7], neural tube defects [N. Engl. J. Med. (2007), 356(14),1432-7], alpha-thalassemia (ATRX) syndrome [The Journal of Neuroscience(2008), 28(47), 12570-12580], fragile X syndrome [PLoS Genetics (2010),6(4), e1000898], ICF syndrome, Angelman syndrome [Brain ResearchBulletin (2002), 57(1), 109-119], Prader-Willi syndrome [Journal ofNeuroscience (2006), 26(20), 5383-5392], Beckwith-Wiedemann Syndrome[Pediatric and Developmental Pathology (2003), 6(4), 299-306] and Rettsyndrome.

Regulation of cell signaling by the Wnt signaling pathway is criticalfor the formation of neuronal circuits. Wnt pathway modulates in neuraltissue, among other things, axon pathfinding, dendritic development, andsynaptic assembly. Through different receptors, Wnt pathway activatesand/or regulates diverse signaling pathways and other processes thatlead to local changes on the cytoskeleton or global cellular changesinvolving nuclear function. Recently, a link between neuronal activity,essential for the formation and refinement of neuronal connections, andWnt signaling has been uncovered. Indeed, neuronal activity regulatesthe release of various Wnt proteins and the localization of theirreceptors. Wnt pathway mediates synaptic structural changes induced byneuronal activity or experience. Evidence suggests that dysfunction inWnt signaling contributes to neurological disorders [Brain ResearchReviews (2000), 33(1), 1-12; Oncogene (2006) 25(57), 7545-7553;Molecular Neurodegeneration (2008), 3, 9; Neurobiology of Disease(2010), 38(2), 148-153; Journal of Neurodevelopmental Disorders (2011),3(2), 162-174 and Cold Spring Harbor Perspectives in Biology February(2012), 4(2)].

SUMMARY OF THE INVENTION

The present invention makes available methods and reagents, involvingcontacting a cell with an agent, such as a 1H-pyrazolo[3,4-b]pyridinecompound, in a sufficient amount to antagonize Wnt activity, e.g., toreverse or control an aberrant growth state or correct a geneticdisorder due to mutations in Wnt signaling components.

Some embodiments disclosed herein include Wnt inhibitors containing a1H-pyrazolo[3,4-b]pyridine core. Other embodiments disclosed hereininclude pharmaceutical compositions and methods of treatment using thesecompounds.

One embodiment disclosed herein includes a compound having the structureof Formula I or a pharmaceutically acceptable salt thereof:

In some embodiments of Formula (I):

R¹ and R² are independently selected from the group consisting of H,lower alkyl, halide, —(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₉alkyl)_(n)heteroaryl(R⁷)_(q), —(C₁₋₉ alkyl)_(n)heterocyclyl(R⁸)_(q),—(C₁₋₉ alkyl)_(n)N(R⁹)₂, —OR¹⁰ and —NHC(═O)R¹¹;

R³ is selected from the group consisting of H, halide and lower alkyl;

with the proviso that at least two of R¹, R² and R³ are H;

R⁴ and R⁵ are independently selected from the group consisting of H,—C(═O)N(R¹²)₂, -aryl(R¹³)_(q), -heterocyclyl(R¹⁴)_(q), and-heteroaryl(R¹⁵)_(q);

with the proviso that at least one of R⁴ and R⁵ is H;

each R⁶ is a substituent attached to the aryl ring and independentlyselected from the group consisting of H, —C₁₋₉ alkyl, halide, CF₃ andCN;

each R⁷ is a substituent attached to the heteroaryl ring andindependently selected from the group consisting of H, —C₁₋₉ alkyl,halide, CF₃ and CN;

each R⁸ is a substituent attached to the heterocyclyl ring andindependently selected from the group consisting of H, halide, —(C₁₋₃alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₄ alkyl;

each R⁹ is independently selected from the group consisting of H, —C₁₋₉alkyl, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃ alkyl)_(n)carbocyclyl and—(C₁₋₉ alkyl)N(R¹⁶)₂;

alternatively, two adjacent R⁹ or two adjacent R¹², may be takentogether with the atoms to which they are attached to form aheterocyclyl(R¹⁷)_(q);

R¹⁰ is selected from the group consisting of H, —CF₃, —(C₁₋₃alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl;

R¹¹ is selected from the group consisting of —(C₁₋₃alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃ alkyl)_(n)carbocyclyl, —C₁₋₉ alkyl and—CF₃;

each R¹² is independently selected from the group consisting of H,—(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q) and —C₁₋₉ alkyl;

each R¹³ is a substituent attached to the aryl ring and independentlyselected from the group consisting of H, halide, —CF₃, CN, —(C₁₋₃alkyl)_(n)heterocyclyl(R⁸)_(q), —(C₁₋₉ alkyl)_(n)N(R⁹)₂ and —(C₁₋₉alkyl)_(n)NHSO₂R¹⁸;

each R¹⁴ is a substituent attached to the heterocyclyl ring andindependently selected from the group consisting of H, lower alkyl,halide, —CF₃ and CN;

each R¹⁵ is a substituent attached to the heteroaryl ring andindependently selected from the group consisting of H, lower alkyl,halide, —CF₃, CN, —C(═O)(C₁₋₃ alkyl), —(C₁₋₉ alkyl)_(n)N(R⁹)₂ and —(C₁₋₉alkyl)_(n)NHSO₂R¹⁸;

each R¹⁶ is independently selected from the group consisting of H andlower alkyl;

each R¹⁷ is a substituent attached to the heterocyclyl ring andindependently selected from the group consisting of H, —(C₁₋₉alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl;

each R¹⁸ is a lower alkyl;

A is N or C;

with the proviso that if A is N then R² is nil;

each q is an integer of 1 to 5;

each n is an integer of 0 or 1; and

with the proviso that Formula I is not a structure selected from thegroup consisting of:

Another embodiment disclosed herein includes a compound having thestructure of Formula II or a pharmaceutically acceptable salt thereof:

In some embodiments of Formula (II):

R¹ and R² are independently selected from the group consisting of H,lower alkyl, halide, —(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₉alkyl)_(n)heteroaryl(R⁷)_(q), —(C₁₋₉ alkyl)_(n)heterocyclyl(R⁸)_(q),—(C₁₋₉ alkyl)_(n)N(R⁹)₂, —OR¹⁰ and —NHC(═O)R¹¹;

R³ is selected from the group consisting of H, halide and lower alkyl;

with the proviso that at least two of R¹, R² and R³ are H;

R⁴ and R⁵ are independently selected from the group consisting of H,—C(═O)N(R¹²)₂, -aryl(R¹³)_(q), -heterocyclyl(R¹⁴)_(q), and-heteroaryl(R¹⁵)_(q);

with the proviso that at least one of R⁴ and R⁵ is H;

each R⁶ is a substituent attached to the aryl ring and independentlyselected from the group consisting of H, —C₁₋₉ alkyl, halide, CF₃ andCN;

each R⁷ is a substituent attached to the heteroaryl ring andindependently selected from the group consisting of H, —C₁₋₉ alkyl,halide, CF₃ and CN;

each R⁸ is a substituent attached to the heterocyclyl ring andindependently selected from the group consisting of H, halide, —(C₁₋₃alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₄ alkyl;

each R⁹ is independently selected from the group consisting of H, —C₁₋₉alkyl, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃ alkyl)_(n)carbocyclyl and—(C₁₋₉ alkyl)N(R¹⁶)₂;

alternatively, two adjacent R⁹ or two adjacent R¹², may be takentogether with the atoms to which they are attached to form aheterocyclyl(R¹⁷)_(q);

R¹⁰ is selected from the group consisting of H, —CF₃, —(C₁₋₃alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl;

R¹¹ is selected from the group consisting of —(C₁₋₃alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃ alkyl)_(n)carbocyclyl, —C₁₋₉ alkyl and—CF₃;

each R¹² is independently selected from the group consisting of H,—(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q) and —C₁₋₉ alkyl;

each R¹³ is a substituent attached to the aryl ring and independentlyselected from the group consisting of H, halide, —CF₃, CN, —(C₁₋₃alkyl)_(n)heterocyclyl(R⁸)_(q), —(C₁₋₉ alkyl)_(n)N(R⁹)₂ and —(C₁₋₉alkyl)_(n)NHSO₂R¹⁸;

each R¹⁴ is a substituent attached to the heterocyclyl ring andindependently selected from the group consisting of H, lower alkyl,halide, —CF₃ and CN;

each R¹⁵ is a substituent attached to the heteroaryl ring andindependently selected from the group consisting of H, lower alkyl,halide, —CF₃, CN, —C(═O)(C₁₋₃ alkyl), —(C₁₋₉ alkyl)_(n)N(R⁹)₂ and —(C₁₋₉alkyl)_(n)NHSO₂R¹⁸;

each R¹⁶ is independently selected from the group consisting of H andlower alkyl;

each R¹⁷ is a substituent attached to the heterocyclyl ring andindependently selected from the group consisting of H, —(C₁₋₉alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl;

each R¹⁸ is is a lower alkyl;

A is N or C;

with the proviso that if A is N then R² is nil;

each q is an integer of 1 to 5;

each n is an integer of 0 or 1; and

with the proviso that Formula II is not a structure selected from thegroup consisting of:

Some embodiments include stereoisomers and pharmaceutically acceptablesalts of a compound of general Formulas (I) or (II).

Some embodiments include pro-drugs of a compound of general Formulas (I)or (II).

Some embodiments of the present invention include pharmaceuticalcompositions comprising a compound of general Formulas (I) or (II) and apharmaceutically acceptable carrier, diluent, or excipient.

Other embodiments disclosed herein include methods of inhibiting one ormore members of the Wnt pathway, including one or more Wnt proteins byadministering to a subject affected by a disorder or disease in whichaberrant Wnt signaling is implicated, such as cancer and other diseasesassociated with abnormal angiogenesis, cellular proliferation, cellcycling and mutations in Wnt signaling components, a compound accordingto Formulas (I) or (II). Accordingly, the compounds and compositionsprovided herein can be used to treat cancer, to reduce or inhibitangiogenesis, to reduce or inhibit cellular proliferation and correct agenetic disorder due to mutations in Wnt signaling components.Non-limiting examples of diseases which can be treated with thecompounds and compositions provided herein include a variety of cancers,diabetic retinopathy, pulmonary fibrosis, idiopathic pulmonary fibrosis,rheumatoid arthritis, scleroderma, mycotic and viral infections,osteochondrodysplasia, Alzheimer's disease, lung disease,osteoarthritis, polyposis coli, osteoporosis-pseudoglioma syndrome,familial exudative vitreoretinopathy, retinal angiogenesis, earlycoronary disease, tetra-ameliasyndrome, Müllerian-duct regression andvirilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmannsyndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation,caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletaldysplasia, focal dermal hypoplasia, autosomal recessive anonychia,neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile Xsyndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome,Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

Another embodiment disclosed herein includes a pharmaceuticalcomposition that has a compound according to any of the above formulasand a pharmaceutically acceptable carrier, diluent, or excipient.

Some embodiments of the present invention include methods to prepare acompound of general Formulas (I) or (II).

It is to be understood that both the foregoing general description andthe following detailed description are exemplary and explanatory onlyand are not restrictive of the invention, as claimed.

DETAILED DESCRIPTION OF THE INVENTION

Compositions and methods for inhibiting one or more members of the Wntpathway, including one or more Wnt proteins would be of tremendousbenefit. Certain embodiments provide such compositions and methods.Certain related compounds and methods are disclosed in U.S. applicationSer. No. 12/968,505, filed Dec. 15, 2010, which claims priority to U.S.Provisional Application Ser. No. 61/288,544, all of which areincorporated by reference in their entirety herein.

Some embodiments relate to a method for treating a disease including,but not limited to, cancers, diabetic retinopathy, idiopathic pulmonaryfibrosis, pulmonary fibrosis, rheumatoid arthritis, scleroderma, mycoticand viral infections, bone and cartilage diseases, Alzheimer's disease,lung disease, osteoarthritis, polyposis coli, bone density and vasculardefects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familialexudative vitreoretinopathy, retinal angiogenesis, early coronarydisease, tetra-amelia, Müllerian-duct regression and virilization,SERKAL syndrome, type II diabetes, Fuhrmann syndrome,Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation,caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia,focal dermal hypoplasia, autosomal recessive anonychia, neural tubedefects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICFsyndrome, Angelman's syndrome, Prader-Willi syndrome, Beckwith-WiedemannSyndrome, Norrie disease and Rett syndrome.

In some embodiments, pharmaceutical compositions are provided that areeffective for treatment of a disease of an animal, e.g., a mammal,caused by the pathological activation or mutations of the Wnt pathway.The composition includes a pharmaceutically acceptable carrier and a Wntpathway inhibitor as described herein.

Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of ordinary skillin the art to which this disclosure belongs. All patents, applications,published applications, and other publications are incorporated byreference in their entirety. In the event that there is a plurality ofdefinitions for a term herein, those in this section prevail unlessstated otherwise.

In this specification and in the claims, the following terms have themeanings as defined. As used herein, “alkyl” means a branched, orstraight chain chemical group containing only carbon and hydrogen, suchas methyl, ethyl, n-propyl isopropyl, n-butyl, isobutyl, sec-butyl,tert-butyl, n-pentyl, tert-pentyl, neopentyl, isopentyl and sec-pentyl.Alkyl groups can either be unsubstituted or substituted with one or moresubstituents, e.g., halide, alkoxy, acyloxy, amino, amido, cyano, nitro,hydroxyl, thio, carboxy, carbonyl, benzyloxy, aryl, heteroaryl,heterocyclyl, carbocyclyl, or other functionality that may be suitablyblocked, if necessary for purposes of the invention, with a protectinggroup. Alkyl groups can be saturated or unsaturated (e.g., containing—C═C— or —C≡C— subunits), at one or several positions. Typically, alkylgroups will comprise 1 to 9 carbon atoms, preferably 1 to 6, morepreferably 1 to 4, and most preferably 1 to 2 carbon atoms.

As used herein, “carbocyclyl” means a cyclic ring system containing onlycarbon atoms in the ring system backbone, such as cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls mayinclude multiple fused rings. Carbocyclyls may have any degree ofsaturation provided that at least one ring in the ring system is notaromatic. Carbocyclyl groups can either be unsubstituted or substitutedwith one or more substituents, e.g., alkyl, halogen, alkoxy, acyloxy,amino, amido, cyano, nitro, hydroxyl, mercapto, carboxy, carbonyl,benzyloxy, aryl, heteroaryl, or other functionality that may be suitablyblocked, if necessary for purposes of the invention, with a protectinggroup. Typically, carbocyclyl groups will comprise 3 to 10 carbon atoms,preferably 3 to 6.

As used herein, “lower alkyl” means a subset of alkyl, and thus is ahydrocarbon substituent, which is linear or branched. Preferred loweralkyls are of 1 to about 3 carbons, and may be branched or linear.Examples of lower alkyl include n-propyl, isopropyl, ethyl, and methyl.Likewise, radicals using the terminology “lower” refer to radicalspreferably with 1 to about 3 carbons in the alkyl portion of theradical.

As used herein, “amido” means a H—CON— or alkyl-CON—, carbocyclyl-CON—,aryl-CON—, heteroaryl-CON— or heterocyclyl-CON group wherein the alkyl,carbocyclyl, heteroaryl, aryl or heterocyclyl group is as hereindescribed.

As used herein, “aryl” means an aromatic radical having a single-ring(e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl)with only carbon atoms present in the ring backbone. Aryl groups caneither be unsubstituted or substituted with one or more substituents,e.g., alkyl, amino, cyano, hydroxyl, lower alkyl, haloalkyl, alkoxy,nitro, halo, mercapto, and other substituents. A preferred carbocyclicaryl is phenyl.

As used herein, the term “heteroaryl” means an aromatic radical havingone or more heteroatom(s) (e.g., N, O, or S) in the ring backbone andmay include a single ring (e.g., pyridine) or multiple condensed rings(e.g., quinoline). Heteroaryl groups can either be unsubstituted orsubstituted with one or more substituents, e.g., amino, cyano, hydroxyl,lower alkyl, haloalkyl, alkoxy, nitro, halo, mercapto, and othersubstituents. Examples of heteroaryls include thienyl, pyridinyl, furyl,oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl,pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl,pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl,benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl,indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl,thienopyridinyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl,quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl,pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-c]pyridinyl,pyrazolo[4,3-c]pyridine, pyrazolo[4,3-b]pyridinyl, tetrazolyl, andothers.

In these definitions it is clearly contemplated that substitution on thearyl and heteroaryl rings is within the scope of certain embodiments.Where substitution occurs, the radical is called substituted aryl orsubstituted heteroaryl. Preferably one to three and more preferably oneor two substituents occur on the aryl or heteroaryl ring. Though manysubstituents will be useful, preferred substituents include thosecommonly found in aryl or heteroaryl compounds, such as alkyl,cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, mercapto and thelike.

As used herein, “amide” includes both RNR′CO— and RCONR′—. R can besubstituted or unsubstituted alkyl, substituted or unsubstitutedheterocyclyl, substituted or unsubstituted heteroaryl, substituted orunsubstituted aryl, or substituted or unsubstituted carbocyclyl. R′ canbe H or substituted or unsubstituted alkyl.

As used herein, “halo”, “halide” or “halogen” is a chloro, bromo, fluoroor iodo atom radical. Chloro, bromo and fluoro are preferred halides.Most preferred halide is fluorine.

As used herein, “haloalkyl” means a hydrocarbon substituent, which islinear or branched or cyclic alkyl, alkenyl or alkynyl substituted withchloro, bromo, fluoro or iodo atom(s). Most preferred of these arefluoroalkyls, wherein one or more of the hydrogen atoms have beensubstituted by fluoro. Preferred haloalkyls are of 1 to about 3 carbonsin length, more preferred haloalkyls are 1 to about 2 carbons, and mostpreferred are 1 carbon in length. The skilled artisan will recognizethen that as used herein, “haloalkylene” means a diradical variant ofhaloalkyl, such diradicals may act as spacers between radicals, otheratoms, or between the parent ring and another functional group.

As used herein, “heterocyclyl” means a cyclic ring system comprising atleast one heteroatom in the ring system backbone. Heterocyclyls mayinclude multiple fused rings. Heterocyclyls may have any degree ofsaturation provided that at least one ring in the ring system is notaromatic. Heterocyclyls may be substituted or unsubstituted with one ormore substituents, e.g., alkyl, halide, alkoxy, acyloxy, amino, amido,cyano, nitro, hydroxyl, mercapto, carboxy, carbonyl, benzyloxy, aryl,heteroaryl, and other substituents, and are attached to other groups viaany available valence, preferably any available carbon or nitrogen. Morepreferred heterocycles are of 5-7 members. In six membered monocyclicheterocycles, the heteroatom(s) are selected from one up to three of O,N or S, and wherein when the heterocycle is five membered, preferably ithas one or two heteroatoms selected from O, N, or S. Examples ofheterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl,thietanyl, 1,4,2-dithiazolyl, 1,3-benzodioxolyl, dihydroisoindolyl,dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl,dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl,dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl,isoindolinyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl,pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl,thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl,piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others.

As used herein, “substituted amino” means an amino radical which issubstituted by one or two alkyl, carbocyclyl, aryl, heteroaryl orheterocyclyl groups, wherein the alkyl, carbocyclyl, aryl, heteroaryl orheterocyclyl are defined as above.

As used herein, “sulfonamido” means an alkyl-S(O)₂N—, aryl-S(O)₂N—,heteroaryl-S(O)₂N—, carbocyclyl-S(O)₂N- or heterocyclyl-S(O)₂N— groupwherein the alkyl, carbocyclyl, aryl, heteroaryl or heterocyclyl groupis as herein described.

As used herein, when two groups are indicated to be “linked” or “bonded”to form a “ring,” it is to be understood that a bond is formed betweenthe two groups and may involve replacement of a hydrogen atom on one orboth groups with the bond, thereby forming a carbocyclyl, heterocyclyl,aryl, or heteroaryl ring. The skilled artisan will recognize that suchrings can and are readily formed by routine chemical reactions, and itis within the purview of the skilled artisan to both envision such ringsand the methods of their formations. Preferred are rings having from 3-7members, more preferably 5 or 6 members. As used herein the term “ring”or “rings” when formed by the combination of two radicals refers toheterocyclic, carbocyclic, aryl, or heteroaryl rings.

The skilled artisan will recognize that some structures described hereinmay be resonance forms or tautomers of compounds that may be fairlyrepresented by other chemical structures, even when kinetically; theartisan recognizes that such structures are only a very small portion ofa sample of such compound(s). Such compounds are clearly contemplatedwithin the scope of this invention, though such resonance forms ortautomers are not represented herein.

The compounds provided herein may encompass various stereochemicalforms. The compounds also encompasses diastereomers as well as opticalisomers, e.g. mixtures of enantiomers including racemic mixtures, aswell as individual enantiomers and diastereomers, which arise as aconsequence of structural asymmetry in certain compounds. Separation ofthe individual isomers or selective synthesis of the individual isomersis accomplished by application of various methods which are well knownto practitioners in the art. Unless otherwise indicated when a disclosedcompound is named or depicted by a structure without specifying thestereochemistry and has one or more chiral centers, it is understood torepresent all possible stereoisomers of the compound.

The term “administration” or “administering” refers to a method ofgiving a dosage of a compound or pharmaceutical composition comprisingthe same to a vertebrate or invertebrate, including a mammal, a bird, afish, or an amphibian, where the method is, e.g., orally,subcutaneously, intravenously, intranasally, topically, transdermally,intraperitoneally, intramuscularly, intrapulmonarilly, vaginally,rectally, ontologically, neuro-otologically, intraocularly,subconjuctivally, via anterior eye chamber injection, intravitreally,intraperitoneally, intrathecally, intracystically, intrapleurally, viawound irrigation, intrabuccally, intra-abdominally, intra-articularly,intra-aurally, intrabronchially, intracapsularly, intrameningeally, viainhalation, via endotracheal or endobronchial instillation, via directinstillation into pulmonary cavities, intraspinally, intrasynovially,intrathoracically, via thoracostomy irrigation, epidurally,intratympanically, intracisternally, intravascularly,intraventricularly, intraosseously, via irrigation of infected bone, orvia application as part of any admixture with a prosthetic devices. Thepreferred method of administration can vary depending on variousfactors, e.g., the components of the pharmaceutical composition, thesite of the disease, the disease involved, and the severity of thedisease.

A “diagnostic” as used herein is a compound, method, system, or devicethat assists in the identification and characterization of a health ordisease state. The diagnostic can be used in standard assays as is knownin the art.

The term “mammal” is used in its usual biological sense. Thus, itspecifically includes humans, cattle, horses, dogs, and cats, but alsoincludes many other species.

The term “pharmaceutically acceptable carrier” or “pharmaceuticallyacceptable excipient” includes any and all solvents, co-solvents,complexing agents, dispersion media, coatings, antibacterial andantifungal agents, isotonic and absorption delaying agents and the likewhich are not biologically or otherwise undesirable. The use of suchmedia and agents for pharmaceutically active substances is well known inthe art. Except insofar as any conventional media or agent isincompatible with the active ingredient, its use in the therapeuticcompositions is contemplated. Supplementary active ingredients can alsobe incorporated into the compositions. In addition, various adjuvantssuch as are commonly used in the art may be included. These and othersuch compounds are described in the literature, e.g., in the MerckIndex, Merck & Company, Rahway, N.J. Considerations for the inclusion ofvarious components in pharmaceutical compositions are described, e.g.,in Gilman et al. (Eds.) (2010); Goodman and Gilman's: ThePharmacological Basis of Therapeutics, 12th Ed., The McGraw-HillCompanies.

The term “pharmaceutically acceptable salt” refers to salts that retainthe biological effectiveness and properties of the compounds providedherein and, which are not biologically or otherwise undesirable. In manycases, the compounds provided herein are capable of forming acid and/orbase salts by virtue of the presence of amino and/or carboxyl groups orgroups similar thereto. Pharmaceutically acceptable acid addition saltscan be formed with inorganic acids and organic acids. Inorganic acidsfrom which salts can be derived include, for example, hydrochloric acid,hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and thelike. Organic acids from which salts can be derived include, forexample, acetic acid, propionic acid, glycolic acid, pyruvic acid,oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,salicylic acid, and the like. Pharmaceutically acceptable base additionsalts can be formed with inorganic and organic bases. Inorganic basesfrom which salts can be derived include, for example, sodium, potassium,lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese,aluminum, and the like; particularly preferred are the ammonium,potassium, sodium, calcium and magnesium salts. Organic bases from whichsalts can be derived include, for example, primary, secondary, andtertiary amines, substituted amines including naturally occurringsubstituted amines, cyclic amines, basic ion exchange resins, and thelike, specifically such as isopropylamine, trimethylamine, diethylamine,triethylamine, tripropylamine, and ethanolamine. Many such salts areknown in the art, as described in WO 87/05297.

“Solvate” refers to the compound formed by the interaction of a solventand a Wnt pathway inhibitor, a metabolite, or salt thereof. Suitablesolvates are pharmaceutically acceptable solvates including hydrates.

“Subject” as used herein, means a human or a non-human mammal, e.g., adog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-humanprimate or a bird, e.g., a chicken, as well as any other vertebrate orinvertebrate.

By “therapeutically effective amount” or “pharmaceutically effectiveamount” of a compound as provided herein is one which is sufficient toachieve the desired effect and may vary according to the nature andseverity of the disease condition, and the potency of the compound.“Therapeutically effective amount” is also intended to include one ormore of the compounds of Formula (I) in combination with one or moreother agents that are effective to inhibit Wnt related diseases and/orconditions. The combination of compounds is preferably a synergisticcombination. Synergy, as described, for example, by Chou, CancerResearch (2010), 70(2), 440-446, occurs when the effect of the compoundswhen administered in combination is greater than the additive effect ofthe compounds when administered alone as a single agent. In general, asynergistic effect is most clearly demonstrated at sub-optimalconcentrations of the compounds. It will be appreciated that differentconcentrations may be employed for prophylaxis than for treatment of anactive disease. This amount can further depend upon the patient'sheight, weight, sex, age and medical history.

A therapeutic effect relieves, to some extent, one or more of thesymptoms of the disease, and includes curing a disease. “Curing” meansthat the symptoms of active disease are eliminated. However, certainlong-term or permanent effects of the disease may exist even after acure is obtained (such as extensive tissue damage).

“Treat,” “treatment,” or “treating,” as used herein refers toadministering a compound or pharmaceutical composition as providedherein for therapeutic purposes. The term “therapeutic treatment” refersto administering treatment to a patient already suffering from a diseasethus causing a therapeutically beneficial effect, such as amelioratingexisting symptoms, preventing additional symptoms, ameliorating orpreventing the underlying metabolic causes of symptoms, postponing orpreventing the further development of a disorder and/or reducing theseverity of symptoms that will or are expected to develop.

“Drug-eluting” and or controlled release as used herein refers to anyand all mechanisms, e.g., diffusion, migration, permeation, and/ordesorption by which the drug(s) incorporated in the drug-elutingmaterial pass therefrom over time into the surrounding body tissue.

“Drug-eluting material” and or controlled release material as usedherein refers to any natural, synthetic or semi-synthetic materialcapable of acquiring and retaining a desired shape or configuration andinto which one or more drugs can be incorporated and from whichincorporated drug(s) are capable of eluting over time.

“Elutable drug” as used herein refers to any drug or combination ofdrugs having the ability to pass over time from the drug-elutingmaterial in which it is incorporated into the surrounding areas of thebody.

Compounds

The compounds and compositions described herein can be used asanti-proliferative agents, e.g., anti-cancer and anti-angiogenesisagents, and/or as inhibitors of the Wnt signaling pathway, e.g., fortreating diseases or disorders associated with aberrant Wnt signaling.In addition, the compounds can be used as inhibitors of one or morekinases, kinase receptors, or kinase complexes. Such compounds andcompositions are also useful for controlling cellular proliferation,differentiation, and/or apoptosis.

Some embodiments of the present invention include compounds, salts,pharmaceutically acceptable salts or pro-drugs thereof of Formula (I):

In some embodiments of Formula I, R¹ and R² are independently selectedfrom the group consisting of H, lower alkyl, halide, —(C₁₋₉alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₉ alkyl)_(n)heteroaryl(R⁷)_(q), —(C₁₋₉alkyl)_(n)heterocyclyl(R⁸)_(q), —(C₁₋₉ alkyl)_(n)N(R⁹)₂, —OR¹⁰ and—NHC(═O)R¹¹.

In some embodiments of Formula I, R³ is selected from the groupconsisting of H, halide and lower alkyl.

In some embodiments of Formula I, there is the proviso that at least twoof R¹, R² and R³ are H.

In some embodiments of Formula I, R⁴ and R⁵ are independently selectedfrom the group consisting of H, —C(═O)N(R¹²)₂, -aryl(R¹³)_(q),-heterocyclyl(R¹⁴)_(q), and -heteroaryl(R¹⁵)_(q) with the proviso thateither R³ or R⁴ is H but not both.

In some embodiments of Formula I, each R⁶ is a substituent attached tothe aryl ring and independently selected from the group consisting of H,—C₁₋₉ alkyl, halide, CF₃ and CN.

In some embodiments of Formula I, each R⁷ is a substituent attached tothe heteroaryl ring and independently selected from the group consistingof H, —C₁₋₉ alkyl, halide, CF₃ and CN.

In some embodiments of Formula I, R⁸ is a substituent attached to theheterocyclyl ring and independently selected from the group consistingof H, halide, —(C₁₋₃ alkyl)_(n)arylR⁶, and —C₁₋₄ alkyl.

In some embodiments of Formula I, each R⁹ is independently selected fromthe group consisting of H, —C₁₋₉ alkyl, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q),—(C₁₋₃ alkyl)_(n)carbocyclyl and —(C₁₋₉ alkyl)N(R¹⁶)₂.

In some embodiments of Formula I, two adjacent R⁹ or two adjacent R¹²,may be taken together with the atoms to which they are attached to forma heterocyclyl(R¹⁷)_(q).

In some embodiments, R¹⁰ is selected from the group consisting of H,—CF₃, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl.

In some embodiments of Formula I, R¹¹ is selected from the groupconsisting of —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃alkyl)_(n)carbocyclyl, —C₁₋₉ alkyl and —CF₃.

In some embodiments of Formula I, each R¹² is independently selectedfrom the group consisting of H, —(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q) and —C₁₋₉alkyl.

In some embodiments of Formula I, each R¹³ is a substituent attached tothe aryl ring and independently selected from the group consisting of H,halide, —CF₃, CN, —(C₁₋₃ alkyl)_(n)heterocyclyl(R⁸)_(q), —(C₁₋₉alkyl)_(n)N(R⁹)₂ and —(C₁₋₉ alkyl)_(n)NHSO₂R¹⁸.

In some embodiments of Formula I, each R¹⁴ is a substituent attached tothe heterocyclyl ring and independently selected from the groupconsisting of H, lower alkyl, halide, —CF₃ and CN.

In some embodiments of Formula I, each R¹⁵ is a substituent attached tothe heteroaryl ring and independently selected from the group consistingof H, lower alkyl, halide, —CF₃, CN, —C(═O)(C₁₋₃ alkyl), —(C₁₋₉alkyl)_(n)N(R⁹)₂ and —(C₁₋₉ alkyl)_(n)NHSO₂R¹⁸.

In some embodiments of Formula I, each R¹⁶ is independently selectedfrom the group consisting of H and lower alkyl.

In some embodiments of Formula I, each R¹⁷ is a substituent attached tothe heterocyclyl ring and independently selected from the groupconsisting of H, —(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl.

In some embodiments of Formula I, each R¹⁸ is a lower alkyl.

In some embodiments of Formula I, A is N or C.

In some embodiments of Formula I, there is the proviso that if A is Nthen R² is nil;

In some embodiments of Formula I, each q is an integer of 1 to 5.

In some embodiments of Formula I, each n is an integer of 0 or 1.

In some embodiments, there is the proviso that Formula I is not astructure selected from the group consisting of:

In some embodiments of either Formula I, A is C.

In some embodiments of Formula I, A is N and R² is nil.

In some embodiments of Formula I, A is N; and R¹ and R³ are both H.

In some embodiments of Formula I, aryl is phenyl.

In some embodiments of Formula I, heteroaryl is pyridinyl.

In some embodiments of Formula I, heterocyclyl is selected from thegroup consisting of azetidinyl, pyrrolidinyl, morpholinyl, piperazinyland piperidinyl.

In some embodiments of Formula I, R² is selected from the groupconsisting of H, —(C₁₋₉ alkyl)_(n)heterocyclyl(R⁸)_(q), —NHC(═O)R¹¹ and—(C₁₋₉ alkyl)_(n)N(R⁹)₂ and R¹ and R³ are both H.

In some embodiments of Formula I, R² is —CH₂N(R⁹)₂ or —N(R⁹)₂.

In some embodiments of Formula I, R⁹ is independently selected from thegroup consisting of H, Me, Et, —CH₂phenyl and —CH₂carbocyclyl.

In some embodiments of Formula I, R² is —NHC(═O)R¹¹.

In some embodiments of Formula I, R¹¹ is selected from the groupconsisting of —C₁₋₅ alkyl, carbocyclyl, phenyl(R⁶)_(q), and—CH₂phenyl(R⁶)_(q).

In some embodiments of Formula I, R⁴ is phenyl(R¹³)_(q).

In some embodiments of Formula I, R⁴ is -heterocyclyl(R¹⁴)_(q).

In some embodiments of Formula I, R⁴ is -heteroaryl(R¹⁵)_(q).

In some embodiments of Formula I, R¹³ is one substituent attached to thephenyl comprising a fluorine atom.

In some embodiments of Formula I, R¹³ is two substituents each attachedto the phenyl comprising a fluorine atom and either a —(CH₂)_(n)N(R⁵)₂or a —(CH₂)_(n)NHSO₂R¹⁸.

In some embodiments of Formula I, the heterocyclyl is selected from thegroup consisting of piperazinyl and piperidinyl; and the R¹⁴ is H or Me.

In some embodiments of Formula I, the heteroaryl is selected from thegroup consisting of pyridinyl, furyl, thiophenyl and imidazolyl; and R¹⁵is lower alkyl or halide.

Some embodiments of the present invention include compounds, salts,pharmaceutically acceptable salts or pro-drugs thereof of Formula (II):

In some embodiments of Formula II, R¹ and R² are independently selectedfrom the group consisting of H, lower alkyl, halide, —(C₁₋₉alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₉ alkyl)_(n)heteroaryl(R⁷)_(q), —(C₁₋₉alkyl)_(n)heterocyclyl(R⁸)_(q), —(C₁₋₉ alkyl)_(n)N(R⁹)₂, —OR¹⁰ and—NHC(═O)R¹¹.

In some embodiments of Formula II, R³ is selected from the groupconsisting of H, halide and lower alkyl.

In some embodiments of Formula II, there is the proviso that at leasttwo of R¹, R² and R³ are H.

In some embodiments of Formula II, there is the proviso that if A is Nthen R² is nil.

In some embodiments of Formula II, R⁴ and R⁵ are independently selectedfrom the group consisting of H, —C(═O)N(R¹²)₂, -aryl(R¹³)_(q),-heterocyclyl(R¹⁴)_(q), and -heteroaryl(R¹⁵)_(q) with the proviso thateither R³ or R⁴ is H but not both.

In some embodiments of Formula II, each R⁶ is a substituent attached tothe aryl ring and independently selected from the group consisting of H,—C₁₋₉ alkyl, halide, CF₃ and CN.

In some embodiments of Formula II, each R⁷ is a substituent attached tothe heteroaryl ring and independently selected from the group consistingof H, —C₁₋₉ alkyl, halide, CF₃ and CN.

In some embodiments of Formula II, each R⁸ is a substituent attached tothe heterocyclyl ring and independently selected from the groupconsisting of H, halide, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₄ alkyl.

In some embodiments of Formula II, each R⁹ is independently selectedfrom the group consisting of H, —C₁₋₉ alkyl, —(C₁₋₃alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃ alkyl)_(n)carbocyclyl and —(C₁₋₉alkyl)N(R¹⁶)₂.

In some embodiments of Formula II, two adjacent R⁹ or two adjacent R¹²,may be taken together with the atoms to which they are attached to forma heterocyclyl(R¹⁷)_(q).

In some embodiments of Formula II, R¹⁰ is selected from the groupconsisting of H, —CF₃, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl.

In some embodiments of Formula II, R¹¹ is selected from the groupconsisting of —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃alkyl)_(n)carbocyclyl, —C₁₋₉ alkyl and —CF₃.

In some embodiments of Formula II, each R¹² is independently selectedfrom the group consisting of H, —(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q) and —C₁₋₉alkyl.

In some embodiments of Formula II, each R¹³ is a substituent attached tothe aryl ring and independently selected from the group consisting of H,halide, —CF₃, CN, —(C₁₋₃ alkyl)_(n)heterocyclyl(R⁸)_(q), —(C₁₋₉alkyl)_(n)N(R⁹)₂ and —(C₁₋₉ alkyl)_(n)NHSO₂R¹⁸.

In some embodiments of Formula II, each R¹⁴ is a substituent attached tothe heterocyclyl ring and independently selected from the groupconsisting of H, lower alkyl, halide, —CF₃ and CN.

In some embodiments of Formula II, each R¹⁵ is a substituent attached tothe heteroaryl ring and independently selected from the group consistingof H, lower alkyl, halide, —CF₃, CN, —C(═O)(C₁₋₃ alkyl), —(C₁₋₉alkyl)_(n)N(R⁹)₂ and —(C₁₋₉ alkyl)_(n)NHSO₂R¹⁸.

In some embodiments of Formula II, each R¹⁶ is independently selectedfrom the group consisting of H and lower alkyl.

In some embodiments of Formula II, each R¹⁷ is a substituent attached tothe heterocyclyl ring and independently selected from the groupconsisting of H, —(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl.

In some embodiments of Formula II, each R¹⁸ is a lower alkyl.

In some embodiments of Formula II, A is N or C.

In some embodiments of Formula II, there is the proviso that if A is Nthen R² is nil;

In some embodiments of Formula II, each q is an integer of 1 to 5.

In some embodiments of Formula II, each n is an integer of 0 or 1.

In some embodiments, Formula II is not a structure selected from thegroup consisting of:

In some embodiments of Formula II, A is C.

In some embodiments of Formula II, A is N and R² is nil.

In some embodiments of Formula II, A is N; and R¹ and R³ are both H.

In some embodiments of Formula II, aryl is phenyl.

In some embodiments of Formula II, heteroaryl is pyridinyl.

In some embodiments of Formula II, heterocyclyl is selected from thegroup consisting of azetidinyl, pyrrolidinyl, morpholinyl, piperazinyland piperidinyl.

In some embodiments of Formula II, R² is selected from the groupconsisting of H, —(C₁₋₉ alkyl)_(n)heterocyclyl(R⁸)_(q), —NHC(═O)R¹¹ and—(C₁₋₉ alkyl)_(n)N(R⁹)₂ and R¹ and R³ are both H.

In some embodiments of Formula II, R² is —CH₂N(R⁹)₂ or —N(R⁹)₂.

In some embodiments of Formula II, R⁹ is independently selected from thegroup consisting of H, Me, Et, —CH₂phenyl and —CH₂carbocyclyl.

In some embodiments of Formula II, R² is —NHC(═O)R¹¹.

In some embodiments of Formula II, R¹¹ is selected from the groupconsisting of —C₁₋₅ alkyl, carbocyclyl, phenyl(R⁶)₂, and—CH₂phenyl(R⁶)_(q).

In some embodiments of Formula II, R⁴ is phenyl(R¹³)_(q).

In some embodiments of Formula II, R⁴ is -heterocyclyl(R¹⁴)_(q).

In some embodiments of Formula II, R⁴ is -heteroaryl(R⁵)_(q).

In some embodiments of Formula II, R¹³ is one substituent attached tothe phenyl comprising a fluorine atom.

In some embodiments of Formula II, R¹³ is two substituents each attachedto the phenyl comprising a fluorine atom and either a —(CH₂)_(n)N(R⁵)₂or a —(CH₂)_(n)NHSO₂R¹⁸.

In some embodiments of Formula II, the heterocyclyl is selected from thegroup consisting of piperazinyl and piperidinyl; and the R¹⁴ is H or Me.

In some embodiments of Formula II, the heteroaryl is selected from thegroup consisting of pyridinyl, furyl, thiophenyl and imidazolyl; and R¹⁵is lower alkyl or halide.

In some embodiments of either Formula I or II, R³ is lower alkyl; and R¹and R² are both H.

In some embodiments of either Formula I or II, R² is —NHC(═O)(C₁₋₂alkyl).

In some embodiments of either Formula I or II, R² is —NHC(═O)(C₁₋₃alkyl).

In some embodiments of either Formula I or II, R² is —NHC(═O)(C₁₋₄alkyl).

In some embodiments of either Formula I or II, R² is —NHC(═O)(C₁₋₅alkyl).

In some embodiments of either Formula I or II, R² is—NHC(═O)carbocyclyl.

In some embodiments of either Formula I or II, R² is

In some embodiments of either Formula I or II, R² is —NH(C₁₋₃ alkyl).

In some embodiments of either Formula I or II, R² is —N(C₁₋₃ alkyl)₂.

In some embodiments of either Formula I or II, R² is —NH₂.

In some embodiments of either Formula I or II, R⁴ is pyridinyl.

In some embodiments of either Formula I or II, R⁴ is furyl.

In some embodiments of either Formula I or II, R⁴ is thiophenyl.

In some embodiments of either Formula I or II, R⁴ is imidazolyl.

In some embodiments of either Formula I or II, R⁴ is piperazinyl

In some embodiments of either Formula I or II, R⁴ is piperidinyl.

In some embodiments of either Formula I or II, R⁴ is1-methylpiperazinyl.

In some embodiments of either Formula I or II, R⁴ is selected from thegroup consisting of:

In some embodiments of either Formula I or II, R¹¹ is cyclopropyl.

In some embodiments of either Formula I or II, R¹¹ is cyclobutyl.

In some embodiments of either Formula I or II, R¹¹ is cyclopentyl.

In some embodiments of either Formula I or II, R¹¹ is cyclohexyl.

In some embodiments of either Formula I or II, R¹³ is 1-2 fluorineatoms.

In some embodiments of either Formula I or II, R¹³ is —(C₁₋₆alkyl)NHSO₂R¹¹.

In some embodiments of either Formula I or II, R¹³ is —(C₁₋₄alkyl)NHSO₂R¹¹.

In some embodiments of either Formula I or II, R¹³ is —(C₁₋₂alkyl)NHSO₂R¹¹.

In some embodiments of either Formula I or II, R¹³ is —CH₂NHSO₂R¹¹.

In some embodiments of either Formula I or II, R¹³ is —CH₂NHSO₂CH₃.

In some embodiments of either Formula I or II, R¹³ is —NR¹²(C₁₋₆alkyl)NR¹¹R¹².

In some embodiments of either Formula I or II, R¹³ is —NR¹²(C₁₋₄alkyl)NR¹¹R¹².

In some embodiments of either Formula I or II, R¹³ is—NR¹²CH₂CH₂NR¹¹R¹².

In some embodiments of either Formula I or II, R¹³ is —NHCH₂CH₂NR¹¹R¹².

In some embodiments of either Formula I or II, R¹³ is —NHCH₂CH₂N(CH₃)₂.

In some embodiments of either Formula I or II, R¹³ is 2 substituentsconsisting of 1 fluorine atom and —NR¹²(C₁₋₆ alkyl)NR¹¹R¹².

In some embodiments of either Formula I or II, R¹³ is 2 substituentsconsisting of 1 fluorine atom and —NHCH₂CH₂NR¹¹R¹².

In some embodiments of either Formula I or II, R¹³ is 2 substituentsconsisting of 1 fluorine atom and —(C₁₋₆ alkyl)NHSO₂R¹¹.

In some embodiments of either Formula I or II, R¹³ is 2 substituentsconsisting of 1 fluorine atom and —CH₂NHSO₂R¹¹.

In some embodiments of either Formula I or II, R¹⁵ is Me.

In some embodiments of either Formula I or II, R¹⁵ is halide.

In some embodiments of either Formula I or II, R¹⁵ is fluorine.

In some embodiments of either Formula I or II, R¹⁵ is —C(═O)(C₁₋₃alkyl).

In some embodiments of either Formula I or II, q is an integer rangingfrom 1 to 5, preferably 1 or 3, more preferably 1-2.

In some embodiments of either Formula I or II, A is C; R¹, R² and R³ areall H; R⁴ is selected from the group consisting of pyridine and-heterocyclyl(R¹⁴)_(q); q is 1 or 2 and R¹⁴ is selected from the groupconsisting of H, F and —(C₁₋₄ alkyl).

In some embodiments of either Formula I or II, A is C; R¹ and R³ are H;R² is amino; R⁴ is selected from the group consisting of-phenyl(R¹³)_(q) and -heterocyclyl(R¹⁴)_(q), -heteroaryl(R¹⁵)_(q); q is1 or 2; R¹⁵ is H; R¹⁴ is selected from the group consisting of H, F and—(C₁₋₄ alkyl); R¹³ is 1-2 fluorine atoms; and the heteroaryl is selectedfrom the group consisting of pyridine, furan and thiophene.

In some embodiments of either Formula I or II, A is C; R¹ and R³ are H;R² is —NHC(═O)R¹¹; R¹¹ is selected from the group consisting of ethyl,propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl and phenyl; R⁴ is selected from thegroup consisting of H, -heteroaryl(R¹⁵)_(q), -phenyl(R¹³)_(q) and-heterocyclyl(R¹⁴)_(q); q is 1 or 2; R¹⁵ is H or F; R¹⁴ is selected fromthe group consisting of H, F and —(C₁₋₄ alkyl); R¹³ is selected from thegroup consisting of 1-2 fluorine atoms and —CH₂NHSO₂R¹⁸; and theheteroaryl is selected from the group consisting of pyridine, furan andthiophene.

In some embodiments of either Formula I or II, A is C; R¹ and R³ are H;R² is —CH₂N(R⁹)₂; R⁴ is selected from the group consisting of H,-heteroaryl(R¹⁵)_(q), -phenyl(R¹³)_(q) and -heterocyclyl(R¹⁴)_(q); q is1 or 2; R¹⁵ is selected from the group consisting of H, F, Me and—C(═O)Me; R¹⁴ is selected from the group consisting of H, F and —(C₁₋₄alkyl); R¹³ is 1-2 fluorine atoms; the two R⁹ are linked to form afive-membered heterocyclyl ring; the heterocyclyl ring is substitutedwith 1-2 fluorine atoms; and the heteroaryl is selected from the groupconsisting of pyridine, furan and thiophene.

Pharmaceutically acceptable salts of all of the above embodiments arealso contemplated.

Illustrative compounds of Formulas (I) and (II) are shown in Table 1.

TABLE 1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

Administration and Pharmaceutical Compositions

Some embodiments include pharmaceutical compositions comprising: (a) asafe and therapeutically effective amount of the1H-pyrazolo[3,4-b]pyridine compound, or its corresponding enantiomer,diastereoisomer or tautomer, or pharmaceutically acceptable salt; and(b) a pharmaceutically acceptable carrier.

The compounds of this invention may also be useful in combination(administered together or sequentially) with other known agents.

Non-limiting examples of diseases which can be treated with acombination of a compound of Formulas (I) or (II) and other known agentsare colorectal cancer, ovarian cancer, retinitis pigmentosa, maculardegeneration, idiopathic pulmonary fibrosis and osteoarthritis.

In some embodiments, colorectal cancer can be treated with a combinationof a compound of either Formulas (I) or (II) and one or more of thefollowing drugs: 5-Fluorouracil (5-FU), which is often given with thevitamin-like drug leucovorin (also called folinic acid); Capecitabine(Xeloda®), Irinotecan (Camptosar®), Oxaliplatin (Eloxatin®). Examples ofcombinations of these drugs which could be further combined with acompound of either Formulas (I) or (II) are FOLFOX (5-FU, leucovorin,and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan), FOLFOXIRI(leucovorin, 5-FU, oxaliplatin, and irinotecan) and CapeOx (Capecitabineand oxaliplatin). For rectal cancer, chemo with 5-FU or capecitabinecombined with radiation may be given before surgery (neoadjuvanttreatment).

In some embodiments, ovarian cancer can be treated with a combination ofa compound of either Formulas (I) or (II) and one or more of thefollowing drugs: Topotecan, Liposomal doxorubicin (Doxil®), Gemcitabine(Gemzar®), Cyclophosphamide (Cytoxan®), Vinorelbine (Navelbine®),Ifosfamide (Ifex®), Etoposide (VP-16), Altretamine (Hexalen®),Capecitabine (Xeloda®), Irinotecan (CPT-11, Camptosar®), Melphalan,Pemetrexed (Alimta®) and Albumin bound paclitaxel (nab-paclitaxel,Abraxane®). Examples of combinations of these drugs which could befurther combined with a compound of either Formulas (I) or (II) are TIP(paclitaxel [Taxol], ifosfamide, and cisplatin), VeIP (vinblastine,ifosfamide, and cisplatin) and VIP (etoposide [VP-16], ifosfamide, andcisplatin).

In some embodiments, a compound of either Formulas (I) or (II) can beused to treat cancer in combination with any of the following methods:(a) Hormone therapy such as aromatase inhibitors, LHRH [luteinizinghormone-releasing hormone] analogs and inhibitors, and others; (b)Ablation or embolization procedures such as radiofrequency ablation(RFA), ethanol (alcohol) ablation, microwave thermotherapy andcryosurgery (cryotherapy); (c) Chemotherapy using alkylating agents suchas cisplatin and carboplatin, oxaliplatin, mechlorethamine,cyclophosphamide, chlorambucil and ifosfamide; (d) Chemotherapy usinganti-metabolites such as azathioprine and mercaptopurine; (e)Chemotherapy using plant alkaloids and terpenoids such as vincaalkaloids (i.e. Vincristine, Vinblastine, Vinorelbine and Vindesine) andtaxanes; (f) Chemotherapy using podophyllotoxin, etoposide, teniposideand docetaxel; (g) Chemotherapy using topoisomerase inhibitors such asirinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, andteniposide; (h) Chemotherapy using cytotoxic antibiotics such asactinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin,idarubicin, epirubicin, bleomycin, plicamycin and mitomycin; (i)Chemotherapy using tyrosine-kinase inhibitors such as Imatinib mesylate(Gleevec®, also known as STI-571), Gefitinib (Iressa, also known asZD1839), Erlotinib (marketed as Tarceva®), Bortezomib (Velcade®),tamoxifen, tofacitinib, crizotinib, Bcl-2 inhibitors (e.g. obatoclax inclinical trials, ABT-263, and Gossypol), PARP inhibitors (e.g. Iniparib,Olaparib in clinical trials), PI3K inhibitors (eg. perifosine in a phaseIII trial), VEGF Receptor 2 inhibitors (e.g. Apatinib), AN-152,(AEZS-108), Braf inhibitors (e.g. vemurafenib, dabrafenib and LGX818),MEK inhibitors (e.g. trametinib and MEK162), CDK inhibitors, (e.g.PD-0332991), salinomycin and Sorafenib; (j) Chemotherapy usingmonoclonal antibodies such as Rituximab (marketed as MabThera® orRituxan®), Trastuzumab (Herceptin also known as ErbB2), Cetuximab(marketed as Erbitux®) and Bevacizumab (marketed as Avastin®); and (k)radiation therapy.

In some embodiments, idiopathic pulmonary fibrosis can be treated with acombination of a compound of either Formulas (I) or (II) and one or moreof the following drugs: pirfenidone (pirfenidone was approved for use in2011 in Europe under the brand name Esbriet®), prednisone, azathioprine,N-acetylcysteine, interferon-γ 1b, bosentan (bosentan is currently beingstudied in patients with IPF, [The American Journal of Respiratory andCritical Care Medicine (2011), 184(1), 92-9]), Nintedanib (BIBF 1120 andVargatef), QAX576 [British Journal of Pharmacology (2011), 163(1),141-172], and anti-inflammatory agents such as corticosteroids.

In some embodiments, a compound of either Formulas (I) or (II) can beused to treat idiopathic pulmonary fibrosis in combination with any ofthe following methods: oxygen therapy, pulmonary rehabilitation andsurgery.

In some embodiments, a compound of either Formulas (I) or (II) can beused to treat osteoarthritis in combination with any of the followingmethods: (a) Nonsteroidal anti-inflammatory drugs (NSAIDs) such asibuprofen, naproxen, aspirin and acetaminophen; (b) physical therapy;(c) injections of corticosteroid medications; (d) injections ofhyaluronic acid derivatives (e.g. Hyalgan, Synvisc); (e) narcotics, likecodeine; (f) in combination with braces and/or shoe inserts or anydevice that can immobilize or support your joint to help you keeppressure off it (e.g., splints, braces, shoe inserts or other medicaldevices); (g) realigning bones (osteotomy); (h) joint replacement(arthroplasty); and (i) in combination with a chronic pain class.

In some embodiments, macular degeneration can be treated with acombination of a compound of either Formulas (I) or (II) and one or moreof the following drugs: Bevacizumab (Avastin®), Ranibizumab (Lucentis®),Pegaptanib (Macugen), Aflibercept (Eylea®), verteporfin (Visudyne®) incombination with photodynamic therapy (PDT) or with any of the followingmethods: (a) in combination with laser to destroy abnormal blood vessels(photocoagulation); and (b) in combination with increased vitamin intakeof antioxidant vitamins and zinc.

In some embodiments, retinitis pigmentosa can be treated with acombination of a compound of either Formulas (I) or (II) and one or moreof the following drugs: UF-021 (Ocuseva™), vitamin A palmitate andpikachurin or with any of the following methods: (a) with the Argus® IIretinal implant; and (b) with stem cell and/or gene therapy.

Compounds of the invention intended for pharmaceutical use may beadministered as crystalline or amorphous products. Pharmaceuticalcompositions as provided herein may be formulated as solids, semisolids, liquids, solutions, colloidals, liposomes, emulsions,suspensions, complexes, coacervates, or aerosols. Dosage forms, such as,e.g., tablets, capsules, powders, liquids, suspensions, suppositories,aerosols, implants, controlled release or the like are also providedherein. They may be obtained, for example, as solid plugs, powders, orfilms by methods such as precipitation, crystallization, milling,grinding, supercritical fluid processing, coacervation, complexcoacervation, encapsulation, emulsification, complexation, freezedrying, spray drying, or evaporative drying. Microwave or radiofrequency drying may be used for this purpose. The compounds can also beadministered in sustained or controlled release dosage forms, includingdepot injections, osmotic pumps, pills (tablets and or capsules),transdermal (including electrotransport) patches, implants and the like,for prolonged and/or timed, pulsed administration at a predeterminedrate. Preferably, the compositions are provided in unit dosage formssuitable for single administration of a precise dose.

Compounds of the invention intended for pharmaceutical use may beadministered as crystalline or amorphous products. Pharmaceuticallyacceptable compositions may include solid, semi-solid, liquid,solutions, colloidal, liposomes, emulsions, suspensions, complexes,coacervates and aerosols. Dosage forms, such as, e.g., tablets,capsules, powders, liquids, suspensions, suppositories, aerosols,implants, controlled release or the like. They may be obtained, forexample, as solid plugs, powders, or films by methods such asprecipitation, crystallization, milling, grinding, supercritical fluidprocessing, coacervation, complex coacervation, encapsulation,emulsification, complexation, freeze drying, spray drying, orevaporative drying. Microwave or radio frequency drying may be used forthis purpose. The compounds can also be administered in sustained orcontrolled release dosage forms, including depot injections, osmoticpumps, pills (tablets and or capsules), transdermal (includingelectrotransport) patches, implants and the like, for prolonged and/ortimed, pulsed administration at a predetermined rate. Preferably, thecompositions are provided in unit dosage forms suitable for singleadministration of a precise dose.

The compounds can be administered either alone or more typically incombination with a conventional pharmaceutical carrier, excipient or thelike. The term “excipient” is used herein to describe any ingredientother than the compound(s) of the invention. Pharmaceutically acceptableexcipients include, but are not limited to, ion exchangers, alumina,aluminum stearate, lecithin, self-emulsifying drug delivery systems(SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate,surfactants used in pharmaceutical dosage forms such as Tweens,poloxamers or other similar polymeric delivery matrices, serum proteins,such as human serum albumin, buffer substances such as phosphates, tris,glycine, sorbic acid, potassium sorbate, partial glyceride mixtures ofsaturated vegetable fatty acids, water, salts or electrolytes, such asprotamine sulfate, disodium hydrogen phosphate, potassium hydrogenphosphate, sodium-chloride, zinc salts, colloidal silica, magnesiumtrisilicate, polyvinyl pyrrolidone, cellulose-based substances,polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates,waxes, polyethylene-polyoxypropylene-block polymers, and wool fat.Cyclodextrins such as α-, β, and γ-cyclodextrin, or chemically modifiedderivatives such as hydroxyalkylcyclodextrins, including 2- and3-hydroxypropyl-b-cyclodextrins, or other solubilized derivatives canalso be advantageously used to enhance delivery of compounds describedherein. Dosage forms or compositions containing a compound as describedherein in the range of 0.005% to 100% with the balance made up fromnon-toxic carrier may be prepared. The contemplated compositions maycontain 0.001%-100% active ingredient, in one embodiment 0.1-95%, inanother embodiment 75-85%, in a further embodiment 20-80%. Actualmethods of preparing such dosage forms are known, or will be apparent,to those skilled in this art; for example, see Remington: The Scienceand Practice of Pharmacy, 22^(nd) Edition (Pharmaceutical Press, London,U K. 2012).

In one preferred embodiment, the compositions will take the form of aunit dosage form such as a pill or tablet and thus the composition maycontain, along with the active ingredient, a diluent such as lactose,sucrose, dicalcium phosphate, or the like; a lubricant such as magnesiumstearate or the like; and a binder such as starch, gum acacia,polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or thelike. In another solid dosage form, a powder, marume, solution orsuspension (e.g., in propylene carbonate, vegetable oils, PEG's,poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin orcellulose base capsule). Unit dosage forms in which the two activeingredients are physically separated are also contemplated; e.g.,capsules with granules (or tablets in a capsule) of each drug; two-layertablets; two-compartment gel caps, etc. Enteric coated or delayedrelease oral dosage forms are also contemplated.

Liquid pharmaceutically administrable compositions can, for example, beprepared by dissolving, dispersing, etc. an active compound as definedabove and optional pharmaceutical adjuvants in a carrier (e.g., water,saline, aqueous dextrose, glycerol, glycols, ethanol or the like) toform a solution, colloid, liposome, emulsion, complexes, coacervate orsuspension. If desired, the pharmaceutical composition can also containminor amounts of nontoxic auxiliary substances such as wetting agents,emulsifying agents, co-solvents, solubilizing agents, pH bufferingagents and the like (e.g., sodium acetate, sodium citrate, cyclodextrinederivatives, sorbitan monolaurate, triethanolamine acetate,triethanolamine oleate, and the like).

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 0.25 mg/Kg to 50 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 0.25 mg/Kg to 20 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 0.50 mg/Kg to 19 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 0.75 mg/Kg to 18 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 1.0 mg/Kg to 17 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 1.25 mg/Kg to 16 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 1.50 mg/Kg to 15 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 1.75 mg/Kg to 14 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 2.0 mg/Kg to 13 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 3.0 mg/Kg to 12 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) is 4.0mg/Kg to 11 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formulas (I) or(II) is 5.0 mg/Kg to 10 mg/Kg in humans.

In some embodiments, the compositions are provided in unit dosage formssuitable for single administration of a precise dose.

In some embodiments, the compositions are provided in unit dosage formssuitable for twice a day administration of a precise dose.

In some embodiments, the compositions are provided in unit dosage formssuitable for three times a day administration of a precise dose.

Injectables can be prepared in conventional forms, either as liquidsolutions, colloid, liposomes, complexes, coacervate or suspensions, asemulsions, or in solid forms suitable for reconstitution in liquid priorto injection. The percentage of active compound contained in suchparenteral compositions is highly dependent on the specific naturethereof, as well as the activity of the compound and the needs of thesubject. However, percentages of active ingredient of 0.01% to 10% insolution are employable, and could be higher if the composition is asolid or suspension, which could be subsequently diluted to the abovepercentages.

In some embodiments, the composition will comprise 0.1-10% of the activeagent in solution.

In some embodiments, the composition will comprise 0.1-5% of the activeagent in solution.

In some embodiments, the composition will comprise 0.1-4% of the activeagent in solution.

In some embodiments, the composition will comprise 0.15-3% of the activeagent in solution.

In some embodiments, the composition will comprise 0.2-2% of the activeagent in solution.

In some embodiments, the compositions are provided in dosage formssuitable for continuous dosage by intravenous infusion over a period of1-96 hours.

In some embodiments, the compositions are provided in dosage formssuitable for continuous dosage by intravenous infusion over a period of1-72 hours.

In some embodiments, the compositions are provided in dosage formssuitable for continuous dosage by intravenous infusion over a period of1-48 hours.

In some embodiments, the compositions are provided in dosage formssuitable for continuous dosage by intravenous infusion over a period of1-24 hours.

In some embodiments, the compositions are provided in dosage formssuitable for continuous dosage by intravenous infusion over a period of1-12 hours.

In some embodiments, the compositions are provided in dosage formssuitable for continuous dosage by intravenous infusion over a period of1-6 hours.

In some embodiments, these compositions can be administered byintravenous infusion to humans at doses of 5 mg/m² to 300 mg/m².

In some embodiments, these compositions can be administered byintravenous infusion to humans at doses of 5 mg/m² to 200 mg/m².

In some embodiments, these compositions can be administered byintravenous infusion to humans at doses of 5 mg/m² to 100 mg/m².

In some embodiments, these compositions can be administered byintravenous infusion to humans at doses of 10 mg/m² to 50 mg/m².

In some embodiments, these compositions can be administered byintravenous infusion to humans at doses of 50 mg/m² to 200 mg/m².

In some embodiments, these compositions can be administered byintravenous infusion to humans at doses of 75 mg/m² to 175 mg/m².

In some embodiments, these compositions can be administered byintravenous infusion to humans at doses of 100 mg/m² to 150 mg/m².

It is to be noted that concentrations and dosage values may also varydepending on the specific compound and the severity of the condition tobe alleviated. It is to be further understood that for any particularpatient, specific dosage regimens should be adjusted over time accordingto the individual need and the professional judgment of the personadministering or supervising the administration of the compositions, andthat the concentration ranges set forth herein are exemplary only andare not intended to limit the scope or practice of the claimedcompositions.

In one preferred embodiment, the compositions can be administered to therespiratory tract (including nasal and pulmonary) e.g., through anebulizer, metered-dose inhalers, atomizer, mister, aerosol, dry powderinhaler, insufflator, liquid instillation or other suitable device ortechnique.

In some embodiments, aerosols intended for delivery to the nasal mucosaare provided for inhalation through the nose. For optimal delivery tothe nasal cavities, inhaled particle sizes of about 5 to about 100microns are useful, with particle sizes of about 10 to about 60 micronsbeing preferred. For nasal delivery, a larger inhaled particle size isdesired to maximize impaction on the nasal mucosa and to minimize orprevent pulmonary deposition of the administered formulation. In someembodiments, aerosols intended for delivery to the lung are provided forinhalation through the nose or the mouth. For optimal delivery to thelung, inhaled aerodynamic particle sizes of about less than 10 μm areuseful, with an aerodynamic particle size of about 1 to about 10 micronsbeing preferred. Inhaled particles may be defined as liquid dropletscontaining dissolved drug, liquid droplets containing suspended drugparticles (in cases where the drug is insoluble in the suspendingmedium), dry particles of pure drug substance, drug substanceincorporated with excipients, liposomes, emulsions, colloidal systems,coacervates, aggregates of drug nanoparticles, or dry particles of adiluent which contain embedded drug nanoparticles.

In some embodiments, compounds of Formulas (I) or (II) disclosed hereinintended for respiratory delivery (either systemic or local) can beadministered as aqueous formulations, as non-aqueous solutions orsuspensions, as suspensions or solutions in halogenated hydrocarbonpropellants with or without alcohol, as a colloidal system, asemulsions, coacervates or as dry powders. Aqueous formulations may beaerosolized by liquid nebulizers employing either hydraulic orultrasonic atomization or by modified micropump systems (like the softmist inhalers, the Aerodose® or the AERx® systems). Propellant-basedsystems may use suitable pressurized metered-dose inhalers (pMDIs). Drypowders may use dry powder inhaler devices (DPIs), which are capable ofdispersing the drug substance effectively. A desired particle size anddistribution may be obtained by choosing an appropriate device.

In some embodiments, the compositions of Formulas (I) or (II) disclosedherein can be administered to the ear by various methods. For example, around window catheter (e.g., U.S. Pat. Nos. 6,440,102 and 6,648,873) canbe used.

Alternatively, formulations can be incorporated into a wick for usebetween the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) orabsorbed to collagen sponge or other solid support (e.g., U.S. Pat. No.4,164,559).

If desired, formulations of the invention can be incorporated into a gelformulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).

In some embodiments, compounds of Formulas (I) or (II) disclosed hereinintended for delivery to the ear can be administered via an implantedpump and delivery system through a needle directly into the middle orinner ear (cochlea) or through a cochlear implant stylet electrodechannel or alternative prepared drug delivery channel such as but notlimited to a needle through temporal bone into the cochlea.

Other options include delivery via a pump through a thin film coatedonto a multichannel electrode or electrode with a specially imbeddeddrug delivery channel (pathways) carved into the thin film for thispurpose. In other embodiments, compounds of Formulas (I) or (II) can bedelivered from the reservoir of an external or internal implantedpumping system.

Formulations of the invention also can be administered to the ear byintratympanic injection into the middle ear, inner ear, or cochlea(e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).

Intratympanic injection of therapeutic agents is the technique ofinjecting a therapeutic agent behind the tympanic membrane into themiddle and/or inner ear. In one embodiment, the formulations describedherein are administered directly onto the round window membrane viatranstympanic injection. In another embodiment, the ion channelmodulating agent auris-acceptable formulations described herein areadministered onto the round window membrane via a non-transtympanicapproach to the inner ear. In additional embodiments, the formulationdescribed herein is administered onto the round window membrane via asurgical approach to the round window membrane comprising modificationof the crista fenestrae cochleae.

In some embodiments, the compounds of Formulas (I) or (II) areformulated in rectal compositions such as enemas, rectal gels, rectalfoams, rectal aerosols, suppositories, jelly suppositories, or retentionenemas, containing conventional suppository bases such as cocoa butteror other glycerides, as well as synthetic polymers such aspolyvinylpyrrolidone, PEG (like PEG ointments), and the like.

Suppositories for rectal administration of the drug (either as asolution, colloid, suspension or a complex) can be prepared by mixingthe drug with a suitable non-irritating excipient that is solid atordinary temperatures but liquid at the rectal temperature and willtherefore melt or erode/dissolve in the rectum and release the drug.Such materials include cocoa butter, glycerinated gelatin, hydrogenatedvegetable oils, poloxamers, mixtures of polyethylene glycols of variousmolecular weights and fatty acid esters of polyethylene glycol. Insuppository forms of the compositions, a low-melting wax such as, butnot limited to, a mixture of fatty acid glycerides, optionally incombination with cocoa butter is first melted.

Solid compositions can be provided in various different types of dosageforms, depending on the physicochemical properties of the drug, thedesired dissolution rate, cost considerations, and other criteria. Inone of the embodiments, the solid composition is a single unit. Thisimplies that one unit dose of the drug is comprised in a single,physically shaped solid form or article. In other words, the solidcomposition is coherent, which is in contrast to a multiple unit dosageform, in which the units are incoherent.

Examples of single units which may be used as dosage forms for the solidcomposition include tablets, such as compressed tablets, film-likeunits, foil-like units, wafers, lyophilized matrix units, and the like.In a preferred embodiment, the solid composition is a highly porouslyophilized form. Such lyophilizates, sometimes also called wafers orlyophilized tablets, are particularly useful for their rapiddisintegration, which also enables the rapid dissolution of the activecompound.

On the other hand, for some applications the solid composition may alsobe formed as a multiple unit dosage form as defined above. Examples ofmultiple units are powders, granules, microparticles, pellets,mini-tablets, beads, lyophilized powders, and the like. In oneembodiment, the solid composition is a lyophilized powder. Such adispersed lyophilized system comprises a multitude of powder particles,and due to the lyophilization process used in the formation of thepowder, each particle has an irregular, porous microstructure throughwhich the powder is capable of absorbing water very rapidly, resultingin quick dissolution. Effervescent compositions are also contemplated toaid the quick dispersion and absorption of the compound.

Another type of multiparticulate system which is also capable ofachieving rapid drug dissolution is that of powders, granules, orpellets from water-soluble excipients which are coated with the drug, sothat the drug is located at the outer surface of the individualparticles. In this type of system, the water-soluble low molecularweight excipient is useful for preparing the cores of such coatedparticles, which can be subsequently coated with a coating compositioncomprising the drug and, preferably, one or more additional excipients,such as a binder, a pore former, a saccharide, a sugar alcohol, afilm-forming polymer, a plasticizer, or other excipients used inpharmaceutical coating compositions.

Also provided herein are kits. Typically, a kit includes one or morecompounds or compositions as described herein. In certain embodiments, akit can include one or more delivery systems, e.g., for delivering oradministering a compound as provided above, and directions for use ofthe kit (e.g., instructions for treating a patient). In anotherembodiment, the kit can include a compound or composition as describedherein and a label that indicates that the contents are to beadministered to a patient with cancer. In another embodiment, the kitcan include a compound or composition as described herein and a labelthat indicates that the contents are to be administered to a patientwith one or more of hepatocellular carcinoma, colon cancer, leukemia,lymphoma, sarcoma, ovarian cancer, diabetic retinopathy, idiopathicpulmonary fibrosis (IPF), pulmonary fibrosis, rheumatoid arthritis,scleroderma, mycotic and viral infections, bone and cartilage diseases,Alzheimer's disease, lung disease, osteoarthritis, polyposis coli, bonedensity and vascular defects in the eye (Osteoporosis-pseudogliomaSyndrome, OPPG), familial exudative vitreoretinopathy, retinalangiogenesis, early coronary disease, tetra-amelia, Müllerian-ductregression and virilization, SERKAL syndrome, type II diabetes, Fuhrmannsyndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation,caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia,focal dermal hypoplasia, autosomal recessive anonychia, neural tubedefects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICFsyndrome, Angelman's syndrome, Prader-Willi syndrome, Beckwith-WiedemannSyndrome, Norrie disease and Rett syndrome

The actual dose of the active compounds of the present invention dependson the specific compound, and on the condition to be treated; theselection of the appropriate dose is well within the knowledge of theskilled artisan.

Methods of Treatment

The compounds and compositions provided herein can be used as inhibitorsand/or modulators of one or more members of the Wnt pathway, which mayinclude one or more Wnt proteins, and thus can be used to treat avariety of disorders and diseases in which aberrant Wnt signaling isimplicated, such as cancer and other diseases associated with abnormalangiogenesis, cellular proliferation, and cell cycling. Accordingly, thecompounds and compositions provided herein can be used to treat cancer,to reduce or inhibit angiogenesis, to reduce or inhibit cellularproliferation, to correct a genetic disorder, and/or to treat aneurological condition/disorder/disease due to mutations ordysregulation of the Wnt pathway and/or of one or more of Wnt signalingcomponents. Non-limiting examples of diseases which can be treated withthe compounds and compositions provided herein include a variety ofcancers, diabetic retinopathy, idiopathic pulmonary fibrosis (IPF),pulmonary fibrosis, rheumatoid arthritis, scleroderma, sarcoidosis,mycotic and viral infections, bone and cartilage diseases, neurologicalconditions/diseases such as Alzheimer's disease, amyotrophic lateralsclerosis (ALS), motor neuron disease, Down's syndrome, frontotemporaldementia (FTDP-17), Pick's disease, surpanuclear palsy, corticobasaldegeneration, multiple sclerosis or autism, lung disease,osteoarthritis, polyposis coli, bone density and vascular defects in theeye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudativevitreoretinopathy, retinal angiogenesis, retinal tumors, early coronarydisease, tetra-amelia, Millerian-duct regression and virilization,SERKAL syndrome, type II diabetes, Fuhrmann syndrome,Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation,caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia,focal dermal hypoplasia, autosomal recessive anonychia, neural tubedefects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICFsyndrome, Angelman's syndrome, Prader-Willi syndrome, Beckwith-WiedemannSyndrome, Norrie disease and Rett syndrome.

With respect to cancer, the Wnt pathway is known to be constitutivelyactivated in a variety of cancers including, for example, colon cancer,hepatocellular carcinoma, lung cancer, ovarian cancer, prostate cancer,pancreatic cancer and leukemias such as CML, CLL, T-ALL, myelodysplasticsyndromes and Mantle Cell Lympohomas. The constitutive activation is dueto constitutively active β-catenin, perhaps due to its stabilization byinteracting factors or inhibition of the degradation pathway.Accordingly, the compounds and compositions described herein may be usedto treat these cancers in which the Wnt pathway is constitutivelyactivated. In certain embodiments, the cancer is chosen fromhepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma andovarian cancer.

Other cancers can also be treated with the compounds and compositionsdescribed herein.

More particularly, cancers that may be treated by the compound,compositions and methods described herein include, but are not limitedto, the following:

1) Breast cancers, including, for example E⁺ breast cancer, ER⁻ breastcancer, her2⁻ breast cancer, her2⁺ breast cancer, stromal tumors such asfibroadenomas, phyllodes tumors, and sarcomas, and epithelial tumorssuch as large duct papillomas; carcinomas of the breast including insitu (noninvasive) carcinoma that includes ductal carcinoma in situ(including Paget's disease) and lobular carcinoma in situ, and invasive(infiltrating) carcinoma including, but not limited to, invasive ductalcarcinoma, invasive lobular carcinoma, medullary carcinoma, colloid(mucinous) carcinoma, tubular carcinoma, and invasive papillarycarcinoma; and miscellaneous malignant neoplasms. Further examples ofbreast cancers can include luminal A, luminal B, basal A, basal B, andtriple negative breast cancer, which is estrogen receptor negative(ER⁻), progesterone receptor negative, and her2 negative (her2⁻). Insome embodiments, the breast cancer may have a high risk Oncotype score.

2) Cardiac cancers, including, for example sarcoma, e.g., angiosarcoma,fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma;fibroma; lipoma and teratoma.

3) Lung cancers, including, for example, bronchogenic carcinoma, e.g.,squamous cell, undifferentiated small cell, undifferentiated large cell,and adenocarcinoma; alveolar and bronchiolar carcinoma; bronchialadenoma; sarcoma; lymphoma; chondromatous hamartoma; and mesothelioma.

4) Gastrointestinal cancer, including, for example, cancers of theesophagus, e.g., squamous cell carcinoma, adenocarcinoma,leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma,lymphoma, and leiomyosarcoma; cancers of the pancreas, e.g., ductaladenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors,and vipoma; cancers of the small bowel, e.g., adenocarcinoma, lymphoma,carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma,neurofibroma, and fibroma; cancers of the large bowel, e.g.,adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, andleiomyoma.

5) Genitourinary tract cancers, including, for example, cancers of thekidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma,and leukemia; cancers of the bladder and urethra, e.g., squamous cellcarcinoma, transitional cell carcinoma, and adenocarcinoma; cancers ofthe prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis,e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma,choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma,fibroadenoma, adenomatoid tumors, and lipoma.

6) Liver cancers, including, for example, hepatoma, e.g., hepatocellularcarcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma;hepatocellular adenoma; and hemangioma.

7) Bone cancers, including, for example, osteogenic sarcoma(osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma,chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cellsarcoma), multiple myeloma, malignant giant cell tumor chordoma,osteochrondroma (osteocartilaginous exostoses), benign chondroma,chondroblastoma, chondromyxofibroma, osteoid osteoma and giant celltumors.

8) Nervous system cancers, including, for example, cancers of the skull,e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans;cancers of the meninges, e.g., meningioma, meningiosarcoma, andgliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma,glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform,oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors;and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma,and sarcoma.

9) Gynecological cancers, including, for example, cancers of the uterus,e.g., endometrial carcinoma; cancers of the cervix, e.g., cervicalcarcinoma, and pre tumor cervical dysplasia; cancers of the ovaries,e.g., ovarian carcinoma, including serous cystadenocarcinoma, mucinouscystadenocarcinoma, unclassified carcinoma, granulosa theca cell tumors,Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma;cancers of the vulva, e.g., squamous cell carcinoma, intraepithelialcarcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of thevagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoidsarcoma, and embryonal rhabdomyosarcoma; and cancers of the fallopiantubes, e.g., carcinoma.

10) Hematologic cancers, including, for example, cancers of the blood,e.g., acute myeloid leukemia, chronic myeloid leukemia, acutelymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferativediseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin'slymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and Waldenström'smacroglobulinemia.

11) Skin cancers and skin disorders, including, for example, malignantmelanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi'ssarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma,keloids, desmoid tumors, and scleroderma.

12) Adrenal gland cancers, including, for example, neuroblastoma.

Cancers may be solid tumors that may or may not be metastatic. Cancersmay also occur, as in leukemia, as a diffuse tissue. Thus, the term“tumor cell,” as provided herein, includes a cell afflicted by any oneof the above identified disorders.

A method of treating cancer using a compound or composition as describedherein may be combined with existing methods of treating cancers, forexample by chemotherapy, irradiation, or surgery (e.g., oophorectomy).In some embodiments, a compound or composition can be administeredbefore, during, or after another anticancer agent or treatment.

The compounds and compositions described herein can be used asanti-angiogenesis agents and as agents for modulating and/or inhibitingthe activity of protein kinases, thus providing treatments for cancerand other diseases associated with cellular proliferation mediated byprotein kinases. Accordingly, provided herein is a method of treatingcancer or preventing or reducing angiogenesis through kinase inhibition.

In addition, and including treatment of cancer, the compounds andcompositions described herein can function as cell-cycle control agentsfor treating proliferative disorders in a patient. Disorders associatedwith excessive proliferation include, for example, cancers, scleroderma,immunological disorders involving undesired proliferation of leukocytes,and restenosis and other smooth muscle disorders. Furthermore, suchcompounds may be used to prevent de-differentiation of post-mitotictissue and/or cells

Diseases or disorders associated with uncontrolled or abnormal cellularproliferation include, but are not limited to, the following:

-   -   a variety of cancers, including, but not limited to, carcinoma,        hematopoietic tumors of lymphoid lineage, hematopoietic tumors        of myeloid lineage, tumors of mesenchymal origin, tumors of the        central and peripheral nervous system and other tumors including        melanoma, seminoma and Kaposi's sarcoma.    -   a disease process which features abnormal cellular        proliferation, e.g., benign prostatic hyperplasia, familial        adenomatosis polyposis, neurofibromatosis, atherosclerosis,        arthritis, glomerulonephritis, restenosis following angioplasty        or vascular surgery, inflammatory bowel disease, transplantation        rejection, endotoxic shock, and fungal infections. Fibrotic        disorders such as skin fibrosis; scleroderma; progressive        systemic fibrosis; lung fibrosis; muscle fibrosis; kidney        fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic        scar formation; uterine fibrosis; renal fibrosis; cirrhosis of        the liver, liver fibrosis; adhesions, such as those occurring in        the abdomen, pelvis, spine or tendons; chronic obstructive        pulmonary disease; fibrosis following myocardial infarction;        pulmonary fibrosis; idiopathic pulmonary fibrosis (IPF);        fibrosis and scarring associated with diffuse/interstitial lung        disease; central nervous system fibrosis, such as fibrosis        following stroke; fibrosis associated with neuro-degenerative        disorders such as Alzheimer's Disease or multiple sclerosis;        fibrosis associated with proliferative vitreoretinopathy (PVR);        restenosis; endometriosis; ischemic disease and radiation        fibrosis.    -   defective apoptosis-associated conditions, such as cancers        (including but not limited to those types mentioned herein),        viral infections (including but not limited to herpesvirus,        poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus),        prevention of AIDS development in HIV-infected individuals,        autoimmune diseases (including but not limited to systemic lupus        erythematosus, rheumatoid arthritis, scleroderma, autoimmune        mediated glomerulonephritis, inflammatory bowel disease and        autoimmune diabetes mellitus), neurodegenerative disorders        (including but not limited to Alzheimer's disease, lung disease,        amyotrophic lateral sclerosis, retinitis pigmentosa, Parkinson's        disease, AIDS-related dementia, spinal muscular atrophy and        cerebellar degeneration), myelodysplastic syndromes, aplastic        anemia, ischemic injury associated with myocardial infarctions,        stroke and reperfusion injury, arrhythmia, atherosclerosis,        toxin-induced or alcohol related liver diseases, hematological        diseases (including but not limited to chronic anemia and        aplastic anemia), degenerative diseases of the musculoskeletal        system (including but not limited to osteoporosis and        arthritis), aspirin-sensitive rhinosinusitis, cystic fibrosis,        multiple sclerosis, kidney diseases and cancer pain.    -   genetic diseases due to mutations in Wnt signaling components,        such as polyposis coli, bone density and vascular defects in the        eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial        exudative vitreoretinopathy, retinal angiogenesis, early        coronary disease, tetra-amelia, Müllerian-duct regression and        virilization, SERKAL syndrome, type II diabetes, Fuhrmann        syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,        odonto-onycho-dermal dysplasia, obesity, split-hand/foot        malformation, caudal duplication, tooth agenesis, Wilms tumor,        skeletal dysplasia, focal dermal hypoplasia, autosomal recessive        anonychia, neural tube defects, alpha-thalassemia (ATRX)        syndrome, fragile X syndrome, ICF syndrome, Angelman's syndrome,        Prader-Willi syndrome, Beckwith-Wiedemann Syndrome and Rett        syndrome.

Furthermore, the compounds and compositions described herein can be usedto treat neurological conditions, disorders and/or diseases caused bydysfunction in the Wnt signaling pathway. Non-limiting examples ofneurological conditions/disorders/diseases which can be treated with thecompounds and compositions provided herein include Alzheimer's disease,aphasia, apraxia, arachnoiditis, ataxia telangiectasia, attentiondeficit hyperactivity disorder, auditory processing disorder, autism,alcoholism, Bell's palsy, bipolar disorder, brachial plexus injury,Canavan disease, carpal tunnel syndrome, causalgia, central painsyndrome, central pontine myelinolysis, centronuclear myopathy, cephalicdisorder, cerebral aneurysm, cerebral arteriosclerosis, cerebralatrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis,cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiarimalformation, chronic fatigue syndrome, chronic inflammatorydemyelinating polyneuropathy (CIDP), chronic pain, Coffin-Lowrysyndrome, complex regional pain syndrome, compression neuropathy,congenital facial diplegia, corticobasal degeneration, cranialarteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulativetrauma disorder, Cushing's syndrome, cytomegalic inclusion body disease(CIBD), Dandy-Walker syndrome, Dawson disease, De Morsier's syndrome,Dejerine-Klumpke palsy, Dejerine-Sottas disease, delayed sleep phasesyndrome, dementia, dermatomyositis, developmental dyspraxia, diabeticneuropathy, diffuse sclerosis, Dravet syndrome, dysautonomia,dyscalculia, dysgraphia, dyslexia, dystonia, empty sella syndrome,encephalitis, encephalocele, encephalotrigeminal angiomatosis,encopresis, epilepsy, Erb's palsy, erythromelalgia, essential tremor,Fabry's disease, Fahr's syndrome, familial spastic paralysis, febrileseizure, Fisher syndrome, Friedreich's ataxia, fibromyalgia, Foville'ssyndrome, Gaucher's disease, Gerstmann's syndrome, giant cell arteritis,giant cell inclusion disease, globoid cell leukodystrophy, gray matterheterotopia, Guillain-Barré syndrome, HTLV-1 associated myelopathy,Hallervorden-Spatz disease, hemifacial spasm, hereditary spasticparaplegia, heredopathia atactica polyneuritiformis, herpes zosteroticus, herpes zoster, Hirayama syndrome, holoprosencephaly,Huntington's disease, hydranencephaly, hydrocephalus, hypercortisolism,hypoxia, immune-mediated encephalomyelitis, inclusion body myositis,incontinentia pigmenti, infantile phytanic acid storage disease,infantile Refsum disease, infantile spasms, inflammatory myopathy,intracranial cyst, intracranial hypertension, Joubert syndrome, Karaksyndrome, Kearns-Sayre syndrome, Kennedy disease, Kinsbourne syndrome,Klippel Feil syndrome, Krabbe disease, Kugelberg-Welander disease, kuru,Lafora disease, Lambert-Eaton myasthenic syndrome, Landau-Kleffnersyndrome, lateral medullary (Wallenberg) syndrome, Leigh's disease,Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Lewy bodydementia, lissencephaly, locked-in syndrome, Lou Gehrig's disease,lumbar disc disease, lumbar spinal stenosis, Lyme disease,Machado-Joseph disease (Spinocerebellar ataxia type 3), macrencephaly,macropsia, megalencephaly, Melkersson-Rosenthal syndrome, Menieresdisease, meningitis, Menkes disease, etachromatic leukodystrophy,microcephaly, micropsia, Miller Fisher syndrome, misophonia,mitochondrial myopathy, Mobius syndrome, monomelic amyotrophy, motorneurone disease, motor skills disorder, Moyamoya disease,mucopolysaccharidoses, multi-infarct dementia, multifocal motorneuropathy, multiple sclerosis, multiple system atrophy, musculardystrophy, myalgic encephalomyelitis, myasthenia gravis, myelinoclasticdiffuse sclerosis, myoclonic Encephalopathy of infants, myoclonus,myopathy, myotubular myopathy, myotonia congenital, narcolepsy,neurofibromatosis, neuroleptic malignant syndrome, lupus erythematosus,neuromyotonia, neuronal ceroid lipofuscinosis, Niemann-Pick disease,O'Sullivan-McLeod syndrome, occipital Neuralgia, occult SpinalDysraphism Sequence, Ohtahara syndrome, olivopontocerebellar atrophy,opsoclonus myoclonus syndrome, optic neuritis, orthostatic hypotension,palinopsia, paresthesia, Parkinson's disease, paramyotonia Congenita,paraneoplastic diseases, paroxysmal attacks, Parry-Romberg syndrome,Pelizaeus-Merzbacher disease, periodic paralyses, peripheral neuropathy,photic sneeze reflex, phytanic acid storage disease, Pick's disease,polymicrogyria (PMG), polymyositis, porencephaly, post-polio syndrome,postherpetic neuralgia (PHN), postural hypotension, Prader-Willisyndrome, primary lateral sclerosis, prion diseases, progressivehemifacial atrophy, progressive multifocal leukoencephalopathy,progressive supranuclear palsy, pseudotumor cerebri, Ramsay Huntsyndrome type I, Ramsay Hunt syndrome type II, Ramsay Hunt syndrome typeIII, Rasmussen's encephalitis, reflex neurovascular dystrophy, Refsumdisease, restless legs syndrome, retrovirus-associated myelopathy, Rettsyndrome, Reye's syndrome, rhythmic movement disorder, Romberg syndrome,Saint Vitus dance, Sandhoff disease, schizophrenia, Schilder's disease,schizencephaly, sensory integration dysfunction, septo-optic dysplasia,Shy-Drager syndrome, Sjögren's syndrome, snatiation, Sotos syndrome,spasticity, spina bifida, spinal cord tumors, spinal muscular atrophy,spinocerebellar ataxia, Steele-Richardson-Olszewski syndrome,Stiff-person syndrome, stroke, Sturge-Weber syndrome, subacutesclerosing panencephalitis, subcortical arteriosclerotic encephalopathy,superficial siderosis, Sydenham's chorea, syncope, synesthesia,syringomyelia, tarsal tunnel syndrome, tardive dyskinesia, tardivedysphrenia, Tarlov cyst, Tay-Sachs disease, temporal arteritis, tetanus,tethered spinal cord syndrome, Thomsen disease, thoracic outletsyndrome, tic douloureux, Todd's paralysis, Tourette syndrome, toxicencephalopathy, transient ischemic attack, transmissible spongiformencephalopathies, transverse myelitis, tremor, trigeminal neuralgia,tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis,ubisiosis, Von Hippel-Lindau disease (VHL), Viliuisk Encephalomyelitis(VE), Wallenberg's syndrome, Werdnig, Hoffman disease, west syndrome,Williams syndrome, Wilson's disease and Zellweger syndrome.

The compounds and compositions may also be useful in the inhibition ofthe development of invasive cancer, tumor angiogenesis and metastasis.

In some embodiment, the invention provides a method for treating adisease or disorder associated with aberrant cellular proliferation byadministering to a patient in need of such treatment an effective amountof one or more of the compounds of Formulas (I) or (II), in combination(simultaneously or sequentially) with at least one other agent.

In some embodiments, the pharmaceutical composition comprises atherapeutically effective amount of a compound of Formulas (I) or (II),or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient.

In some embodiments, the method of treats a disorder or disease in whichaberrant Wnt signaling is implicated in a patient, the method comprisesadministering to the patient a therapeutically effective amount of acompound of Formulas (I) or (II), or a pharmaceutically acceptable saltthereof.

In some embodiments, the disorder or disease is cancer.

In some embodiments, the disorder or disease is diabetic retinopathy.

In some embodiments, the disorder or disease is pulmonary fibrosis.

In some embodiments, the disorder or disease is idiopathic pulmonaryfibrosis (IPF).

In some embodiments, the disorder or disease is rheumatoid arthritis.

In some embodiments, the disorder or disease is scleroderma.

In some embodiments, the disorder or disease is a mycotic or viralinfection.

In some embodiments, the disorder or disease is a bone or cartilagedisease.

In some embodiments, the disorder or disease is Alzheimer's disease.

In some embodiments, the disorder or disease is dementia.

In some embodiments, the disorder or disease is Parkinson's disease.

In some embodiments, the disorder or disease is osteoarthritis.

In some embodiments, the disorder or disease is lung disease

In some embodiments, the disorder or disease is a genetic disease causedby mutations in Wnt signaling components, wherein the genetic disease isselected from: polyposis coli, osteoporosis-pseudoglioma syndrome,familial exudative vitreoretinopathy, retinal angiogenesis, earlycoronary disease, tetra-amelia syndrome, Müllerian-duct regression andvirilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmannsyndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation,caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletaldysplasia, focal dermal hypoplasia, autosomal recessive anonychia,neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile Xsyndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome,Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

In some embodiments, the patient is a human.

In some embodiments, the cancer is chosen from: hepatocellularcarcinoma, colon cancer, breast cancer, pancreatic cancer, chronicmyeloid leukemia (CML), chronic myelomonocytic leukemia, chroniclymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocyticleukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.

In some embodiments, the cancer is chosen from: lung cancer—non-smallcell, lung cancer—small cell, multiple myeloma, nasopharyngeal cancer,neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostatecancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skincancer—basal and squamous cell, skin cancer—melanoma, small intestinecancer, stomach cancers, testicular cancer, thymus cancer, thyroidcancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal orhypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestationaltrophoblastic disease, gastrointestinal stromal tumor, gastrointestinalcarcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma),Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer,cervical cancer, brain or spinal cord tumor, bone metastasis, bonecancer, bladder cancer, bile duct cancer, anal cancer and adrenalcortical cancer.

In some embodiments, the cancer is hepatocellular carcinoma.

In some embodiments, the cancer is colon cancer.

In some embodiments, the cancer is breast cancer.

In some embodiments, the cancer is pancreatic cancer.

In some embodiments, the cancer is chronic myeloid leukemia (CML).

In some embodiments, the cancer is chronic myelomonocytic leukemia.

In some embodiments, the cancer is chronic lymphocytic leukemia (CLL).

In some embodiments, the cancer is acute myeloid leukemia.

In some embodiments, the cancer is acute lymphocytic leukemia.

In some embodiments, the cancer is Hodgkin lymphoma.

In some embodiments, the cancer is lymphoma.

In some embodiments, the cancer is sarcoma.

In some embodiments, the cancer is ovarian cancer.

In some embodiments, the cancer is lung cancer—non-small cell.

In some embodiments, the cancer is lung cancer—small cell.

In some embodiments, the cancer is multiple myeloma.

In some embodiments, the cancer is nasopharyngeal cancer.

In some embodiments, the cancer is neuroblastoma.

In some embodiments, the cancer is osteosarcoma.

In some embodiments, the cancer is penile cancer.

In some embodiments, the cancer is pituitary tumors.

In some embodiments, the cancer is prostate cancer.

In some embodiments, the cancer is retinoblastoma.

In some embodiments, the cancer is rhabdomyosarcoma.

In some embodiments, the cancer is salivary gland cancer.

In some embodiments, the cancer is skin cancer—basal and squamous cell.

In some embodiments, the cancer is skin cancer—melanoma.

In some embodiments, the cancer is small intestine cancer.

In some embodiments, the cancer is stomach cancers.

In some embodiments, the cancer is testicular cancer.

In some embodiments, the cancer is thymus cancer.

In some embodiments, the cancer is thyroid cancer.

In some embodiments, the cancer is uterine sarcoma.

In some embodiments, the cancer is vaginal cancer.

In some embodiments, the cancer is vulvar cancer.

In some embodiments, the cancer is Wilms tumor.

In some embodiments, the cancer is laryngeal or hypopharyngeal cancer.

In some embodiments, the cancer is kidney cancer.

In some embodiments, the cancer is Kaposi sarcoma.

In some embodiments, the cancer is gestational trophoblastic disease.

In some embodiments, the cancer is gastrointestinal stromal tumor.

In some embodiments, the cancer is gastrointestinal carcinoid tumor.

In some embodiments, the cancer is gallbladder cancer.

In some embodiments, the cancer is eye cancer (melanoma and lymphoma).

In some embodiments, the cancer is Ewing tumor.

In some embodiments, the cancer is esophagus cancer.

In some embodiments, the cancer is endometrial cancer.

In some embodiments, the cancer is colorectal cancer.

In some embodiments, the cancer is cervical cancer.

In some embodiments, the cancer is brain or spinal cord tumor.

In some embodiments, the cancer is bone metastasis.

In some embodiments, the cancer is bone cancer.

In some embodiments, the cancer is bladder cancer.

In some embodiments, the cancer is bile duct cancer.

In some embodiments, the cancer is anal cancer.

In some embodiments, the cancer is adrenal cortical cancer.

In some embodiments, the disorder or disease is a neurologicalcondition, disorder or disease, wherein the neurologicalcondition/disorder/disease is selected from: Alzheimer's disease,frontotemporal dementias, dementia with lewy bodies, prion diseases,Parkinson's disease, Huntington's disease, progressive supranuclearpalsy, corticobasal degeneration, multiple system atrophy, amyotrophiclateral sclerosis (ALS), inclusion body myositis, autism, degenerativemyopathies, diabetic neuropathy, other metabolic neuropathies, endocrineneuropathies, orthostatic hypotension, multiple sclerosis andCharcot-Marie-Tooth disease.

In some embodiments, the compound of Formulas (I) or (II) inhibits oneor more proteins in the Wnt pathway.

In some embodiments, the compound of Formulas (I) or (II) inhibitssignaling induced by one or more Wnt proteins.

In some embodiments, the Wnt proteins are chosen from: WNT1, WNT2,WNT2B, WNT3, WNT3A, WNT4. WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A,WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

In some embodiments, the compound of Formulas (I) or (II) inhibits akinase activity.

In some embodiments, the method of treats a disease or disorder mediatedby the Wnt pathway in a patient, the method comprises administering tothe patient a therapeutically effective amount of a compound (orcompounds) of Formulas (I) or (II), or a pharmaceutically acceptablesalt thereof.

In some embodiments, the compound of Formulas (I) or (II) inhibits oneor more Wnt proteins.

In some embodiments, the method of treats a disease or disorder mediatedby kinase activity in a patient, the method comprises administering tothe patient a therapeutically effective amount of a compound (orcompounds) of Formulas (I) or (II), or a pharmaceutically acceptablesalt thereof.

In some embodiments, the disease or disorder comprises tumor growth,cell proliferation, or angiogenesis.

In some embodiments, the method of inhibits the activity of a proteinkinase receptor, the method comprises contacting the receptor with aneffective amount of a compound (or compounds) of Formulas (I) or (II),or a pharmaceutically acceptable salt thereof.

In some embodiments, the method treats a disease or disorder associatedwith aberrant cellular proliferation in a patient; the method comprisesadministering to the patient a therapeutically effective amount of acompound (or compounds) of Formulas (I) or (II), or a pharmaceuticallyacceptable salt thereof.

In some embodiments, the method prevents or reduces angiogenesis in apatient; the method comprises administering to the patient atherapeutically effective amount of a compound (or compounds) ofFormulas (I) or (II), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method prevents or reduces abnormal cellularproliferation in a patient; the method comprises administering to thepatient a therapeutically effective amount of a compound (or compounds)of Formulas (I) or (II), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method of treats a disease or disorderassociated with aberrant cellular proliferation in a patient, the methodcomprising administering to the patient a pharmaceutical compositioncomprising one or more of the compounds of Formulas (I) or (II) incombination with a pharmaceutically acceptable carrier and one or moreother agents

Moreover, the compounds and compositions, for example, as inhibitors ofthe cyclin-dependent kinases (CDKs), can modulate the level of cellularRNA and DNA synthesis and therefore are expected to be useful in thetreatment of viral infections such as HIV, human papilloma virus, herpesvirus, Epstein-Barr virus, adenovirus, Sindbis virus, pox virus and thelike.

Compounds and compositions described herein can inhibit the kinaseactivity of, for example, CDK/cyclin complexes, such as those active inthe G.₀, G.₁ or mitotic stage of the cell cycle, e.g., CDK1, CDK2, CDK4,and/or CDK6 complexes.

Evaluation of Biological Activity

The biological activity of the compounds described herein can be testedusing any suitable assay known to those of skill in the art, e.g., WO2001/053268 or WO 2005/009997. For example, the activity of a compoundmay be tested using one or more of the test methods outlined below.

In one example, tumor cells may be screened for Wnt independent growth.In such a method, tumor cells of interest are contacted with a compound(i.e. inhibitor) of interest, and the proliferation of the cells, e.g.by uptake of tritiated thymidine, is monitored. In some embodiments,tumor cells may be isolated from a candidate patient who has beenscreened for the presence of a cancer that is associated with a mutationin the Wnt signaling pathway. Candidate cancers include, withoutlimitation, those listed above.

In another example, one may utilize in vitro assays for Wnt biologicalactivity, e.g. stabilization of β-catenin and promoting growth of stemcells. Assays for biological activity of Wnt include stabilization ofβ-catenin, which can be measured, for example, by serial dilutions of acandidate inhibitor composition. An exemplary assay for Wnt biologicalactivity contacts a Wnt composition in the presence of a candidateinhibitor with cells, e.g. mouse L cells. The cells are cultured for aperiod of time sufficient to stabilize β-catenin, usually at least about1 hour, and lysed. The cell lysate is resolved by SDS PAGE, thentransferred to nitrocellulose and probed with antibodies specific forβ-catenin.

In a further example, the activity of a candidate compound can bemeasured in a Xenopus secondary axis bioassay (Leyns, L. et al. Cell(1997), 88(6), 747-756).

To further illustrate this invention, the following examples areincluded. The examples should not, of course, be construed asspecifically limiting the invention. Variations of these examples withinthe scope of the claims are within the purview of one skilled in the artand are considered to fall within the scope of the invention asdescribed, and claimed herein. The reader will recognize that theskilled artisan, armed with the present disclosure, and skill in the artis able to prepare and use the invention without exhaustive examples.

EXAMPLES Compound Preparation

The starting materials used in preparing the compounds of the inventionare known, made by known methods, or are commercially available. It willbe apparent to the skilled artisan that methods for preparing precursorsand functionality related to the compounds claimed herein are generallydescribed in the literature. The skilled artisan given the literatureand this disclosure is well equipped to prepare any of the compounds.

It is recognized that the skilled artisan in the art of organicchemistry can readily carry out manipulations without further direction,that is, it is well within the scope and practice of the skilled artisanto carry out these manipulations. These include reduction of carbonylcompounds to their corresponding alcohols, oxidations, acylations,aromatic substitutions, both electrophilic and nucleophilic,etherifications, esterification and saponification and the like. Thesemanipulations are discussed in standard texts such as March's AdvancedOrganic Chemistry: Reactions, Mechanisms, and Structure 7^(th) Ed., JohnWiley & Sons (2013), Carey and Sundberg, Advanced Organic Chemistry5^(th) Ed., Springer (2007), Comprehensive Organic Transformations: AGuide to Functional Group Transformations, 2^(nd) Ed., John Wiley & Sons(1999) (incorporated herein by reference in its entirety) and the like.

The skilled artisan will readily appreciate that certain reactions arebest carried out when other functionality is masked or protected in themolecule, thus avoiding any undesirable side reactions and/or increasingthe yield of the reaction. Often the skilled artisan utilizes protectinggroups to accomplish such increased yields or to avoid the undesiredreactions. These reactions are found in the literature and are also wellwithin the scope of the skilled artisan. Examples of many of thesemanipulations can be found for example in T. Greene and P. WutsProtecting Groups in Organic Synthesis, 4th Ed., John Wiley & Sons(2007), incorporated herein by reference in its entirety.

Trademarks used herein are examples only and reflect illustrativematerials used at the time of the invention. The skilled artisan willrecognize that variations in lot, manufacturing processes, and the like,are expected. Hence the examples, and the trademarks used in them arenon-limiting, and they are not intended to be limiting, but are merelyan illustration of how a skilled artisan may choose to perform one ormore of the embodiments of the invention.

(¹H) nuclear magnetic resonance spectra (NMR) were measured in theindicated solvents on a Bruker NMR spectrometer (Avance™ DRX300, 300 MHzfor ¹H or Avance™ DRX500, 500 MHz for ¹H) or Varian NMR spectrometer(Mercury 400BB, 400 MHz for ¹H). Peak positions are expressed in partsper million (ppm) downfield from tetramethylsilane. The peakmultiplicities are denoted as follows, s, singlet; d, doublet; t,triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep,septet; non, nonet; dd, doublet of doublets; d/ABq, doublet of ABquartet; dt, doublet of triplets; td, triplet of doublets; m, multiplet.

The following abbreviations have the indicated meanings:

-   -   n-BuOH=n-butyl alcohol    -   brine=saturated aqueous sodium chloride    -   CDCl₃=deuterated chloroform    -   CDI=1,1′-carbonyldiimidazole    -   DCE=dichloroethane    -   DCM=dichloromethane    -   DIPEA=diisopropylethylamine    -   DMF=N,N-dimethylformamide    -   DMSO-d₆=deuterated dimethylsulfoxide    -   EDC=1-ethyl-3-(3-dimethylaminopropyl)carbodiimide    -   ESIMS=electron spray mass spectrometry    -   EtOAc=ethyl acetate    -   EtOH=ethanol    -   HCl=hydrochloric acid    -   HOAc=acetic acid    -   H₂SO₄=sulfuric acid    -   K₃CO₄=potassium carbonate    -   KMnO₄=potassium permanganate    -   KOAc=potassium acetate    -   KO^(t)Bu=potassium t-butoxide    -   K₃PO₄=potassium phosphate    -   LDA=lithium diisopropylamide    -   MeOH=methanol    -   MgSO₄=magnesium sulfate    -   NaBH(OAc)₃=sodium triacetoxyborohydride    -   NaCNBH₃=sodium cyanoborohydride    -   NaHCO₃=sodium bicarbonate    -   NaHSO₄=sodium bisulfate    -   NaOAc=sodium acetate    -   NaOCl=sodium hypochlorite    -   NaOH=sodium hydroxide    -   Na₂S₂O₃*7H₂O=sodium thiosulfate pentahydrate    -   NH₄OH=ammonium hydroxide    -   NMR=nuclear magnetic resonance    -   Pd/C=palladium(0) on carbon    -   Pd(dppf)₂Cl₂=1,1′-bis(diphenylphosphino)ferrocene]palladium(II)        chloride    -   Pd(PPh₃)₄=tetrakis(triphenylphosphine)palladium(0)    -   Pd(PPh₃)₂Cl₂=bis(triphenylphosphine)palladium(II) chloride    -   PPTS=pyridinium p-toluenesulfonate    -   r.t.=room temperature    -   S(O)=elemental sulfur    -   TEA=triethylamine    -   TEMPO=(2,2,6,6-Tetramethylpiperidin-1-yl)oxyl or        (2,2,6,6-tetramethyl    -   piperidin-1-yl)oxidanyl    -   TFA=trifluoroacetic acid    -   THF=tetrahydrofuran    -   TLC=thin layer chromatography    -   TrCl=triphenylmethyl chloride or trityl chloride

The following example schemes are provided for the guidance of thereader, and collectively represent an example method for making thecompounds provided herein. Furthermore, other methods for preparingcompounds of the invention will be readily apparent to the person ofordinary skill in the art in light of the following reaction schemes andexamples. The skilled artisan is thoroughly equipped to prepare thesecompounds by those methods given the literature and this disclosure. Thecompound numberings used in the synthetic schemes depicted below aremeant for those specific schemes only, and should not be construed as orconfused with same numberings in other sections of the application.Unless otherwise indicated, all variables are as defined above.

General Procedures

Compounds of Formulas (I) or (II) of the present invention can beprepared as depicted in Scheme 1.

Scheme 1 describes a method for preparation of1H-pyrazolo[3,4-b]pyridine derivatives (VIII) by reacting aldehyde IIIwith various boronic acid derivatives (XII) under Suzuki couplingconditions to give aldehyde V. Aldehyde V is reacted with varioussubstituted and unsubstituted aryl/heteroaryl-3,4-diamines (VI) to formVII. Final deprotection of the pyrazolone nitrogen yields the desired1H-pyrazolo[3,4-b]pyridine derivative (VIII).

Compounds of Formulas (I) or (II) of the present invention can also beprepared as depicted in Scheme 2.

Scheme 2 describes an alternative method for preparation of1H-pyrazolo[3,4-b]pyridine derivatives (VIII) by reacting5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde(III) with bis(pinacolato)diboron to form the borate ester (IX). Suzukicoupling with various bromides (X) or chlorides yields1H-pyrazolo[3,4-b]pyridine derivatives (V). Aldehyde (V) is reacted withvarious 1,2-diamines (VI) to produce (VII). Final deprotection of thepyrazole nitrogen yields the desired 1H-pyrazolo[3,4-b]pyridinederivatives (VIII).

Illustrative Compound Examples

Synthesis of intermediate5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde(III) is depicted below in Scheme 3.

Step 1

A solution of 2-chloropyridine (XI) (9.39 mL, 0.1 mol) in anhydrous THF(50 mL) was added slowly to a solution of LDA (2.0 M solution inTHF/hexane/ethylbenzene, 50 mL, 0.1 mol) in THF (200 mL) stirred at −78°C. under nitrogen. The stirring was continued at −78° C. for anadditional 3 h before adding acetaldehyde (6.17 mL, 0.110 mol). Thesolution was stirred at −78° C. for another 2 h before allowing thetemperature to rise to −40° C. A solution of water (4 mL) in THF (40 mL)was added slowly to the solution. When the temperature reached −10° C.,additional water (200 mL) was added to the solution. The solution wasextracted with ethyl ether (3×100 mL). The combined organic phase wasdried over MgSO₄, filtered and evaporated under reduced pressure to geta brown viscous residue. The crude product was purified on a flashsilica gel column (1:1 DCM:hexane→100% DCM) to produce1-(2-chloropyridin-3-yl)ethanol (XII) as a brown viscous oil (6 g, 38.1mmol, 38% yield). ¹H NMR (CDCl₃) δ ppm 1.52 (d, J=6.41 Hz, 3H), 2.51(brs, 1H), 5.24 (m, 1H), 7.28 (m, 1H), 7.97 (dd, J=7.72 Hz, J=1.70 Hz,1H), 8.27 (dd, J=7.72 Hz, J=1.79 Hz, 1H).

Step 2

To a solution of 1-(2-chloropyridin-3-yl)ethanol (XII) in dry acetone at−30° C. under nitrogen was added in portions chromium (VI) oxide (1.80g, 18 mmol). The solution was further stirred 15 min at −30° C. andallowed to warm to room temperature. The solution was stirred for 3 h atroom temperature before adding isopropanol (10 mL). The solution wasmade alkaline by slowly adding a saturated aqueous NaHCO₃ solution. Thesolution was filtered through a bed of Celite. The solids were washed byDCM. The organic phase of the filtrate was separated and the aqueousphase extracted with DCM (2×50 mL). The combined organic layers weredried over MgSO₄, filtered and concentrated under reduced pressure toyield 1-(2-chloropyridin-3-yl)ethanone (XIII) as a brown liquid (0.72 g,4.63 mmol, 77% yield). ¹H NMR (CDCl₃) δ ppm 2.71 (s, 3H), 7.35 (dd,J=7.63 Hz, J=4.80 Hz, 1H), 7.91 (dd, J=7.54 Hz, J=1.88 Hz, 1H), 8.55(dd, J=4.71 Hz, J=1.88 Hz, 1H).

Step 3

To a solution of 1-(2-Chloropyridin-3-yl)ethanone (XIII) (0.311 g, 2mmol) in n-butanol (10 mL) was added hydrazine hydrate (1.45 mL, 30mmol). The reaction was refluxed overnight. The solution was cooled andthe solvent was evaporated under vacuum. The residue was dissolved inDCM and washed successively by water and brine. The organic layers weredried over MgSO₄, filtered and concentrated under reduced pressure togive 3-methyl-1H-pyrazolo[3,4-b]pyridine (XIV) as a white solid (192 mg,1.44 mmol, 72% yield). ¹H NMR (CDCl₃) δ ppm 2.64 (s, 3H), 7.14 (dd,J=8.01 Hz, J=4.62 Hz, 1H), 8.14 (dd, J=7.54 Hz, J=1.88 Hz, 1H), 8.59(dd, J=4.52 Hz, J=1.32 Hz, 1H), 11.68 (brs, 1H).

Step 4

To a solution of NaOH (0.88 g, 22 mmol) in water (20 mL) was added3-methyl-1H-pyrazolo[3,4-b]pyridine (XIV) (0.4 g, 3 mmol). Thesuspension was heated at 80° C. until a clear solution was obtained. Asolution of KMnO₄ (1.73 g, 11 mmol) in water (180 mL) was added slowlyover 2 h while heating the solution at 80° C. The solution was heated at90° C. for an additional 2 h until the complete disappearance ofstarting material was observed by TLC. The solution was cooled to 70° C.and filtered through a pad of Celite. The solids were washed by boilingwater. The combined filtrate was cooled to 0° C., acidified with conc.H₂SO₄ to pH=2 and extracted with n-butanol (2×10 mL). The n-butanollayer was concentrated under reduced pressure to get a white residuewhich was dissolved in DCM by adding minimum amount of MeOH and thenfiltered. The filtrate was concentrated to give1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid (XV) as a white solid (390mg, 2.39 mmol, 81% yield). ¹H NMR (CDCl₃) δ ppm 7.37 (dd, J=8.10 Hz,J=4.52 Hz, 1H), 8.47 (dd, J=7.54 Hz, J=1.88 Hz, 1H), 8.62 (dd, J=4.52Hz, J=1.32 Hz, 1H), 14.37 (brs, 1H).

Step 5

To a solution of 1H-pyrazole[3,4-b]pyridine-3-carboxylic acid (XV) (0.39g, 2.4 mmol) in dry MeOH (10 mL) was added concentrated H₂SO₄ (4 drops)and refluxed for 6 h under nitrogen. The solution was cooled and thesolvent was evaporated under vacuum. The residue was partitioned betweenDCM and saturated aqueous NaHCO₃ solution. The organic layer wasseparated, dried over MgSO₄, filtered and concentrated under reducedpressure. The crude product was purified on a flash silica gel column(100% DCM→3:97 MeOH:DCM) to produce methyl1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XVI) as a white solid (382 mg,2.16 mmol, 90% yield). ¹H NMR (CDCl₃) δ ppm 4.08 (s, 3H), 7.38 (m, 1H),8.63 (dd, J=8.10 Hz, J=1.51 Hz, 1H), 8.72 (dd, J=4.62 Hz, J=1.41 Hz,1H); ESIMS found for C₈H₇N₃O₂ m/z 178.2 (M+H).

Step 6

A mixture of methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XVI)(0.177 g, 1 mmol), sodium acetate (0.492 g, 6 mmol) and bromine (0.308mL, 6 mmol) in glacial acetic acid (5 mL) was heated overnight at 120°C. in a sealed tube. The solution was cooled and poured into water. Thesolids formed were filtered, washed with water and dried at roomtemperature under vacuum. The crude product was purified on a flashsilica gel column (100% DCM→2:98 MeOH:DCM) to produce methyl5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XVII) as a white solid(78 mg, 0.31 mmol, 30% yield). ¹H NMR (CDCl₃) δ ppm 3.95 (s, 3H), 8.62(d, J=3.01 Hz, 1H), 8.73 (d, J=3.01 Hz, 1H); ESIMS found for C₈H₆BrN₃O₂m/z 256.3 (M+H).

Step 7

A suspension of methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate(XVII) (70 mg, 0.27 mmol) in aqueous 1N NaOH solution (20 mL) was heatedat 90° C. for 3 h until the solution became clear. The solution was thencooled to 0° C. and acidified with a 10% HCl solution. The solids formedwere filtered, washed with cold water and dried at room temperatureunder vacuum to give 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylicacid (XVIII) as a white solid (60 mg, 0.25 mmol, 92% yield). ¹H NMR(CDCl₃) δ ppm 8.58 (d, J=3.01 Hz, 1H), 8.66 (d, J=3.01 Hz, 1H); ESIMSfound for C₇H₄BrN₃O₂ m/z 242.1 (M+H).

Step 8

To a solution of 5-bromo-1H-pyrazole[3,4-b]pyridine-3-carboxylic acid(XVIII) (0.242 g, 1 mmol) in dry DMF (5 mL) was added CDI (0.178 g, 1.1mmol) and heated for 3 h at 65° C. under nitrogen. The solution wascooled to room temperature and N,O-dimethyl hydroxylamine hydrochloride(0.107 g, 1.1 mmol) was added to the solution. The solution was againheated for 3 h at 65° C. under nitrogen. The solution was cooled and thesolvent was evaporated under reduced pressure. The residue was dissolvedin DCM, washed successively with a 10% HCl solution, a saturated aqueousNaHCO₃ solution and brine. The organic phase was dried over MgSO₄,filtered and concentrated under reduced pressure to produce5-bromo-N-methoxy-N-methyl-1H-pyrazolo[3,4-b]pyridine-3-carboxamide(XIX) as a white solid (260 mg, 0.91 mmol, 92% yield). ¹H NMR (CDCl₃) δppm 3.55 (s, 3H), 3.78 (s, 3H), 8.59 (d, J=3.01 Hz, 1H), 8.67 (d, J=3.01Hz, 1H); ESIMS found for C₉H₉BrN₄O₂ m/z 285.4 (M+H).

Step 9

To a solution of5-bromo-N-methoxy-N-methyl-1H-pyrazolo[3,4-b]pyridine-3-carboxamide(XIX) (0.250 g, 0.88 mmol) in dry DCM (10 mL) was added3,4-dihydro-2H-pyran (0.179 mL, 1.98 mmol) and PPTS (22 mg, 0.08 mmol)and refluxed 5 h under nitrogen. Another equivalent of3,4-dihydro-2H-pyran (0.179 mL, 1.98 mmol) and PPTS (22 mg, 0.08 mmol)was added and the solution was further heated at refluxed overnightunder nitrogen. The solution was cooled, diluted with DCM, washedsubsequently with a saturated aqueous NaHCO₃ solution and brine. Theorganic layer was dried over MgSO₄, filtered and concentrated underreduced pressure to give5-bromo-N-methoxy-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide(XX) as a viscous liquid (302 mg, 0.82 mmol, 93% yield). ¹H NMR (CDCl₃)δ ppm 1.51-1.62 (m, 2H), 1.91-2.13 (m, 2H), 2.33-2.44 (m, 2H), 3.40 (s,3H), 3.66 (m, 1H), 3.75 (s, 3H), 3.87-3.98 (m, 1H), 6.07 (dd, J=10.07Hz, J=2.52 Hz, 1H), 8.57 (d, J=3.01 Hz, 1H), 8.73 (d, J=3.01 Hz, 1H);ESIMS found for C₁₄H₁₇BrN₄O₃ m/z 369.4 (M+H).

Step 10

To a solution of5-bromo-N-methoxy-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide(XX) (0.290 g, 0.78) in dry THF (5 mL) stirred at 0° C. under nitrogenwas added lithium aluminum hydride (36 mg, 0.94 mmol). The solution wasfurther stirred at 0° C. for 30 min. The reaction was quenched with a0.4 N NaHSO₄ solution (10 mL). The solution was extracted with DCM (3×15mL). The combined organic layer was washed subsequently with water andbrine. The organic layer was dried over MgSO₄, filtered and concentratedunder reduced pressure to produce5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde(III) as a viscous liquid (218 mg, 0.70 mmol, 91% yield). ¹H NMR (CDCl₃)δ ppm 1.52-1.74 (m, 2H), 1.95-2.18 (m, 2H), 2.37-2.49 (m, 2H) 3.87-3.98(m, 1H), 3.99 (m, 1H), 6.18 (dd, J=10.20 Hz, J=2.39 Hz, 1H), 8.73 (d,J=3.01 Hz, 1H), 8.85 (d, J=3.01 Hz, 1H), 10.16 (s, 1H); ESIMS found forC₁₂H₁₂BrN₃O₂ m/z 310.4 (M+H).

Synthesis of intermediate5-bromo-1-trityl-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (XI) isdepicted below in Scheme 4.

To a solution of 2-chloropyridine (XI) (31.0 kg, 273 mol) in dry THF(275 L) cooled to −78° C. under nitrogen was added LDA (113 L, 1220 mol)dropwise while maintaining the temperature at −78° C. and stirred for 5hours. Acetaldehyde (16 L, 463 mol) was then added and the reaction wasstirred at −78° C. for another 5 hours before warming to 0° C. andadding water (310 L) to quench the reaction. The solution was stirredfor 50 min and then warmed to room temperature. The solution wasextracted 3×EtOAc (279 L) by adding EtOAc, stirring for 50 min, allowingto stand for 50 min, separating the layers and then repeating twice. Thecombined EtOAc was concentrated under vacuum to a volume of 300-500 L.To the crude 1-(2-chloropyridin-3-yl)ethanol (XII) was added DCM (705 L)followed by an aqueous solution of KBr (3.3 Kg, 27.7 mol) dissolved inwater (33 L). The solution was cooled to 0° C. before adding TEMPO (1.7Kg, 10.9 mol) and then stirred for 50 min. In a second container, water(980 L) was added followed by KHCO₃ (268 Kg, 2677 mol) and 10% aqueousNaClO (233 L, 313 mol). This aqueous mixture was then added dropwise tothe TEMPO mixture. This combined mixture was stirred at 0° C. for 5hours. To this mixture was added dropwise Na₂S₂O₃*7H₂O (22.5 Kg, 90 mol)in water (107 L) with stirring for 50 min at 0° C. The mixture wasallowed to warm to room temperature and the organic phase was separated.The aqueous phase was extracted 2×DCM (353 L) by adding DCM, stirringfor 50 min, allowing to stand for 50 min, separating the layers and thenrepeating. The combined organic layers were washed with aqueous 25% NaCl(274 L) and concentrated under vacuum to give crude1-(2-chloropyridin-3-yl)ethanone (XIII) which was used for the next stepwithout additional purification.

Step 3

To a solution of the above crude 1-(2-chloropyridin-3-yl)ethanone (XIII)in n-BuOH (512 L) was added 85% hydrazine hydrate (78 L, 1360 mol). Thereaction was heated at refluxed (˜120° C.) for 48 hours. The reactionwas cooled and evaporated under vacuum. The crude material was taken upin DCM (834 L) and washed with 2× aqueous 25% NaCl (214 L) by addingaqueous 25% NaCl, stirring for 50 min, allowing to stand for 50 min,separating the layers and then repeating. The organic layer wasevaporated to produce 3-methyl-1H-pyrazolo[3,4-b]pyridine (XIV) as asolid (13.2 Kg, 99 mol, 94.1% purity, 36.3% assay yield for 3 steps). ¹HNMR (DMSO-d₆, 400 MHz) δ ppm 2.50 (s, 3H), 7.13 (dd, J=4.4 Hz, J=8 Hz,1H), 8.19 (dd, J=1.2 Hz, J=8 Hz, 1H), 8.47 (dd, J=1.6 Hz, J=4.8 Hz, 1H),13.18 (brs, 1H); ESIMS found C₇H₇N₃ m/z 133.8 (M+H).

Step 4

To a solution of 3-methyl-1H-pyrazolo[3,4-b]pyridine (XIV) (12.7 Kg,95.4 mol) in HOAc (57 L) was added NaOAc (20.4 Kg, 248 mol), water (13.3L), and Br₂ (40 L, 780 mol). The reaction was stirred at roomtemperature for 5 hours and then at 115° C. for 6 hours. The reactionwas cooled to room temperature and diluted with DCM (686 L). To thissolution was added water (508 L) and cooled to 0° C. followed bydropwise addition of aqueous 30% NaOH while maintaining the temperature<20° C. under pH=9. The mixture was filtered through diatomaceous earth(14 Kg) followed by washing the diatomaceous earth with 3×DCM (50 L).The organic layer was separated, washed with aqueous 25% NaCl (200 L)and concentrated under vacuum to a volume of 70 L. The product wascrystallized by charging the solution with 3× n-heptane (88 L) whileconcentrating the volume to 70 L after each addition of n-heptane. Thesolid was filtered and washed 3× n-heptane (22 L). The solid was driedunder vacuum at 45° C. to yield5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine (XXI) (9.8 Kg, 46.2 mol,92.6% purity, 48.4% assay yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.48(s, 3H), 8.50-8.55 (m, 2H), 13.42 (brs, 1H); ESIMS found C₇H₆BrN₃ m/z213.7 (M+H).

Step 5

To a solution of NaOH (27 Kg, 675 mol) in water (617 L) was added5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine (XXI) (9.8 Kg, 46.2 mol).The solution was heated at 90° C. for 3 hours under nitrogen beforeadding a solution of KMnO₄ (53.6 Kg, 339 mol) in water (870 L) slowlyover 2 hours. The reaction was heated at 95° C. for 5 hours undernitrogen. The solution was cooled to 75° C. and filtered throughdiatomaceous earth (11 Kg) followed by washing the diatomaceous earthwith water (150 L) heated at 75° C. The solution was cooled to 0° C.under nitrogen before the pH was adjusted to 1 with aqueous 35% HCl (˜75L). The solution was warmed to room temperature before adding n-BuOH(473 L) which was stirred for 25 min and then the organic layer wasseparated. n-BuOH (473 L) was again added to the aqueous layer, stirredfor 25 min and separated. The combined organic phases were concentratedunder vacuum to a volume of ˜54 L. The n-BuOH was removed by adding tothe solution 9× n-heptane (78 L) dropwise over 1 hour and thenconcentrating the volume to ˜54 L after each addition of n-heptane. Thesolid was filtered and washed 3× n-heptane (17 L). The solid was driedunder vacuum at 45° C. to give5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid (XVIII) (3.2 Kg,13.2 mol, 64.4% purity, 29.0% assay yield). ¹H NMR (DMSO-d₆, 400 MHz) δppm 8.57 (d, J=2.4 Hz, 1H), 8.71 (d, J=2 Hz, 1H), 13.45 (brs, 1H), 14.65(s, 1H); ESIMS found C₇H₄BrN₃O₂ m/z 243.8 (M+H).

Step 6

To a solution of 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid(XVIII) (1.6 Kg, 6.6 mol) in anhydrous MeOH (32 L) was added H₂SO₄ (160mL). The reaction was slowly heated to 70° C. and stirred for 20 hours.The solution was concentrated under vacuum to a volume of 1.6 L. Theresidue was partitioned between DCM (120 L) and aqueous 10% NaHCO₃ (32L). The organic phase was separated and washed with aqueous 25% NaCl (32L), dried over Na₂SO₄ and concentrated to a volume of 4.8 L. The productwas crystallized by charging the solution with 3× n-heptane (8 L) whileconcentrating the volume to 4.8 L after each addition of n-heptane. Thesolid was filtered and dried under vacuum at 50° C. to produce methyl5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XVII) (1.53 Kg, 6.0mol, 80.6% purity, 90.4% assay yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm3.95 (s, 3H), 8.62 (d, J=2 Hz, 1H), 8.73 (d, J=2.4 Hz, 1H), 14.78 (brs,1H); ESIMS found C₈H₆BrN₃O₂ m/z 256.0 (M+H).

Step 7

To a solution of methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate(XVII) (2.92 Kg, 11.4 mol) in anhydrous DCM (88 L) was added TEA (2.38L, 17.1 mol). The solution was cooled to 0° C. before adding dropwise asolution of TrCl (4.0 Kg, 14.3 mol) in anhydrous DCM (51 L). Thesolution was warmed to room temperature and stirred for 20 hours. Thereaction was then washed once with water (29 L), once with aqueous 25%NaCl (29 L), dried over Na₂SO₄ and concentrated to a volume of 3.0 L togive methyl 5-bromo-1-trityl-1H-pyrazolo[3,4-b]pyridine-3-carboxylate(XXII) (5.69 Kg, 11.4 mol, 77.3% purity, 99.5% assay yield). ¹H NMR(DMSO-d₆, 400 MHz) δ ppm 3.91 (s, 3H), 7.19 (d, J=8.4 Hz, 5H), 7.21-7.32(m, 10H), 8.45 (d, J=2.4 Hz, 1H), 8.61 (d, J=2 Hz, 1H); ESIMS foundC₂₇H₂₀BrN₃O₂ m/z 520.0 (M+Na).

Step 8

To a solution of methyl5-bromo-1-trityl-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (XXII) (4.16Kg, 8.3 mol) in anhydrous THF (62 L) cooled to 10° C. was addedanhydrous EtOH (0.97 L, 16.6 mol) and LiBH₄ (271 g, 12.5 mol). Thereaction was warmed to room temperature and stirred for 24 hours. Thesolution was concentrated under vacuum to a volume of 4 L then taken upin DCM (80 L). The pH was then adjusted to 8.0 by dropwise addition ofaqueous 0.4N HCl (˜280 L). The organic layer was separated and washedwith aqueous 25% NaCl (28 L) and then concentrated under vacuum to avolume of 4 L to produce(5-bromo-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)methanol (XXIII) (3.9Kg, 8.3 mol, 82.3% purity, 100% assay yield). ¹H NMR (DMSO-d₆, 400 MHz)δ ppm 4.70 (d, J=6 Hz, 2H), 5.49 (t, J=6 Hz, 1H), 7.19 (d, J=7.2 Hz,5H), 7.20-7.35 (m, 10H), 8.31 (d, J=2.4 Hz, 1H), 8.51 (d, J=2.4 Hz, 1H);ESIMS found C₂₆H₂₀BrN₃O m/z 492.0 (M+Na).

Step 9

To a solution of(5-bromo-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)methanol (XXIII) (4.05Kg, 8.6 mol) in DCM (97 L) was added a solution of KBr (205 g, 1.72 mol)in water (4 L). The solution was cooled to 0° C. before adding TEMPO(107.5 g, 688 mmol) and stirring for 30 min. To this solution was addeda solution of KHCO₃ (10.8 Kg, 107.4 mol) and aqueous 7% NaClO (13.4 L)in water (40 L). The reaction was stirred at 0° C. for 18 hours. Asolution of Na₂S₂O₃*5H₂O (1.4 Kg, 5.7 mol) in water (9.1 L) was addeddropwise to the reaction at 0° C. and stirred for 30 min. The aqueouslayer was then separated and washed with DCM (48 L). The combinedorganic phases were washed with aqueous 25% NaCl (48 L), dried overNa₂SO₄, filtered and concentrated under vacuum. The residue wasco-evaporated with 3×MeOH (20 L) and the solid was washed with 2×n-heptane (8 L). The solid was dried under vacuum at 45° C. to give5-bromo-1-trityl-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (XXIV) (3.25Kg, 6.94 mol, 92.3% purity, 80.6% assay yield). ¹H NMR (CDCl₃, 400 MHz)δ ppm 7.19 (d, J=6 Hz, 5H), 7.22-7.34 (m, 10H), 8.28 (d, J=2.4 Hz, 1H),8.70 (d, J=2.4 Hz, 1H), 10.07 (s, 1H); ESIMS found C₂₆H₁₈BrN₃O m/z 490.0(M+Na).

Preparation of intermediateN-(5-bromopyridin-3-yl)-2,2,2-trifluoroacetamide (XXVI) is depictedbelow in Scheme 5.

Step 1

To a solution of 5-bromopyridin-3-amine (XXV) (1.0 g, 5.78 mmol) in dryTHF (20 mL) under argon was added TEA (0.826 mL, 6.35 mmol) and dropwisetrifluoroacetic anhydride (0.902 mL, 6.35 mmol). The solution wasstirred at room temperature for 3 h. The reaction was poured into icewater, basified by saturated aqueous NaHCO₃, and then extracted withEtOAc. The combined organic phases were dried over MgSO₄, concentratedand concentrated under vacuum to yieldN-(5-bromopyridin-3-yl)-2,2,2-trifluoroacetamide (XXVI) as an off-whitesolid (1.5 g, 5.60 mmol, 96% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm8.36 (t, J=2 Hz, 1H), 8.58 (d, J=2 Hz, 1H), 8.81 (d, J=2 Hz, 1H), 11.57,(brs, 1H); ESIMS found C₇H₄BrF₃N₂O m/z 269.0 (M+H).

The following intermediate was prepared in accordance with the proceduredescribed in the above Scheme 5.

tert-Butyl 5-bromopyridin-3-ylcarbamate (XXVII): Brown viscous oil (421mg, 1.54 mmol, 23% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.48 (s, 9H),8.17-8.18 (m, 1H), 8.29 (d, J=2 Hz, 1H), 8.56 (d, J=2 Hz, 1H), 9.82 (s,1H); ESIMS found C₁₀H₁₃BrN₂O₂ m/z 273 (M+H).

Preparation of intermediate N-(5-bromopyridin-3-yl)pivalamide (XXIX) isdepicted below in Scheme 6.

To a solution of 3-amino-5-bromo pyridine (XXV) (1.0 g, 5.78 mmol) indry pyridine (10 mL) was added pivaloyl chloride (XXVIII) (769 mg, 6.38mmol). The reaction mixture was stirred at room temperature for 3 h. Thereaction was poured into an ice water/saturated aqueous NaHCO₃ mixtureand stirred for 30 min. The precipitate was filtered, washed with coldwater and dried at room temperature to yieldN-(5-bromopyridin-3-yl)pivalamide (XXIX) as an off-white solid (1.082 g,4.22 mmol, 73.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.23 (s, 9H),8.37 (d, J=2 Hz, 1H), 8.39 (t, J=2 Hz, 1H), 8.80 (d, J=2 Hz, 1H), 9.58(brs, 1H); ESIMS found C₁₀H₁₃BrN₂O m/z 257.0 (M+H).

The following intermediates were prepared in accordance with theprocedure described in the above Scheme 6.

N-(5-Bromopyridin-3-yl)isobutyramide (XXX): Off-white solid, (71%yield). ¹H NMR (CDCl₃) δ ppm 8.55-8.35 (m, 3H), 7.32 (s, 1H), 2.59-2.48(m, 1H), 1.28-1.27 (d, 6H); ESIMS found C₉H₁₁BrN₂O m/z 243.05 (M+H).

N-(5-Bromopyridin-3-yl)propionamide (XXXI): Off white solid (92% yield).¹H NMR (DMSO-d₆) δ ppm 1.09 (t, J=7.54 Hz, 3H), 2.36 (q, J=7.54 Hz, 2H),8.36 (m, 2H), 8.65 (d, J=2.07 Hz, 1H), 10.26 (s, 1H); ESIMS foundC₈H₉BrN₂O m/z 231 (M+H).

N-(5-Bromopyridin-3-yl)butyramide (XXXII): Yellow solid (2.1 g, 8.64mmol, 88.8% yield). ESIMS found C₉H₁₁BrN₂O m/z 243 (M+H).

N-(5-Bromopyridin-3-yl)pentanamide (XXXIII): Yellow solid (2.0 g, 7.78mmol, 85.3% yield). ESIMS found C₁₀H₁₃BrN₂O m/z 257 (M+H).

N-(5-Bromopyridin-3-yl)-3-methylbutanamide (XXXIV): Off white solid,(67% yield), ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.55-8.42 (m, 3H), 7.62 (s,1H), 2.31-2.18 (m, 3H), 1.02-1.01 (d, J=6 Hz, 6H); ESIMS foundC₁₀H₁₃BrN₂O m/z 258.80 (M+H).

N-(5-Bromopyridin-3-yl)-3,3-dimethylbutanamide (XXXV): Yellow solid (1.7g, 6.27 mmol, 78.6% yield). ESIMS found C₁₁H₁₅BrN₂O m/z 271 (M+H).

N-(5-Bromopyridin-3-yl)-2-phenylacetamide (XXXVI): White solid (2.5 g,8.59 mmol, 77.9% yield). ESIMS found C₁₃H₁₁BrN₂O m/z 291 (M+H).

N-(5-Bromopyridin-3-yl)benzamide (XXXVII): White solid (2.7 g, 9.74mmol, 60% yield). ESIMS found C₁₂H₉BrN₂O m/z 277 (M+H).

N-(5-Bromopyridin-3-yl)cyclopropanecarboxamide (XXXVIII): Off-whitesolid, (83% yield), ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.46-8.39 (m, 3H),7.54 (bs, 1H), 1.56-1.50 (m, 1H), 1.13-1.07 (m, 2H), 0.96-0.90 (m, 2H);ESIMS found for C₉H₉BrN₂O m/z 240.9 (M+H).

N-(5-Bromopyridin-3-yl)cyclobutanecarboxamide (XXXIX): Yellow solid (2.1g, 6.27 mmol, 86.6% yield). ESIMS found C₁₀H₁₁BrN₂O m/z 255 (M+H).

N-(5-Bromopyridin-3-yl)cyclopentanecarboxamide (XL): Yellow solid (1.9g, 7.06 mmol, 80.2% yield). ESIMS found C₁₁H₁₃BrN₂O m/z 269 (M+H).

N-(5-bromopyridin-3-yl)cyclohexanecarboxamide (XLI): Yellow solid (2.0g, 7.06 mmol, 84.3% yield). ESIMS found C₁₂H₁₅BrN₂O m/z 283 (M+H).

Preparation of intermediate 5-bromo-N,N-dimethylpyridin-3-amine (XLIII)is depicted below in Scheme 7.

Step 1

To a solution of 3,5-dibromopyridine (XLII) (2.37 g, 10.0 mmol) in dryDMF (20.0 mL) was added K₂CO₃ (4.5 g, 33 mmol) and dimethylaminohydrochloride (1.79 g, 22 mmol). The mixture was heated overnight at200° C. in a sealed tube. The solution was cooled to room temperatureand excess DMF was removed under vacuum. The residue was partitionedbetween EtOAc and water. The organic phase was separated. The aqueousphase was washed with EtOAc and the combined organic phases were driedover MgSO₄, and concentrated to afford5-bromo-N,N-dimethylpyridin-3-amine (XLIII) as an off-white solid (1.78g, 8.85 mmol, 88% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.94 (s, 6H),7.25 (t, J=2 Hz, 1H), 7.91 (d, J=2 Hz, 1H), 8.07 (d, J=2 Hz, 1H); ESIMSfound C₇H₉BrN₂ m/z 201.1 (M+H).

The following intermediates were prepared in accordance with theprocedure described in the above Scheme 7.

N¹-(5-bromopyridin-3-yl)-N²,N²-dimethylethane-1,2-diamine (XLIV): Brownviscous oil (326 mg, 1.33 mmol, 14% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 2.17 (s, 6H), 2.42 (t, J=6.4 Hz, 2H), 3.08-3.12 (m, 2H), 6.03 (t,J=5.2 Hz, 1H), 7.12-7.13 (m, 1H), 7.78 (d, J=2 Hz, 1H), 7.97 (d, J=2 Hz,1H); ESIMS found C₉H₁₄BrN₃ m/z 244 (M+H).

1-(5-bromopyridin-3-yl)-4-methylpiperazine (XLV): Brown viscous oil (815mg, 3.18 mmol, 28% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.21 (s, 3H),2.41-2.43 (m, 4H), 3.22-3.24 (m, 4H), 7.51-7.52 (m, 1H), 8.02 (d, J=2Hz, 1H), 8.28 (d, J=2 Hz, 1H); ESIMS found C₁₀H₁₄BrN₃ m/z 256 (M+H).

Preparation of intermediate 5-bromo-N-isopropylpyridin-3-amine (XLVI) isdepicted below in Scheme 8.

Steps 1

To a solution of 5-bromopyridin-3-amine (XXV) (535 mg, 3.09 mmol) inMeOH (62 mL) was added acetone (296 μL, 4.02 mL). The pH was adjusted to4 using HOAc and stirred for 30 min. NaCNBH₃ (272 mg, 4.33 mmol) wasadded and stirred at room temperature overnight. The MeOH was removedunder vacuum and the residue was partitioned between EtOAc and saturatedaqueous NaHCO₃. The organic layer was dried over MgSO₄ and evaporatedunder vacuum. The crude product was purified on a silica gel column(100% hexane→90:10 hexane:EtOAc) to produce5-bromo-N-isopropylpyridin-3-amine (XLVI) as an oil which slowlysolidified into an off-white solid (309 mg, 1.44 mmol, 47% yield). ¹HNMR (DMSO-d₆, 500 MHz) δ ppm 1.12 (d, J=6.3 Hz, 6H), 3.55-3.59 (m, 1H),6.03 (d, J=7.9 Hz, 1H), 7.05-7.06 (m, 1H), 7.75 (d, J=2 Hz, 1H), 7.90(d, J=2 Hz, 1H); ESIMS found C₈H₁₁BrN₂ m/z 215 (M+H).

Preparation of intermediate1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (XLVIII) is depictedbelow in Scheme 9.

Steps 1

Preparation of 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (XLVIII)was performed following the procedure listed in Scheme 6, Step 1. Brownoil (1.20 g, 5.59 mmol, 45% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.15(s, 6H), 3.43 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=1.1 Hz, 1H), 8.59 (d,J=2.2 Hz, 1H); ESIMS found C₈H₁₁BrN₂ m/z 215 (M^(Br79)+H) and 217(M^(Br81)+H).

Preparation of intermediate N-(3-bromo-5-fluorobenzyl)methanesulfonamide (L) is depicted below in Scheme 10.

Steps 1

Preparation of 3-bromo-5-fluorobenzaldehyde (XLIX) (2.03 g, 10.0 mmol)in DCE (50 mL) was added methanesulfonamide (1.43 g, 15.0 mmol) and TEA(2.79 mL, 20.0 mmol). The solution was stirred for a few minutes beforeNaBH(OAc)₃ (3.00 g, 14.1 mmol) was added. The reaction was stirred atroom temperature overnight. The solvent was removed under vacuum and theresidue was partitioned between EtOAc and water. The organic layer wasseparated, dried over MgSO₄ and evaporated under vacuum to giveN-(3-bromo-5-fluorobenzyl)methanesulfonamide (L) as a clear oil (2.65 g,9.39 mmol, 99% yield). ESIMS found C₈H₉BrFNO₂S m/z 282 (M+H).

The following intermediates were prepared in accordance with theprocedure described in the above Scheme 9 or Scheme 10.

3-Bromo-5-(pyrrolidin-1-ylmethyl)pyridine (LI): Golden liquid (1.35 g,97% yield). ¹H NMR (DMSO-d₆) 1.68-1.71 (m, 4H), 2.42-2.44 (m, 4H), 3.60(s, 2H), 7.96 (s, 1H), 8.48 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMSfound for C₁₀H₁₃BrN₂ m/z 242 (M+H).

3-Bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridine (LII): Brown oil(6.4 g, 81% yield). ESIMS found for C₁₀H₁₁BrF₂N₂ m/z 277.0 (M+H).

3-Bromo-5-(piperidin-1-ylmethyl)pyridine (LIII): Brown liquid (13.1 g,94% yield). ¹H NMR (DMSO-d₆) 1.36-1.39 (m, 2H), 1.46-1.51 (m, 4H),2.31-2.32 (m, 4H), 3.46 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=2 Hz, 1H),8.58 (d, J=3 Hz, 1H); ESIMS found for C₁₁H₁₅BrN₂ m/z 257 (M+H).

N-((5-Bromopyridin-3-yl)methyl)ethanamine (LIV): Golden liquid (1.29 g,6.00 mmol, 60% yield). ESIMS found for C₈H₁₁BrN₂ m/z 215 (M+H).

N-Benzyl-1-(5-bromopyridin-3-yl)methanamine (LV): Golden liquid (77 mg,0.28 mmol, 25% yield). ESIMS found for C₁₃H₁₃BrN₂ m/z 277 (M+H).

Preparation of intermediate tert-butyl (5-bromopyridin-3-yl)methyl(cyclopentylmethyl)carbamate (LX) is depicted below in Scheme 11.

Step 1

To a solution of 5-bromonicotinaldehyde (XLVII) (2.0 g, 10.8 mmol, 1 eq)in MeOH (20 mL) was added NaBH₄ (2.4 g, 64.9 mmol, 6 eq) and thereaction mixture was stirred at room temperature for 3 h. The mixturewas concentrated in vacuo and the residue was diluted in water (15 mL),the aqueous phase was extracted with DCM (10 mL×3). The combined organiclayers were dried over MgSO₄, filtered and concentrated in vacuo toafford (5-bromopyridin-3-yl)methanol (LVI) (1.8 g, 9.57 mmol, 90.0%yield) as a colorless oil. ¹H NMR (CDCl₃, 500 MHz) δ ppm 4.73 (s, 2H),7.90 (s, 1H), 8.47 (s, 1H), 8.57 (s, 1H). ESIMS found for C₆H₆BrNO m/z188 (M+H).

Step 2

To a stirred solution of (5-bromopyridin-3-yl)methanol (LVI) (1.60 g,8.5 mmol, 1 eq), phthalimide (1.24 g, 8.5 mmol, 1 eq) and PPh₃ (3.33 g,12.75 mmol, 1.5 eq) in anhydrous THF (15 mL) was added DEAD (2.21 g,12.75 mmol, 1.5 eq) dropwise at 0° C. under N₂. Then the reactionmixture was stirred at room temperature for 6 h. The mixture was washedwith saturated NaHCO₃ solution (15 mL), water (15 mL) and brine (15 mL)subsequently. The organic layers were dried over MgSO₄, concentratedunder reduced pressure, the resultant residue was purified by flashchromatography on silica gel (PE:EtOAc=4:1) to give2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (LVII) (2.5 g, 7.88mmol, 82.3% yield) as a white solid. ESIMS found for C₁₄H₉BrN₂O₂ m/z 317(M+H).

Step 3

A solution of 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione(LVII) (1.9 g, 6.0 mmol, 1 eq) and hydrazine hydrate (2.0 g, 40 mmol, 6eq) in EtOH (20 mL) was heated at 70° C. for 3 h. The mixture wasfiltered through a Celite® pad and the filtrate was concentrated invacuo, the crude product was dissolved in 1N HCl solution (15 mL) andconcentrated to dryness, then it was washed with acetone (10 mL×3), theprecipitate was collected by filtration, dried in vacuo to give(5-bromopyridin-3-yl)methanamine (LVIII) (1.3 g, 6.95 mmol, 97.7% yield)as a white solid. ¹H NMR (D₂O, 500 MHz) δ ppm 4.34 (s, 2H), 8.56 (s,1H), 8.75 (d, J=1.2 Hz, 1H), 8.91 (d, J=1.6 Hz, 1H). ESIMS found forC₆H₇BrN₂ m/z 187 (M+H).

Step 4

A solution of (5-bromopyridin-3-yl)methanamine (LVIII) (1.30 g, 5.8mmol, 1.0 eq), cyclopentanecarbaldehyde (0.57 g, 5.8 mmol, 1.0 eq) andTEA (0.60 g, 5.8 mmol, 1.0 eq) in MeOH (15 mL) was stirred at roomtemperature for 2 h. Then NaBH₃CN (1.98 g, 34.6 mmol, 6.0 eq) was addedand the mixture was stirred at the same temperature for another 3 h. Thesolvent was removed under reduced pressure and the residue was dilutedin water (20 mL) and extracted with DCM (10 mL×3), combined organiclayers were dried over MgSO₄ and concentrated in vacuo to give1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl)methanamine (LIX) (1.23 g,4.57 mmol, 79.3% yield) as a brown oil. ESIMS found for C₁₂H₁₇BrN₂ m/z269 (M+H).

Step 5

To a solution of 1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl)methanamine (LIX) (1.00 g, 3.7 mmol, 1 eq) and TEA (0.93 g, 9.2 mmol,2.5 eq) in DCM (20 mL) was added portionwise (Boc)₂O (0.85 g, 4.0 mmol,1.1 eq) at 0° C., the reaction mixture was stirred at room temperaturefor 1 h. The mixture was washed with water (10 mL), brine (10 mL), theorganic layer was separated, dried over MgSO₄ and concentrated in vacuoto give tert-butyl (5-bromopyridin-3-yl)methyl(cyclopentylmethyl)carbamate (LX) (1.25 g, 3.38 mmol, 91.9% yield) as awhite solid. ESIMS found for C₁₇H₂₅BrN₂O₂ m/z 369 (M+H).

Preparation of intermediate1-(3-bromo-5-fluorophenyl)-4-methylpiperazine (LXII) is depicted belowin Scheme 12.

Step 1

To a solution of 1,3-dibromo-5-fluorobenzene (LXI) (2.0 g, 7.88 mmol) intoluene (20 ml) was added potassium t-butoxide (2.65 g, 23.6 mmol) and1-methylpiperazine (1.75 mL, 15.8 mmol). The reaction was heated at 105°C. overnight. The toluene was removed under vacuum and the residue wasdissolved in water and extracted with EtOAc. The organic phase wasseparated, washed with brine, dried over MgSO₄ and concentrated todryness. The crude product was purified on a silica gel column (1:99MeOH:CHCl₃→7:93 MeOH:CHCl₃) to produce1-(3-bromo-5-fluorophenyl)-4-methylpiperazine (LXII) as an orange oil(800 mg, 2.93 mmol, 37.2% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.20(s, 3H), 2.39 (t, J=5 Hz, 4H), 3.33 (t, J=5 Hz, 4H), 6.74-6.81 (m, 2H),6.91 (s, 1H); ESIMS found for C₁₁H₁₄BrFN₂ m/z 273 (M+H).

The following intermediates were prepared in accordance with theprocedure described in the above Scheme 12.

N1-(3-Bromo-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine (LXIII) asan orange oil (800 mg, 3.06 mmol, 38.9% yield). ¹H NMR (DMSO-d₆) δ ppm1.28 (s, 6H), 2.39 (t, J=4 Hz, 2H), 3.07 (q, J=6 Hz, 2H), 6.10 (t, J=5Hz, 1H), 6.38 (td, J=12 Hz, J=2 Hz, 1H), 6.51 (td, J=8.6 Hz, J=2 Hz,1H), 6.61 (t, J=2 Hz, 1H); ESIMS found C₁₀H₁₄BrFN₂ m/z 262.9(M+H^(81Br)).

4-(3-Bromo-5-fluorophenyl)morpholine (LXIV) as a yellow oil (1.14 g,4.38 mmol, 55.6% yield). ¹H NMR (DMSO-d₆) δ ppm 3.16 (t, J=5 Hz, 4H),3.70 (t, J=5 Hz, 4H), 6.79 (td, J=12.8 Hz, J=2 Hz, 1H), 6.83 (td, J=8Hz, J=2 Hz, 1H), 6.93 (s, 1H); ESIMS found C₁₀H₁₁BrFNO m/z 261.8(M+H^(81Br)).

1-(3-Bromo-5-fluorophenyl)-4-isopropylpiperazine (LXV) as a light yellowoil (200 mg, 0.66 mmol, 34.1% yield). ESIMS found C₁₃H₁₈BrFN₂ m/z 301.1(M+H^(79Br)).

1-(3-Bromo-5-fluorophenyl)-4-methylpiperidine (LXVI) as a brown solid(870 mg, 3.20 mmol, 40.6% yield). ¹H NMR (DMSO-d₆) δ ppm; ESIMS foundC₁₂H₁₅BrFN m/z 272.0 (M+H^(79Br)).

tert-Butyl 4-(3-bromo-5-fluorophenyl)piperazine-1-carboxylate (LXVII) asa yellow oil (232 mg, 0.65 mmol, 16.4% yield). ESIMS found C₁₅H₂₀BrFN₂O₂m/z 361.0 (M+H^(81Br)).

Preparation of intermediate 5′-fluoro-3,3′-bipyridine-4,5-diamine(LXXII) is depicted below in Scheme 13.

Step 1

A mixture of 3-nitropyridin-4-amine (LXVIII) (10 g, 71.88 mmol) andacetic acid (100 ml) was added to a sealed tube followed by addition ofNaOAc (29.50 g, 359 mmol) and dropwise addition of bromine (4.43 ml 86.3mmol) under stirring. The sealed tube was heated at 100° C. forovernight. The reaction mixture was concentrated under vacuum to obtaina solid which was dissolved in water, basified with saturated aqueousNaHCO₃ and extracted with DCM. The combined organic extracts were driedand concentrated to produce 3-bromo-5-nitropyridin-4-amine (LXIX) as ayellow solid (13.7 g, 62.8 mmol, 87% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 8.58 (s, 1H), 9.19 (s, 1H); ESIMS found for C₅H₄BrN₃O₂ m/z 218.1(M+H).

Step 2

A solution of 3-bromo-5-nitropyridin-4-amine (LXIX) (790 mg, 3.62 mmol),3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (LXX)(1.01 g, 4.35 mmol), K₃PO₄ (1.15 g, 5.44 mmol), water (10 mL) and DMF(10 mL) was degassed with argon thrice. Pd(PPh₃)₄ (209 mg, 0.18 mmol)was added to the reaction and the solution was heated at 90° C. for 4 h.The reaction was passed through a pad of Celite and then concentratedunder reduced pressure. The reaction mixture was concentrated and theresidue was taken up in EtOAc. The organic extract was washed withwater, dried and concentrated under vacuum. The crude product waspurified on a silica gel column (100% CHCl₃→1.5:98.5 MeOH[7N NH₃]:CHCl₃)to give 5′-fluoro-5-nitro-3,3′-bipyridin-4-amine (LXXI) as a yellowsolid (626 mg, 2.67 mmol, 74% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm7.62 (brs, 2H), 7.86-7.89 (m, 1H), 8.15 (s, 1H), 8.47-8.48 (m, 1H), 8.67(d, J=2.7 Hz, 1H), 9.07 (s, 1H); ESIMS found C₁₀H₇FN₄O₂ m/z 235 (M+H).

Step 3

To a solution of 5′-fluoro-5-nitro-3,3′-bipyridin-4-amine (LXXI) (621mg, 2.65 mmol) in EtOH (18 mL) was added 10% Pd/C (93 mg, 15% by wt).The solution was purged with hydrogen and stirred for overnight at roomtemperature under hydrogen. The suspension was filtered through Celiteand concentrated under vacuum. The crude product was purified through asilica gel column (100% CHCl₃→3:97 MeOH[7N NH₃]:CHCl₃) to produce5′-fluoro-3,3′-bipyridine-4,5-diamine (LXXII) as an off-white solid (542mg, 2.65 mmol, 100% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 4.78 (brs,2H), 5.28 (brs, 2H), 7.46 (s, 1H), 7.70 (s, 1H), 7.73-7.76 (m, 1H),8.44-8.45 (m, 1H), 8.56 (d, J=2.8 Hz, 1H); ESIMS found C₁₀H₉FN₄ m/z 205(M+H).

Preparation of intermediate 3,3′-bipyridine-4,5-diamine (LXXIV) isdepicted below in Scheme 14.

Step 1

A mixture of 3-nitropyridin-4-amine (LXVIII) (10 g, 71.94 mmol) andacetic acid (120 mL) was added to a sealed tube followed by addition ofNaOAc (29.50 g, 93.52 mmol) and dropwise addition of bromine (4.7 ml359.7 mmol) under stirring. The sealed tube was heated at 100° C. for 28h until TLC showed consumption of starting material. The reactionmixture was concentrated to obtain a solid which was dissolved in water,basified with NaHCO₃ and extracted with EtOAc. The combined organicextracts were dried and concentrated to produce3-bromo-5-nitropyridin-4-amine (LXIX) as a yellow solid (12 g, 55 mmol,77% yield). ¹H NMR (DMSO-d₆) δ ppm 9.19 (s, 1H), 8.58 (s, 1H); ESIMSfound for C₅H₄BrN₃O₂ m/z 217, 219 (M+, M+2).

Step 2

A solution of 3-bromo-5-nitropyridin-4-amine (LXIX) (6 g, 26 mmol),pyridin-3-ylboronic acid (3.54 g, 29 mmol), 1 N Na₂CO₃ solution (78 ml)and 1,4-dioxane (150 mL) was degassed with argon thrice. Pd(PPh₃)₂Cl₂(927 mg, 5 mmol %) was added to the reaction and the solution wasrefluxed for 15 h until TLC showed the reaction was complete. Thereaction was passed through a pad of Celite® and then concentrated underreduced pressure. The reaction mixture was concentrated and the residuewas taken up in EtOAc. The organic extract was washed with water, driedand concentrated under vacuum. The crude product was purified on asilica gel column (100% EtOAc→2:98 MeOH:DCM) to give5-nitro-3,3′-bipyridin-4-amine (LXXIII) as a yellow solid (5 g, 23.1mmol, 87% yield). ¹H NMR (CDCl₃, 500 MHz,) δ ppm 9.31 (s, 1H), 8.80-8.79(m, 1H), 8.70 (s, 1H), 8.23 (s, 1H), 7.80-7.73 (m, 1H), 7.52-7.48 (m,1H). ESIMS found C₁₀H₈N₄O₂ m/z 216.95 (M+H).

Step 3

To a solution of 5-nitro-3,3′-bipyridin-4-amine (LXXIII) (5 g, 23 mmol)in MeOH (20 mL) was added 10% Pd/C. The solution was purged withhydrogen and stirred at room temperature under hydrogen for 15 h. Thesuspension was filtered through Celite® and the concentrated undervacuum to produce 3,3′-bipyridine-4,5-diamine (LXXIV) as off white solid(3.3 g, 17.7 mmol, 76% yield). ¹H NMR (DMSO-d₆, 500 MHz,): δ ppm8.63-8.53 (m, 1H), 7.90-7.83 (m, 1H), 7.75 (s, 1H), 7.58 (s, 1H),7.48-7.43 (m, 2H), 6.13 (bs, 2H), 5.31 (bs, 2H). ESIMS found C₁₀H₁₀N₄m/z 187.10 (M+H).

The following intermediates were prepared in accordance with theprocedure described in the above Scheme 13 or Scheme 14.

5-(3-Fluorophenyl)pyridine-3,4-diamine (LXXV) as a brown solid (2.03 g,9.99 mmol, 50% yield). ¹H NMR (DMSO-d₆) δ ppm 7.16-7.27 (m, 2H), 4.86(brs, 2H), 5.34 (brs, 2H), 7.45-7.53 (m, 3H), 7.70 (s, 1H); ESIMS foundC₁₁H₁₀FN₃ m/z 203.6 (M+H).

5-(4-Fluorophenyl)pyridine-3,4-diamine (LXXVI): Light yellow solid, (97%yield). ESIMS found C₁₁H₁₀FN₃ m/z 204.3 (M+H).

5-(2-Fluorophenyl)pyridine-3,4-diamine (LXXVII): Light red solid, (44%yield). ESIMS found C₁₁H₁₀FN₃ m/z 204.4 (M+H).

3,4′-Bipyridine-4,5-diamine (LXXVIII): Light tan solid, (84% yield).ESIMS found C₁₀H₁₀N₄ m/z 187.0 (M+H).

2,3′-Bipyridine-4′,5′-diamine (LXXIX): Tan amorphous solid, (76% yield).ESIMS found C₁₀H₁₀N₄ m/z 187.0 (M+H).

5-(Furan-3-yl)pyridine-3,4-diamine (LXXX): Light pink solid, (68%yield). ESIMS found C₉H₉N₃O m/z 176.0 (M+H).

5-(Thiophen-3-yl)pyridine-3,4-diamine (LXXXI): Light brown amorphoussolid (100% yield) EMIMS found C₉H₉N₃S m/z 192.0 (M+H).

5-(Thiophen-2-yl)pyridine-3,4-diamine (LXXXII): White amorphous solid(1.257 g, 6.57 mmol, 1000% yield). ESIMS found C₉H₉N₃S m/z 192.2 (M+H).

3-(Thiophen-2-yl)benzene-1,2-diamine (LXXXIII): Brown oil (925.5 mg,4.86 mmol, 60.9% yield). ESIMS found C₁₀H₁₀N₂S m/z 191.1 (M+H).

2′-Fluorobiphenyl-2,3-diamine (LXXXIV): Black solid (0.8 g, 3.96 mmol,92% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 3.99 (s, 2H), 4.62 (s, 2H),6.32 (d, J=7.6 Hz, 1H), 6.49 (t, J=7.6 Hz, 1H), 6.60 (d, J=7.6 Hz, 1H),7.21-7.35 (m, 3H), 7.35-7.45 (m, 1H); ESIMS found for C₁₂H₁₁FN₂ m/z 203(M+H).

3′-Fluorobiphenyl-2,3-diamine (LXXXV): White solid (2.0 g, 9.89 mmol,81% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 4.16 (s, 2H), 4.64 (s, 2H),6.38 (dd, J=7.6 Hz, J=1.6 Hz, 1H), 6.51 (t, J=7.6 Hz, 1H), 6.60 (d, J=6Hz, 1H), 7.11-7.26 (m, 3H), 7.48 (q, J=6.4 Hz, 1H); ESIMS found forC₁₂H₁₁FN₂ m/z 203 (M+H).

4′-Fluorobiphenyl-2,3-diamine (LXXXVI): White solid (2.4 g, 11.87 mmol,98% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 4.07 (s, 2H), 4.60 (s, 2H),6.34 (dd, J=7.6 Hz, J=1.6 Hz, 1H), 6.50 (t, J=7.6 Hz, 1H), 6.58 (dd,J=7.6 Hz, J=1.6 Hz, 1H), 7.26 (t, J=7.6 Hz, 2H), 7.40 (q, J=5.6 Hz, 2H);ESIMS found for C₁₂H₁₁FN₂ m/z 203 (M+H).

3-(Pyridin-3-yl)benzene-1,2-diamine (LXXXVII): White solid (1.36 g, 7.34mmol, 92.5% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.57 (brs, 2H), 3.42(brs, 2H), 6.66 (dd, J=6 Hz, J=3.2 Hz, 1H), 6.68-6.72 (m, 2H), 7.31 (dd,J=8 Hz, J=4.8 Hz, 1H), 7.71 (td, J=8 Hz, J=2 Hz, 1H), 8.54 (dd, J=4.8Hz, J=1.6 Hz, 1H), 8.64 (d, J=1.6 Hz, 1H); ESIMS found for C₁₁H₁₁N₃ m/z186 (M+H).

3-(Thiophen-3-yl)benzene-1,2-diamine (LXXXVIII): White solid (1.2 g,6.31 mmol, mmol, 94% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 4.19 (s,2H), 4.59 (s, 2H), 6.47 (dd, J=4.8 Hz, J=1 Hz, 2H), 6.55 (q, J=4.8 Hz,1H), 7.24 (dd, J=4.8 Hz, J=1 Hz, 1H), 7.50 (t, J=1.6 Hz, 1H), 7.63 (dd,J=4.8 Hz, J=2.8 Hz, 1H); ESIMS found for C₁₀H₁₀N₂S m/z 191 (M+H).

3-(Furan-3-yl)benzene-1,2-diamine (LXXXIX): White solid (1.3 g, 7.46mmol, mmol, 85% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 4.24 (brs, 2H),4.57 (brs, 2H), 6.46-6.50 (m, 1H), 6.50-6.56 (m, 2H), 6.72 (s, 1H), 7.74(t, J=1.6 Hz, 1H), 7.87 (s, 1H); ESIMS found for C₁₀H₁₀N₂O m/z 175(M+H).

Preparation of intermediate 3-(pyridin-4-yl)benzene-1,2-diamine (XCV) isdepicted below in Scheme 15.

Step 1

To a solution of 2-bromoaniline (XC) (50 g, 0.29 mol, 1 eq) in aceticanhydride (265 mL) was added dropwise nitric acid (fuming) (36.75 mL,0.93 mol, 3.2 eq) at 0° C. and then stirred at that temperature, whenthe starting material was consumed, the mixture was filtered, thefiltrate was poured into ice water. The aqueous phase was basified withaqueous solution of sodium bicarbonate to pH=7, then the mixture wasextracted with EtOAc (30 mL×3). The organic layers were combined, driedand concentrated in vacuo to give the N-(2-bromo-6-nitrophenyl)acetamide(XCI) (12.6 g, 48.6 mmol, 16.7% yield) as a white solid. ¹H NMR(DMSO-d₆, 400 MHz) δ ppm 2.06 (s, 3H), 7.43 (t, J=8 Hz, 1H), 7.94 (d,J=8 Hz, 1H), 8.05 (d, J=8 Hz, 1H); ESIMS found for C₈H₇BrN₂O₃ m/z 259(M+H).

Step 2

A degassed mixture of N-(2-bromo-6-nitrophenyl)acetamide (XCI) (2.59 g,10 mmol, 1.0 eq),4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (XCII) (2.05 g,10 mmol, 1.3 eq), Na₂CO₃ (2.12 g, 20 mmol, 2 eq) and Pd(PPh₃)₄ (1.16 g,1 mmol, 0.1 eq) in a mixed solvent of DME (30 mL) and H₂O (10 mL) washeated to reflux under nitrogen overnight, the mixture was poured ontowater (40 ml) and extracted with ethyl acetate (30 mL×3). The combinedorganic layers were dried over Na₂SO₄, filtered and concentrated invacuo, purification the resultant residue was purified by columnchromatography (EtOAc:PE=1:4→100% EtOAc) to affordN-(2-nitro-6-(pyridin-4-yl)phenyl)acetamide (XCIII) (1.42 g, 5.52 mmol,55% yield) as a yellow solid. ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.92 (s,3H), 7.46 (d, J=5.6 Hz, 2H), 7.69 (t, J=8 Hz, 1H), 7.80 (dd, J=7.6 Hz,J=1.2 Hz, 1H), 8.06 (dd, J=8 Hz, J=1.6 Hz, 1H), 8.73 (d, J=6 Hz, 2H),9.96 (s, 1H); ESIMS found for C₁₃H₁₁N₃O₃ m/z 258 (M+H).

Step 3

To a solution of N-(2-nitro-6-(pyridin-4-yl)phenyl)acetamide (XCIII)(3.94 g, 15 mmol, 1 eq) in methanol (20 mL) was added 2 N aqueous NaOHsolution (50 mL) and the mixture was refluxed until the startingmaterial was consumed completely, the precipitate was collected byfiltration to afford the 2-nitro-6-(pyridin-4-yl)aniline (XCIV) (3.0 g,13.9 mmol, 91% yield) as yellow solid. ESIMS found for C₁₁H₉N₃O₂ m/z 216(M+H).

Step 4

To a solution of 2-nitro-6-(pyridin-4-yl)aniline (XCIV) (3 g, 14 mmol, 1eq) in EtOAc (350 mL) was added Pd/C (0.3 g) and the mixture was stirredat room temperature under 1 atm of H₂ atmosphere overnight, the mixturewas filtered and concentrated in vacuo to give the product3-(pyridin-4-yl)benzene-1,2-diamine (XCV) (2.4 g, 13.0 mmol, 93% yield)as a white solid. ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 4.35 (s, 2H), 4.75 (s,2H), 6.45 (dd, J=7.6 Hz, J=1 Hz, 1H), 6.58 (t, J=7.6 Hz, 1H), 6.67 (d,J=6.8 Hz, 1H), 7.47 (d, J=6 Hz, 2H), 8.65 (d, J=6 Hz, 2H); ESIMS foundfor C₁₁H₁₁N₃ m/z 186 (M+H).

Preparation of intermediate 3-(pyridin-2-yl)benzene-1,2-diamine 3HCl(LXII) is depicted below in Scheme 16.

Step 1

To a solution of 2-bromopyridine (XCVI) (10 g, 63 mmol, 1.00 eq) in THF(150 mL) was added n-BuLi (25.3 mL, 63 mmol, 1.00 eq) and the mixturewas stirred at −70° C. for 30 min under nitrogen atmosphere. Thenn-Bu₃SnCl (21.7 g, 67 mmol, 1.06 eq) was added and the mixture wasstirred at the same temperature for another 2 h. Saturated ammoniumchloride solution (150 mL) was added to the solution and extracted withethyl acetate (150 mL×3). The combined organic layers were dried overNa₂SO₄, filtered and concentrated in vacuo to afford the crude2-(tributylstannyl)pyridine (XCVII) (25.9 g, 63 mmol, 100% yield) as ayellow oil. The crude product was used without further purification.

Step 2

A degassed mixture of N-(2-bromo-6-nitrophenyl)acetamide (XCI) (4.8 g,19 mmol, 1.00 eq), 2-(tributylstannyl)pyridine (XCVII) (7.5 g, 20 mmol,1.05 eq) and Pd(PPh₃)₄ (2.1 g, 1.8 mmol, 0.01 eq) in toluene (60 mL) washeated to reflux under nitrogen overnight. Saturated sodium bicarbonatesolution (50 mL) was then added to the mixture and it was extracted withethyl acetate (50 mL×3). The combined organic layers were dried overNa₂SO₄, filtered and concentrated in vacuo, the residue was purified bycolumn chromatography on silica gel (EtOAc:PE=1:2→100% EtOAc) to affordN-(2-nitro-6-(pyridin-2-yl)phenyl)acetamide (XCVIII) (4.4 g, 17.1 mmol,92% yield) as a white-off solid. ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.93(s, 3H), 7.43-7.51 (m, 1H), 7.51-7.65 (m, 1H), 7.67 (d, J=7.6 Hz, 1H),7.97 (dd, J=7.6 Hz, J=2.4 Hz, 3H), 8.75 (d, J=4.4 Hz, 1H), 10.52 (s,1H); ESIMS found for C₁₃H₁₁N₃O₃ m/z 258 (M+H).

Step 3

To a solution of N-(2-nitro-6-(pyridin-2-yl)phenyl)acetamide (XCVIII)(4.41 g, 17 mmol, 1 eq) in MeOH (20 mL) was added 2N NaOH aqueous (50mL) and the mixture was refluxed until the stirring material wasconsumed completely. The mixture was concentrated in vacuo to remove theMeOH and the precipitate was collected by filtration to afford2-nitro-6-(pyridin-2-yl)aniline (XCIX) (2.4 g, 11.2 mmol, 65% yield) asa yellow solid. ESIMS found for C₁₁H₉N₃O₂ m/z 216 (M+H).

Step 4

To a solution of 2-nitro-6-(pyridin-2-yl)aniline (XCIX) (2.4 g, 0.01mmol, 1 eq) in EtOAc (350 mL) was added Pd/C (1 g) and the mixture wasstirred at room temperature overnight, filtered and then concentrated invacuo, to give 3-(pyridin-2-yl)benzene-1,2-diamine (1.9 g, 10.3 mmol,89% yield) as a yellow oil. ESIMS found for C₁₁H₁₁N₃ m/z 186 (M+H).

Step 5

To a solution of 3-(pyridin-2-yl)benzene-1,2-diamine (1.86 g, 0.01 mmol)in EtOAc (200 mL) was added HCl in EtOAc (40 mL) and the mixture wasstirred at 0° C. for 20 min. The precipitate was collected by filtrationto give 3-(pyridin-2-yl)benzene-1,2-diamine-3HCl (C) as a yellow solid.¹H NMR (DMSO-d₆, 400 MHz) δ ppm 6.89 (t, J=7.6 Hz, 1H), 7.33 (brs, 1H),7.51 (d, J=7.2 Hz, 1H), 7.54-7.66 (m, 2H), 7.97 (d, J=8 Hz, 1H), 8.16(brs, 1H), 8.75 (brs, 1H).

Preparation of intermediate5-(3-fluoro-5-((4-methylpiperazin-1-yl)methyl)phenyl)pyridine-3,4-diamine(XLV) is depicted below in Scheme 17.

Step 1

A solution of 3-bromo-5-fluorobenzaldehyde (CI) (2.12 g, 10.42 mmol) inMeOH (200 mL) was added 1-methylpiperazine (2.3 mL, 20.84 mL). The pHwas adjusted to 6 using HOAc and stirred for 1 h. NaCNBH₃ (917 mg, 14.59mmol) was added and stirred at room temperature overnight. The MeOH wasremoved under vacuum and the residue was partitioned between CHCl₃ andsaturated aqueous NaHCO₃. The organic layer was dried over MgSO₄ andevaporated under vacuum. The crude product was purified on a silica gelcolumn (100% CHCl₃→3:97 MeOH[7N NH₃]:CHCl₃) to produce1-(3-bromo-5-fluorobenzyl)-4-methylpiperazine (CII) as a yellow oil(1.52 g, 5.29 mmol, 51% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.14 (s,3H), 2.28-2.40 (m, 8H), 3.46 (s, 2H), 7.15-7.17 (m, 1H), 7.35 (s, 1H),7.40-7.42 (m, 1H); ESIMS found C₁₂H₁₆BrFN₂ m/z 287 (M+H).

Step 2-3

A solution of 1-(3-bromo-5-fluorobenzyl)-4-methylpiperazine (CII) (528mg, 1.84 mmol), bis(pinacolato)diboron (560 mg, 2.21 mmol), KOAc (541mg, 5.51 mmol) and dry DMF (26 mL) was purged with argon. PdCl₂(dppf)₂(90 mg, 0.11 mmol) was added to the reaction and purged again withargon. The solution was heated at 90° C. for 2 h. Once TLC showed thedisappearance of (CII), the solution was cooled to room temperature. Tothis solution was added K₃PO₄ (588 mg, 2.76 mmol),3-bromo-5-nitropyridin-4-amine (LXIX) (400 mg, 1.84 mmol), Pd(PPh₃)₄(106 mg, 0.09 mmol) and water (5 mL). The solution was purged with argonand heated at 90° C. for 4 h. The solution was cooled to roomtemperature and then concentrated under reduced pressure. The residuewas partitioned between CHCl₃ and water. The aqueous phase was separatedand washed 2×CHCl₃. The combined organic phases were washed with brine,dried over MgSO₄, filtered and then evaporated under vacuum. The residuewas purified on a silica gel column (100% CHCl₃→2:98 MeOH[7N NH₃]:CHCl₃)to give3-(3-fluoro-5-((4-methylpiperazin-1-yl)methyl)phenyl)-5-nitropyridin-4-amine(CIV) as a yellow amorphous solid (419 mg, 1.21 mmol, 42% yield for 2steps). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.14 (s, 3H), 2.27-2.41 (m, 8H),3.52 (s, 2H), 7.16-7.22 (m, 3H), 7.42 (brs, 2H), 8.11 (s, 1H), 9.04 (s,1H); ESIMS found for C₁₇H₂₀FN₅O₂ m/z 346.0 (M+H).

Step 4

To a solution of 3-(3-fluoro-5-((4-methylpiperazin-1-yl)methyl)phenyl)-5-nitropyridin-4-amine (CIV) (265 mg, 0.77 mmol) in MeOH (5 mL)was added 10% Pd/C (40 mg, 15% by wt). The solution was purged withhydrogen and stirred for 4 h at room temperature under hydrogen. Thesuspension was filtered through Celite and concentrated under vacuum toproduce5-(3-fluoro-5-((4-methylpiperazin-1-yl)methyl)phenyl)pyridine-3,4-diamine(CV) as a tan solid (210 mg, 0.66 mmol, 86% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.14 (s, 3H), 2.32-2.40 (m, 8H), 3.51 (s, 2H), 4.71 (brs,2H), 5.05 (brs, 2H), 7.06-7.10 (m, 2H), 7.14 (s, 1H), 7.43 (s, 1H), 7.67(s, 1H); ESIMS found C₁₇H₂₂FN₅ m/z 316 (M+H).

The following intermediates were prepared in accordance with theprocedure described in the above Scheme 17.

5-(3-((Dimethylamino)methyl)-5-fluorophenyl)pyridine-3,4-diamine (CVI):Light brown solid (551 mg, 2.11 mmol, 71% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.18 (s, 6H), 3.44 (s, 2H), 4.71 (brs, 2H), 5.04 (brs, 2H),7.07-7.10 (m, 2H), 7.13 (s, 1H), 7.44 (s, 1H), 7.67 (s, 1H); ESIMS foundC₁₄H₁₇FN₄ m/z 261 (M+H).

5-(3-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)pyridine-3,4-diamine (CVII):Light brown solid (551 mg, 2.11 mmol, 71% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.69-1.71 (m, 4H), 2.45-2.48 (m, 4H), 3.63 (s, 2H), 4.71(brs, 2H), 5.04 (brs, 2H), 7.05-7.07 (m, 1H), 7.09-7.11 (m, 1H), 7.14(s, 1H), 7.43 (s, 1H), 7.67 (s, 1H); ESIMS found C₁₆H₁₉FN₄ m/z 287(M+H).

5-(3-((diisopropylamino)methyl)-5-fluorophenyl)pyridine-3,4-diamine(CVIII): Light brown solid (551 mg, 2.11 mmol, 71% yield). ¹H NMR(DMSO-d₆, 500 MHz) δ ppm 1.00 (d, J=6.6 Hz, 12H), 2.99 (sep, J=6.6 Hz,2H), 3.67 (s, 2H), 4.71 (brs, 2H), 5.03 (brs, 2H), 6.99-7.01 (m, 1H),7.13-7.15 (m, 1H), 7.22 (s, 1H), 7.43 (s, 1H), 7.67 (s, 1H); ESIMS foundC₁₈H₂₅FN₄ m/z 317 (M+H).

Preparation of 5′-(trifluoromethyl)-3,3′-bipyridine-4,5-diamine (CIX)was performed following the procedure listed in Scheme 11, Steps 2-4.Off-white solid (378 mg, 1.49 mmol, 98% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 4.78 (brs, 2H), 5.30 (brs, 2H), 7.46 (s, 1H), 7.72 (s, 1H),8.13-8.14 (m, m, 1H), 8.86 (d, J=1.7 Hz, 1H), 8.95 (d, J=1.1 Hz, 1H);ESIMS found C₁₁H₉F₃N₄ m/z 255 (M+H).

Preparation of 5-(3-fluoro-5-morpholinophenyl)pyridine-3,4-diamine (CX)was performed following the procedure listed in Scheme 11, Steps 2-4.Yellow solid (156 mg, 0.54 mmol, 86% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 3.18 (t, J=5 Hz, 4H), 3.72 (t, J=5 Hz, 4H), 4.69 (s, 2H), 5.02 (s,2H), 6.57 (d, J=9 Hz, 1H), 6.70 (s, 1H), 6.76 (td, J=12 Hz, J=2 Hz, 1H),7.45 (s, 1H), 7.73 (s, 1H); ESIMS found C₁₅H₁₇FN₄O m/z 288.6 (M+H).

Preparation of5-(3-fluoro-5-(4-methylpiperazin-1-yl)phenyl)pyridine-3,4-diamine (CXI)was performed following the procedure listed in Scheme 11, Steps 2-4.Amorphous solid (170 mg, 0.56 mmol, 98.4% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.22 (s, 3H), 2.44 (t, J=5 Hz, 4H), 3.21 (t, J=5 Hz, 1H),4.90 (brs, 2H), 5.41 (brs, 2H), 6.55 (d, J=9 Hz, 1H), 6.69 (s, 1H), 6.77(d, J=13 Hz, 1H), 7.12 (t, J=7 Hz, 1H), 7.60-7.71 (m, 1H); ESIMS foundC₁₆H₂₀FN₅ m/z 302.0 (M+H).

Preparation of 5-(3-(2-(dimethylamino)ethylamino)-5-fluorophenyl)pyridine-3,4-diamine (CXII) was performed following the procedure listedin Scheme 11, Steps 2-4. Brown solid (148 mg, 0.51 mmol, 94.9% yield).¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.20 (s, 6H), 2.46 (t, J=7 Hz, 2H), 3.12(q, J=6 Hz, 2H), 4.79 (s, 2H), 5.21 (s, 2H), 5.91 (t, J=5 Hz, 1H), 6.28(dd, J=9 Hz, J=1 Hz, 1H), 6.36 (t, J=2 Hz, 1H), 6.37-6.42 (m, 1H), 7.46(s, 1H), 7.64 (s, 1H); ESIMS found C₁₅H₂₀FN₅ m/z 290.0 (M+H).

Preparation of N-(3-(4,5-Diaminopyridin-3-yl)-5-fluorobenzyl)methanesulfonamide (CXIII) was performed following the procedure listedin Scheme 11, Steps 2-4. Light tan solid (428.4 mg, 1.38 mmol,quantitative yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.92 (s, 3H), 4.24(d, J=6.3 Hz, 2H), 4.80 (s, 2H), 5.23 (s, 2H), 7.11-7.13 (m, 1H),7.16-7.18 (m, 1H), 7.22 (s, 1H), 7.47 (s, 1H), 7.64 (d, J=6.3 Hz, 1H),7.68 (s, 1H); ESIMS found C₁₃H₁₅FN₄O₂S m/z 311 (M+H).

Preparation of 5-(3-fluoro-5-(4-isopropylpiperazin-1-yl)phenyl)pyridine-3,4-diamine (CXIV) was performed following the procedure listedin Scheme 11, Steps 2-4. Light yellow amorphous solid (100 mg, 0.30mmol, 99% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.99 (d, J=6.5 Hz,6H), 2.52-2.58 (m, 4H), 2.67 (sep, J=6.5 Hz, 1H), 3.14-3.23 (m, 4H),4.74 (brs, 2H), 5.11 (s, 2H), 6.53 (d, J=9 Hz, 1H), 6.67 (s, 1H), 6.74(d, J=13 Hz, 1H), 7.45 (brs, 1H), 7.66 (brs, 1H); ESIMS found C₁₈H₂₄FN₅m/z 330.0 (M+H).

Preparation of tert-butyl 4-(3-(4,5-diaminopyridin-3-yl)-5-fluorophenyl)piperazine-1-carboxylate (CXV) was performed following the procedurelisted in Scheme 11, Steps 2-4. Light brown amorphous solid (376 mg,0.97 mmol, 87.4% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.42 (s, 9H),3.20 (t, J=5 Hz, 4H), 3.44 (t, J=5 Hz, 4H), 4.69 (s, 2H), 5.02 (s, 2H),6.56 (d, J=9 Hz, 1H), 6.71 (s, 1H), 6.77 (td, J=13 Hz, J=2 Hz, 1H), 7.44(s, 1H), 7.66 (s, 1H); ESIMS found C₂₀H₂₆FN₅O₂ m/z 388.1 (M+H).

Preparation of5-(3-fluoro-5-(4-methylpiperidin-1-yl)phenyl)pyridine-3,4-diamine (CXVI)was performed following the procedure listed in Scheme 11, Steps 2-4.Light brown amorphous solid (150 mg, 0.50 mmol, 99% yield). ¹H NMR(DMSO-d₆, 500 MHz) δ ppm 0.93 (d, J=6.5 Hz, 3H), 1.20 (dq, J=12 Hz, J=4Hz, 2H), 1.46-1.58 (m, 1H), 1.67 (d, J=11 Hz, 2H), 2.71 (dt, J=12 Hz,J=2 Hz, 2H), 3.74 (d, J=12.7 Hz, 2H), 4.68 (s, 2H), 5.00 (s, 2H), 6.48(dd, J=8.7 Hz, J=1 Hz, 1H), 6.66 (s, 1H), 6.72 (td, J=13 Hz, J=2 Hz,1H), 7.44 (s, 1H), 7.65 (s, 1H); ESIMS found C₁₇H₂₁FN₄ m/z 301.0 (M+H).

Preparation of intermediate5-(4-methylpiperazin-1-yl)pyridine-3,4-diamine (CXVIII) is depictedbelow in Scheme 18.

Step 1

A solution of 3-bromo-5-nitropyridin-4-amine (LXIX) (618 mg, 2.83 mmol)in 1-methylpiperazine (1 mL, 8.51 mmol) was heated at 140° C. overnight.The reaction was poured into an EtOAc/H₂O mixture; the organic layer wasseparated, dried over MgSO₄ and concentrated under vacuum. The crudeproduct was purified on a silica gel column (100% CHCl₃→3:97 MeOH(7NNH₃):CHCl₃) to give 3-(4-methylpiperazin-1-yl)-5-nitropyridin-4-amine(CXVII) as a yellow solid (382 mg, 1.61 mmol, 56.7% yield). ¹H NMR(CDCl₃, 500 MHz,) δ ppm 2.20 (s, 3H), 2.35-2.37 (m, 4H), 4.52-3.54 (m,4H), 5.96 (s, 1H), 7.42 (s, 2H), 8.78 (s, 1H); ESIMS found C₁₀H₁₅N₅O₂m/z 238 (M+H).

Step 2

To a solution of 3-(4-methylpiperazin-1-yl)-5-nitropyridin-4-amine(CXVII) (382 mg, 1.61 mmol) in MeOH (11 mL) was added 10% Pd/C. Thesolution was purged with hydrogen and stirred at room temperature underhydrogen for 4 h. The suspension was filtered through Celite® and theconcentrated under vacuum to produce5-(4-methylpiperazin-1-yl)pyridine-3,4-diamine (CXVIII) as purple solid(330 mg, 1.59 mmol, 99% yield). ¹H NMR (DMSO-d₆, 500 MHz,): δ 2.18 (s,3H), 2.34-2.36 (m, 4H), 3.13-3.16 (m, 4H), 3.89 (s, 2H), 5.20 (s, 2H),5.94 (s, 1H), 7.31 (s, 1H); ESIMS found C₁₀H₁₇N₅ m/z 208 (M+H).

The following intermediates were prepared in accordance with theprocedure described in the above Scheme 18.

5-(Piperidin-1-yl)pyridine-3,4-diamine (CXIX): Purple solid, (83%yield). ESIMS found C₁₀H₁₆N₄ m/z 193.1 (M+H).

5-(Piperidin-1-yl)pyridine-3,4-diamine (CXX): Black solid (1.31 g, 6.35mmol, 92% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.30 (s, 3H), 3.30 (brs,2H), 3.68 (brs, 2H), 6.46 (dd, J=7.2 Hz, J=2 Hz, 1H), 6.54-6.63 (m, 2H);ESIMS found for C₁₁H₁₈N₄ m/z 207 (M+H).

Preparation of intermediate 3-(piperidin-1-yl)benzene-1,2-diamine(CXXIII) is depicted below in Scheme 19.

Step 1

To a solution of 3-chloro-2-nitroaniline (CXXI) (2.00 g, 11.6 mmol, 1eq) and piperidine (2.95 g, 34.7 mmol, 3 eq) in DMF (60 ml) was addedK₂CO₃ (4.78 g, 34.4 mmol, 3 eq) in one portion and the mixture wasstirred at 120° C. under nitrogen overnight. The reaction mixture wasdiluted with ethyl acetate (60 ml) and washed with saturated NaHCO₃solution (50 mL). The organic phases were dried over Na₂SO₄ andconcentrated in vacuo, the resultant residue was purified by silica gelcolumn chromatography (PE:EtOAc=5:1-1:1) to give2-nitro-3-(piperidin-1-yl)aniline (CXXII) (1.8 g, 8.14 mmol, 70.3%yield) as a black solid. ESIMS found for C₁₁H₁₅N₃O₂ m/z 222 (M+H).

Step 2

A mixture of 2-nitro-3-(piperidin-1-yl)aniline (CXXII) (1.64 g, 6.9mmol, 1 eq) and Pd/C (0.50 g) in MeOH (20 mL) was stirred at roomtemperature under 30 psi H₂ overnight. After the starting material wasconsumed completely, the mixture was filtered through a Celite pad andthe filtrate was concentrated in vacuo to give the3-(piperidin-1-yl)benzene-1,2-diamine (CXXIII) (1.1 g, 5.75 mmol, 76%yield) as a yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.59 (brs, 2H),1.73 (quin, J=5.6 Hz, 4H), 2.84 (brs, 4H), 3.50 (brs, 4H), 6.52 (dd,J=6.4 Hz, J=1.6 Hz, 1H), 6.59-6.75 (m, 2H); ESIMS found for C₁₁H₁₇N₃ m/z192 (M+H).

Preparation of 4,5-diamino-N-ethylnicotinamide (LX) is depicted below inScheme 20.

Step 1

To a solution of concentrated sulfuric acid (2 mL) was slowly added2-aminobenzoic acid (CXXIV) (1.0 g, 7.24 mmol). A mixture ofconcentrated sulfuric acid (1.5 mL) and fuming nitric acid (1.5 mL) wasthen slowly added and the reaction was stirred at room temperatureovernight. The reaction mixture was poured into crushed ice and treatedwith aqueous NH₄OH until pH 3.0. The yellow-orange solid was washed withcold water and dried to produce 2-(nitroamino)benzoic acid (CXXV) as ayellow solid (1.0 g, 5.46 mmol, 75.4% yield). The crude product was usedfor the next step without further purification. ESIMS found for C₇H₆N₂O₄m/z 183.9 (M+H).

Step 2

To a solution of concentrated sulfuric acid (2 mL) was slowly added2-(nitroamino)benzoic acid (CXXV) (183 mg, 1.0 mmol). The mixture wasstirred at 100° C. for 1 h. The solution was cooled, poured into crushedice and treated with aqueous NH₄OH until pH 3.0 while maintaining thetemperature under 20° C. The solid was washed with cold water and driedto produce 2-amino-3-nitrobenzoic acid (CXXVI) as a yellow solid (55 mg,0.30 mmol, 30.2% yield). Used for the next step without furtherpurification. ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 8.50 (brs, 1H), 8.89 (s,1H), 8.99 (brs, 1H), 9.14 (s, 1H), 13.88 (brs, 1H); ESIMS found forC₇H₆N₂O₄ m/z 184.1 (M+H).

Step 3

To a solution of 2-amino-3-nitrobenzoic acid (CXXVI) (366 mg, 2.0 mmol)in DCM (5 mL) and DMF (1 mL) was added ethylamine hydrochloride and EDC.The mixture was cooled to 0° C. under argon before added DIPEA. Thereaction was stirred at room temperature for 3 h. The solution wasconcentrated under vacuum, dissolved in water and extracted with EtOAc.The combined organic phases were washed with brine, dried over MgSO₄ andconcentrated under vacuum. The residue was purified on a silica gelcolumn (100% CHCl₃→5:95 MeOH[7N NH₃]:CHCl₃) to give4-amino-N-ethyl-5-nitronicotinamide (CXXVII) as a yellow solid (200 mg,0.95 mmol, 47.6% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.14 (t, J=7Hz, 3H), 3.28 (q, J=6 Hz, 2H), 8.97 (s, 1H), 9.06 (s, 1H).

Step 4

To a solution of 4-amino-N-ethyl-5-nitronicotinamide (CXXVII) (180 mg,0.856 mmol) in MeOH (5 mL) was added 10% Pd/C (27 mg, 15% by wt). Thesolution was purged with hydrogen and stirred for 16 h at roomtemperature under hydrogen. The suspension was filtered through Celiteand concentrated under vacuum. The residue was purified on a silica gelcolumn (100% CHCl₃→10:90 MeOH[7N NH₃]:CHCl₃) to produce4,5-diamino-N-ethylnicotinamide (CXXVIII) as a dark yellow solid (80 mg,0.44 mmol, 51.9% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.14 (t, J=7Hz, 3H), 3.92 (q, J=7 Hz, 2H) 5.56 (brs, 2H), 6.60 (brs, 1H), 7.66 (s,1H), 8.30 (s, 1H); ESIMS found C₈H₁₂N₄O m/z 181 (M+H).

Preparation of intermediate3-(4-methyl-imidazol-1-yl)-benzene-1,2-diamine (CXXX) is depicted belowin Scheme 21.

Step 1

A solution of 3-chloro-2-nitro-aniline (CXXI) (1.0 g, 5.8 mmol),potassium carbonate (2.4 g, 17.4 mmol), and 4-methylimidazole in dry DMFwas heated overnight at 120° C. under nitrogen. The reaction was cooledand the solvent was evaporated in vacuo. The residue was suspended in asaturated NaHCO₃ solution and extracted with CH₂Cl₂. The combinedorganic phases were dried over MgSO₄ and concentrated in vacuo. Thecrude product was purified by flash chromatography to provide3-(4-methyl-imidazol-1-yl)-2-nitro-phenylamine (CXXIX). ¹H NMR (CDCl₃,400 MHz) δ ppm 2.19 (s, 3H), 6.53 (m, 1H), 6.79 (m, 1H), 6.93 (m, 1H),7.32 (m, 1H), 7.60 (m, 1H).

Step 2

To a solution of 3-(4-methyl-imidazol-1-yl)-2-nitro-phenylamine (CXXIX)in methanol was added with 5% Pd/C. The combination was stirred under ahydrogen filled balloon at 40° C. for 6 hours. The solution was thenfiltered through a pad of Celite. The filtrate was concentrated in vacuoto get 3-(4-methyl-imidazol-1-yl)-benzene-1,2-diamine (CXXX). ¹H NMR(CDCl₃, 400 MHz) δ ppm 2.17 (s, 3H), 6.54 (m, 1H), 6.80 (m, 1H), 6.97(m, 1H), 7.28 (m, 1H), 7.56 (m, 1H).

Example 1

Preparation of3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine(3) is depicted below in Scheme 22.

Step 1

To a heterogeneous solution of5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde(III) (328 mg, 1.05 mmol) and K₃PO₄ (334 mg, 1.57 mmol) in DMF (10 mL)and water (2 mL) was added pyridin-3-ylboronic acid (143 mg, 1.16 mmol).The solution was purged with argon by using argon/vacuum cycle (3×).Pd(PPh₃)₄ (36 mg, 0.03 mmol) was added to the solution and again purgedwith argon. The solution was heated at 90° C. for 4 h under argon. TheDMF was removed under vacuum. The residue was partitioned between EtOAcand water. The organic layer was separated and the aqueous layer wasextracted with EtOAc. The combined EtOAc was dried over MgSO₄, filteredand concentrated under reduced pressure. The crude product was purifiedthrough a silica gel column (10:90 EtOAc:hexane→50:50 EtOAc:hexane) toproduce 5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde (CXXXI) as an off-white waxy solid (283mg, 0.92 mmol, 91% yield). ¹H NMR (DMSO-d₆) δ ppm 1.57-1.68 (m, 3H),1.75-1.89 (m, 1H), 2.01-2.13 (m, 2H), 2.49-2.56 (m, 1H), 3.78 (dt, J=11Hz, J=4 Hz, 1H), 3.94-4.03 (m, 1H), 6.25 (dd, J=10 Hz, J=2 Hz, 1H),7.58-7.64 (m, 1H), 8.25 (td, J=8 Hz, J=2 Hz, 1H), 8.66 (dd, J=5 Hz, J=2Hz, 1H), 8.77 (d, J=2 Hz, 1H), 9.02 (d, J=2 Hz, 1H), 9.09 (d, J=2 Hz,1H), 10.21 (s, 1H); ESIMS found for C₁₇H₁₆N₄O₂ m/z 309.4 (M+H).

Step 2-3

A solution of5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde(CXXXI) (65 mg, 0.21 mmol), 5-(3-fluorophenyl)pyridine-3,4-diamine(LXXV) (45 mg, 0.22 mmol) and sulfur (7 mg, 0.22 mmol) in n-butanol (10mL) was heated at reflux overnight. The solution was cooled to roomtemperature, filtered and the solvent was evaporated under reducedpressure to give crude3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine(CXXXII). CXXXII was dissolved in dry DCM (5 mL) before addingtriethylsilane (84 μL, 0.52 mmol) and TFA (2.5 mL). The reaction wasstirred at room temperature for 2 h under argon. The solvent wasevaporated under reduced pressure; the residue was taken up water (10mL), and basified with 5N NH₄OH. The precipitates were filtered, washedby cold water and dried under vacuum at room temperature. The crudeproduct was suspended in DCM (10 mL), sonicated briefly and then heatedto boiling for 5 min. The solution was cooled to room temperature andthe solids were filtered, washed with DCM and dried under vacuum at roomtemperature to produce3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine(3) as a yellow solid (53 mg, 0.13 mmol, 62% yield). ¹H NMR (DMSO-d₆) δppm 7.25-7.34 (m, 1H), 7.54-7.65 (m, 2H), 8.11-8.21 (m, 1H), 8.23-8.30(m, 1H), 8.37-8.50 (m, 1H), 8.63-8.70 (m, 1H), 8.70-8.80 (m, 1H),9.02-9.09 (m, 2H), 9.09-9.15 (m, 1H), 13.94 (brs, 1H), 14.59 (s, 1H);ESIMS found for C₂₃H₁₄FN₇ m/z 408.1 (M+H).

The following compounds were prepared in accordance with the proceduredescribed in the above Example 1.

N-Ethyl-2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide8.

Brown solid (4.4 mg, 0.01 mmol, 35.8% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.23-1.34 (m, 3H), 3.48-3.59 (m, 2H), 5.76 (s, 1H), 7.58 (q, J=5Hz, 1H), 8.27-8.33 (m, 1H), 8.67 (d, J=5 Hz, 1H), 9.01 (s, 1H), 9.03 (s,1H), 9.07 (s, 1H), 9.33 (brs, 1H), 14.19 (brs, 1H), 14.75 (brs, 1H);ESIMS found C₂₀H₁₆N₈O m/z 385.0 (M+H).

3-(7-(3-Fluoro-5-((4-methylpiperazin-1-yl)methyl)phenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine10.

Off-white solid (62 mg, 0.12 mmol, 73% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 2.21 (brs, 3H), 2.30-2.47 (m, 8H), 3.59 (s, 2H), 7.21 (d, J=9 Hz,1H), 7.59 (dd, J=8 Hz, J=5 Hz, 1H), 8.13-8.29 (m, 2H), 8.25 (d, J=8 Hz,1H), 8.68 (dd, J=5 Hz, J=1.4 Hz, 1H), 8.75 (brs, 1H), 8.89 (brs, 1H),9.04 (dd, J=9 Hz, J=2 Hz, 2H), 9.08 (s, 1H), 13.91 (brs, 1H), 14.61(brs, 1H); ESIMS found C₂₉H₂₆FN₉ m/z 520.3 (M+H).

3-(7-(3-Fluoro-5-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine11.

Off-white solid (72 mg, 0.14 mmol, 75% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 2.16 (brs, 3H), 2.23-2.40 (m, 4H), 3.19-3.30 (m, 4H), 6.84 (d,J=12 Hz, 1H), 7.54-7.65 (m, 2H), 7.79 (s, 1H), 8.21 (d, J=8 Hz, 1H),8.69 (d, J=2 Hz, 2H), 8.73 (s, 1H), 8.87 (s, 1H), 8.97-9.05 (m, 2H),13.86 (brs, 1H), 14.61 (brs, 1H); ESIMS found C₂₈H₂₄FN₉ m/z 506.3 (M+H).

N1-(3-Fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-7-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine12.

Off-white solid (21 mg, 0.04 mmol, 50% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 2.14 (s, 6H), 2.40 (brs, 2H), 3.17 (t, J=6 Hz, 2H), 5.94 (brs,1H), 6.48 (d, J=12 Hz, 1H), 7.32-7.47 (m, 2H), 7.58 (dd, J=8 Hz, J=5 Hz,1H), 8.25 (d, J=8 Hz, 1H), 8.64 (s, 1H), 8.68 (dd, J=5 Hz, J=1.5 Hz,1H), 8.85 (s, 1H), 9.06 (d, J=2 Hz, 2H), 9.11 (s, 1H), 13.83 (brs, 1H),14.58 (brs, 1H); ESIMS found C₂₇H₂₄FN₉ m/z 494 (M+H).

4-(3-Fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-7-yl)phenyl)morpholine13.

Off-white solid (38 mg, 0.08 mmol, 77% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 3.14-3.21 (m, 4H), 3.51-3.59 (m, 4H), 6.86 (d, J=12 Hz, 1H), 7.58(dd, J=8 Hz, J=5 Hz, 1H), 7.63 (d, J=10 Hz, 1H), 7.74 (s, 1H), 8.22 (d,J=8 Hz, 1H), 8.68 (d, J=5 Hz, 1H), 8.73 (s, 1H), 8.87 (s, 1H), 9.01 (d,J=2 Hz, 2H), 9.04 (s, 1H), 13.87 (s, 1H), 14.61 (s, 1H); ESIMS foundC₂₇H₂₁FN₈O m/z 493.1 (M+H).

1-(3-Fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-7-yl)phenyl)-N,N-dimethylmethanamine14.

Off-white solid (38 mg, 0.08 mmol, 62.9% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.10 (s, 6H), 3.51 (s, 2H), 7.20 (brd, 1H), 7.59 (dd, J=8 Hz,J=5 Hz, 1H), 8.13 (brd, 1H), 8.20-8.27 (m, 2H), 8.69 (d, J=3 Hz, 1H),8.75 (s, 1H), 8.89 (s, 1H), 9.03 (d, J=2 Hz, 1H), 9.04 (d, J=2 Hz, 1H),9.06 (s, 1H), 13.90 (s, 1H), 14.62 (s, 1H); ESIMS found C₂₆H₂₁FN₈ m/z465.3 (M+H).

3-(7-(3-Fluoro-5-(4-isopropylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine 15.

Off-white solid (41 mg, 0.08 mmol, 57.3% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 0.93 (brs, 6H), 2.32-2.41 (m, 4H), 2.51-2.60 (m, 1H),3.13-3.23 (m, 4H), 6.84 (brd, 1H), 7.52-7.61 (m, 1H), 7.58 (dd, J=8 Hz,J=5 Hz, 1H), 7.77 (brs, 1H), 8.22 (brd, 1H), 8.68 (d, J=5 Hz, 1H), 8.72(s, 1H), 9.02 (d, J=2 Hz, 1H), 9.02-9.06 (m, 2H), 13.87 (s, 1H), 14.61(s, 1H); ESIMS found C₃₀H₂₈FN₉ m/z 534.5 (M+H).

3-(7-(3-Fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine16.

Off-white solid (24 mg, 0.05 mmol, 33.5% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.54-1.67 (m, 4H), 2.33-2.47 (m, 4H), 3.69 (brs, 2H), 7.21(brd, 1H), 7.59 (dd, J=8 Hz, J=5 Hz, 1H), 8.12 (brd, 1H), 8.22-8.30 (m,2H), 8.69 (d, J=5 Hz, 1H), 8.75 (s, 1H), 8.89 (s, 1H), 9.01-9.05 (m,2H), 9.08 (s, 1H), 13.90 (brs, 1H), 14.61 (brs, 1H); ESIMS foundC₂₈H₂₃FN₈ m/z 491.1 (M+H).

N-(3-Fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-7-yl)benzyl)-N-isopropylpropan-2-amine17.

White solid (61 mg, 0.12 mmol, 65.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 0.93 (d, J=6 Hz, 12H), 2.90-3.00 (m, 2H), 3.70 (s, 2H), 7.25 (d, J=9Hz, 1H), 7.58 (dd, J=8 Hz, J=5 Hz, 1H), 8.09 (s, 1H), 8.14 (brd, 1H),8.24 (d, J=8 Hz, 2H), 8.67 (dd, J=5 Hz, J=2 Hz, 1H), 8.70 (s, 1H), 8.88(s, 1H), 9.03 (d, J=2 Hz, 1H), 9.05 (d, J=2 Hz, 1H), 9.07 (s, 1H), 13.88(brs, 1H), 14.58 (brs, 1H); ESIMS found C₃₀H₂₉FN₈ m/z 521.3 (M+H).

3-(7-(3-Fluoro-5-(4-methylpiperidin-1-yl)phenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine19.

Yellow solid (72 mg, 0.14 mmol, 100% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 0.79 (brd, 3H), 0.96-1.09 (m, 2H), 1.12-1.23 (m, 1H), 1.34-1.44 (m,2H), 2.55-2.66 (m, 2H), 3.77 (brd, 2H), 6.81 (brd, 1H), 7.38-7.47 (m,1H), 7.59 (dd, J=8 Hz, J=5 Hz, 1H), 7.90 (s, 1H), 8.22 (brd, 1H), 8.68(d, J=4 Hz, 1H), 8.72 (s, 1H), 8.88 (s, 1H), 9.00 (s, 1H), 9.02 (s, 2H),13.92 (brs, 1H), 14.62 (s, 1H); ESIMS found C₂₉H₂₅FN₈ m/z 505.1 (M+H).

3-(7-(3-Fluoro-5-(piperazin-1-yl)phenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine21.

Yellow solid (68 mg, 0.14 mmol, 86.5% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 2.69-2.77 (m, 4H), 3.13-3.21 (m, 4H), 6.82 (dd, J=10 Hz, J=2 Hz,1H), 7.57 (dd, J=8 Hz, J=5 Hz, 1H), 7.56-7.67 (m, 2H), 8.20 (td, J=8 Hz,J=2 Hz, 1H), 8.66 (dd, J=5 Hz, J=2 Hz, 2H), 8.87 (s, 1H), 8.99 (d, J=2Hz, 1H), 9.02 (s, 2H); ESIMS found C₂₇H₂₂FN₉ m/z 492.4 (M+H).

3-(7-(5-Fluoropyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine23.

Off-white solid (69 mg, 0.17 mmol, 93.9% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 7.60 (dd, J=8 Hz, J=5 Hz, 1H), 8.27 (d, J=8 Hz, 1H),8.64-8.71 (m, 2H), 8.83-8.92 (m, 2H), 8.94 (s, 1H), 9.06 (d, J=2 Hz,1H), 9.08 (s, 1H), 9.10 (s, 1H), 9.44 (s, 1H), 14.00 (brs, 1H), 14.63(brs, 1H); ESIMS found C₂₂H₁₃FN₈ m/z 409.1 (M+H).

5-(Pyridin-3-yl)-3-(7-(thiophen-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine443.

Beige solid (3.4 mg, 0.009 mmol, 40.9% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 7.27 (t, J=4 Hz, 1H), 7.65 (dd, J=5 Hz, J=8 Hz, 1H), 7.74 (d,J=5.5 Hz, 1H), 8.22 (d, J=3.5 Hz, 1H), 8.29 (d, J=8 Hz, 1H), 8.70 (d,J=4.5 Hz, 1H), 8.79 (s, 1H), 8.82 (s, 1H), 9.09 (d, J=1.5 Hz, 2H), 9.26(s, 1H), 13.87 (s, 1H), 14.60 (s, 1H); ESIMS found C₂₁H₁₃N₇S m/z 396.1(M+H).

3-(4-(2-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine590.

Brown solid (39.5 mg, 0.10 mmol, 30.0% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 7.31-7.40 (m, 4H), 7.45-7.52 (m, 1H), 7.54-7.63 (m, 2H), 8.09 (dt,J=1.5 Hz, J=7 Hz, 1H), 8.19 (d, J=8 Hz, 1H), 8.67 (d, J=4 Hz, 1H), 9.00(d, J=2 Hz, 1H), 9.03 (s, 2H), 13.36 (brs, 1H), 14.35 (brs, 1H); ESIMSfound C₂₄H₁₅FN₆ m/z 407.2 (M+H).

5-(Pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridine888.

Off-white solid (32.3 mg, 0.08 mmol, 25.3% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 7.23 (dd, J=3.5 Hz, J=5 Hz, 1H), 7.31 (t, J=7.5 Hz, 1H), 7.48(d, J=7.5 Hz, 1H), 7.62-7.68 (m, 3H), 8.16 (d, J=3 Hz, 1H), 8.29 (td,J=2 Hz, J=8 Hz, 1H), 8.70 (dd, J=1 Hz, J=4.5 Hz, 1H), 9.08 (d, J=2 Hz,1H), 9.10 (d, J=2 Hz, 1H), 9.34 (d, J=2.5 Hz, 1H), 13.41 (s, 1H), 14.39(s, 1H); ESIMS found C₂₂H₁₄N₆S m/z 395.1 (M+H).

Example 2

Preparation ofN-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide(2) is depicted below in Scheme 23.

Steps 1-2

A solution of5-bromo-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-carbaldehyde(XI) (436 mg, 1.4 mmol), bis(pinacolato)diboron (426 mg, 1.6 mmol), andKOAc (412 mg, 4.2 mmol) in dry DMF (20 ml) was purged with argon.PdCl₂(dppf)₂ (68 mg, 0.08 mmol) was added to the solution and purgedagain with argon. The solution was heated at 90° C. for 2 h under argonand cooled to the room temperature. N-(5-bromopyridin-3-yl)pivalamide(XVII) (358 mg, 1.4 mmol), potassium phosphate (446 mg, 2.1 mmol) andwater (2 mL) was added to the solution and purged with argon. Pd(PPh₃)₄was then added and the solution was again purged with the argon. Thesolution was heated at 90° C. for 4 h under argon. The solution wasfiltered through a bed of Celite and the solvent was distilled undervacuum. The crude product was suspended in water, sonicated briefly. Thesolids were filtered, dried under vacuum and purified by flashchromatography (100% DCM→3:97 MeOH:DCM) to getN-(5-(3-formyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide(LXV) as a brown solid (390 mg, 0.96 mmol, 68% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 1.27 (s, 9H), 1.58-1.69 (m, 2H), 1.78-1.90 (m, 1H),2.02-2.14 (m, 2H), 2.49-2.57 (m, 1H), 3.78 (dt, J=11 Hz, J=4 Hz, 1H),3.94-4.03 (d, J=11 Hz, 1H), 6.25 (dd, J=10 Hz, J=2 Hz, 1H), 8.44 (t, J=2Hz, 1H), 8.72 (dd, J=4 Hz, J=2 Hz, 2H), 8.98 (d, J=2 Hz, 1H), 9.09 (d,J=2 Hz, 1H), 9.60 (s, 1H), 10.21 (s, 1H); ESIMS found C₂₂H₂₅N₅O₃ m/z 408(M+H).

Steps 3-4

A solution ofN-(5-(3-formyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide(LXV) (75 mg, 0.18 mmol), sulfur (64 mg, 0.20 mmol) and5-(3-fluorophenyl)pyridine-3,4-diamine (XL) (41 mg, 0.20 mmol) inn-butanol (10 mL) was refluxed overnight under argon. The solution wascooled and filtered and dried under vacuum for 1 h. The residue wastaken in dry DCM (5 mL). Triethylsilane (72 μL, 0.45 mmol) followed byTFA (2.5 mL) was added to the solution and stirred for 2 h at roomtemperature. The solvent was removed under vacuum. Water was added tothe residue, sonicated briefly and basified with a 5N NH₄OH solution.The solids formed were filtered, washed with cold water and dried atroom temperature. The solids were boiled in DCM, cooled to roomtemperature and sonicated briefly. The solids were filtered, washed withDCM and dried under vacuum to giveN-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide(2) as a brown solid (66 mg, 0.13 mmol, 72% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.30 (s, 9H), 7.22 (t, 1H), 7.57-7.66 (m, 1H), 8.25 (d, 1H),8.36 (d, 1H), 8.55 (s, 1H), 8.74 (s, 1H), 8.78 (s, 1H), 8.89 (s, 1H),8.97 (s, 1H), 9.04 (s, 1H), 9.07 (s, 1H), 9.61 (s, 1H), 13.92 (brs, 1H),14.63 (brs, 1H); ESIMS found C₂₈H₂₃FN₈₀ m/z 507.5 (M+H).

The following compounds were prepared in accordance with the proceduredescribed in the above Example 2.

2,2,2-Trifluoro-N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)acetamide1.

Yellow solid (22 mg, 0.04 mmol, 92.3% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 7.20 (t, 1H), 7.60 (q, J=7 Hz, 1H), 8.18 (d, 1H), 8.42 (d, 1H),8.53 (s, 1H), 8.78 (s, 1H), 8.90 (s, 1H), 8.92 (s, 1H), 8.94 (s, 1H),9.08 (s, 1H), 9.12 (s, 1H), 13.94 (brs, 1H), 14.64 (brs, 1H); ESIMSfound C₂₅H₁₄F₄N₈O m/z 519.3 (M+H).

3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine4.

Brown solid (72 mg, 0.14 mmol, 53% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 2.29 (s, 3H), 2.52-2.58 (m, 4H), 3.29-3.38 (m, 4H), 7.29 (t, 1H),7.58 (q, J=7 Hz, 1H), 7.68 (s, 1H), 8.17 (d, J=8 Hz, 1H), 8.36 (d, J=11Hz, 1H), 8.41 (d, J=6 Hz, 2H), 8.75 (s, 1H), 8.89 (s, 1H), 9.06 (s, 2H),13.89 (brs, 1H), 14.59 (brs, 1H); ESIMS found C₂₈H₂₄FN₉ m/z 506.4 (M+H).

5-(3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine5.

Brown solid (68 mg, 0.16 mmol, 85% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 5.51 (s, 2H), 7.26-7.34 (m, 2H), 7.61 (q, J=8 Hz, 1H), 8.03 (d, J=2Hz, 1H), 8.17 (d, J=2 Hz, 1H), 8.21 (d, J=8 Hz, 1H), 8.35 (d, J=11 Hz,1H), 8.68 (s, 1H), 8.89 (s, 1H), 8.93 (d, J=2 Hz, 1H), 9.01 (s, 1H),13.89 (s, 1H), 14.57 (s, 1H); ESIMS found C₂₃H₁₅FN₈ m/z 423.1 (M+H).

N1-(5-(3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N2,N2-dimethylethane-1,2-diamine6.

Brown solid (68 mg, 0.14 mmol, 53% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 2.26 (s, 6H), 2.53-2.61 (m, 2H), 3.22-3.31 (m, 2H), 5.91 (brs, 1H),7.24-7.34 (m, 2H), 7.59 (q, J=8 Hz, 1H), 8.11 (d, J=2 Hz, 1H), 8.19 (d,J=2 Hz, 2H), 8.37 (brd, 1H), 8.75 (s, 1H), 8.90 (s, 1H), 9.00 (s, 1H),9.03 (s, 1H), 13.87 (brs, 1H), 14.56 (brs, 1H); ESIMS found C₂₇H₂₄FN₉m/z 494.4 (M+H).

5-(3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine7.

Brown solid (68 mg, 0.15 mmol, 63% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 3.05 (s, 6H), 7.30 (t, J=7 Hz, 1H), 7.41 (s, 1H), 7.57 (q, J=7 Hz,1H), 8.15 (d, J=8 Hz, 1H), 8.21 (d, J=2.5 Hz, 1H), 8.30 (s, 1H), 8.35(d, J=11 Hz, 1H), 8.74 (s, 1H), 8.89 (s, 1H), 9.05 (s, 2H), 13.89 (s,1H), 14.58 (s, 1H); ESIMS found C₂₅H₁₉FN₈ m/z 451.1 (M+H).

5-(3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine9.

Brown solid (79 mg, 0.17 mmol, 68% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 1.18 (d, J=6 Hz, 6H), 3.71 (sep, J=7 Hz, 1H), 5.91 (d, J=8 Hz, 1H),7.21 (s, 1H), 7.28 (t, J=8 Hz, 1H), 7.58 (q, J=8 Hz, 1H), 8.04 (d, J=2.5Hz, 1H), 8.14 (d, J=2 Hz, 1H), 8.17 (d, J=8 Hz, 1H), 8.32 (d, J=10 Hz,1H), 8.74 (s, 1H), 8.89 (s, 1H), 8.97 (s, 1H), 9.00 (s, 1H), 13.89 (s,1H), 14.57 (s, 1H); ESIMS found C₂₆H₂₁FN₈ m/z 465.3 (M+H).

1-(5-(3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine18.

Off-white solid (39 mg, 0.08 mmol, 76.4% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.25 (s, 6H), 3.58 (s, 2H), 7.31 (t, J=8 Hz, 1H), 7.61 (q,J=7 Hz, 1H), 8.12 (s, 1H), 8.20 (d, J=8 Hz, 1H), 8.37 (d, J=10 Hz, 1H),8.60 (s, 1H), 8.76 (s, 1H), 8.89 (s, 1H), 8.98 (s, 1H), 9.10 (s, 2H),13.91 (s, 1H), 14.61 (s, 1H); ESIMS found C₂₆H₂₁FN₈ m/z 465.3 (M+H).

1-(5-(3-(7-(5-Fluoropyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine20.

Off-white solid (14 mg, 0.03 mmol, 21.5% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.22 (s, 6H), 3.58 (s, 2H), 8.11 (s, 1H), 8.59 (s, 1H), 8.67(s, 1H), 8.77-8.90 (m, 2H), 8.95 (s, 2H), 9.07 (s, 2H), 9.43 (brs, 1H),13.99 (brs, 1H), 14.63 (brs, 1H); ESIMS found C₂₅H₂₀FN₉ m/z 466 (M+H).

N-(3-(2-(5-(5-((Dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-7-yl)-5-fluorobenzyl)methanesulfonamide22.

Off-white solid (49 mg, 0.09 mmol, 62.6% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.23 (brs, 6H), 2.90 (s, 3H), 3.58 (brs, 2H), 4.32 (d, J=6Hz, 2H), 7.28 (d, J=9 Hz, 1H), 7.73 (t, J=8 Hz, 1H), 8.08 (s, 1H), 8.35(d, J=10 Hz, 1H), 8.60 (s, 1H), 8.75 (s, 1H), 8.90 (s, 1H), 8.97 (s,1H), 9.07 (s, 1H), 9.09 (s, 1H), 13.92 (s, 1H), 14.61 (s, 1H); ESIMSfound C₂₈H₂₆FN₉O₂S m/z 572.0 (M+H).

1-(5-(3-(7-(3-Fluoro-5-morpholinophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine24.

Off-white solid (52 mg, 0.09 mmol, 72.8% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.22 (s, 6H), 3.14-3.21 (m, 4H), 3.47-3.56 (m, 4H), 3.57 (s,2H), 6.85 (d, J=12 Hz, 1H), 7.62 (d, J=10 Hz, 1H), 7.74 (s, 1H), 8.07(s, 1H), 8.59 (s, 1H), 8.72 (s, 1H), 8.87 (s, 1H), 8.90 (s, 1H), 9.02(s, 1H), 9.03 (s, 1H), 13.86 (brs, 1H), 14.60 (brs, 1H); ESIMS foundC₃₀H₂₈FN₉O m/z 550.5 (M+H).

N,N-Dimethyl-1-(5-(3-(7-(5-(trifluoromethyl)pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine25.

Off-white solid (51 mg, 0.10 mmol, 91.6% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.20 (s, 6H), 3.56 (s, 2H), 8.03 (s, 1H), 8.60 (d, J=1.5 Hz,1H), 8.87 (s, 1H), 8.91-9.00 (m, 3H), 9.02 (d, J=2 Hz, 1H), 9.03 (s,1H), 9.36 (s, 1H), 9.73 (s, 1H), 14.01 (brs, 1H), 14.65 (brs, 1H); ESIMSfound C₂₆H₂₀F₃N₉ m/z 516.3 (M+H).

3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine27.

Beige solid (13.5 mg, 0.028 mmol, 15.1% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.75 (brs, 4H), 2.62 (brs, 4H), 3.84 (brs, 2H), 7.39 (t, J=9Hz, 2H), 8.17 (s, 1H), 8.41 (brs, 2H), 8.62 (d, J=1.5 Hz, 1N), 8.65(brs, 1H), 8.86 (brs, 1H), 8.98 (s, 1H), 9.09 (s, 2H), 13.84 (brs, 1H),14.57 (brs, 1H); ESIMS found C₂₈H₂₃FN₈ m/z 491.2 (M+H).

3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine28.

Yellow solid (23 mg, 0.046 mmol, 35.1% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.40 (brs, 2H), 1.50 (brs, 4H), 2.40 (brs, 4H), 3.60 (s, 2H), 7.28(t, J=7 Hz, 1H), 7.60 (q, J=7 Hz, 1H), 8.09 (s, 1H), 8.17 (brs, 1H),8.39 (brd, J=9 Hz, 1H), 8.58 (s, 1H), 8.75 (brs, 1H), 8.89 (s, 1H), 8.95(s, 1H), 9.08 (s, 1H), 9.09 (s, 1H), 13.90 (brs, 1H), 14.58 (brs, 1H);ESIMS found C₂₉H₂₅FN₈ m/z 505.5 (M+H).

N-(5-(3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide114.

Off-white solid (6.8 mg, 0.014 mmol, 12.7% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 0.81-0.92 (m, 4H), 1.82-1.91 (m, 1H), 7.27 (brs, 1H), 7.61(ABq, J=8 Hz, 1H), 8.25 (brs, 1H), 8.30 (brs, 1H), 8.55 (brs, 1H), 8.72(d, J=2 Hz, 1H), 8.77 (brs, 2H), 8.91 (brs, 1H), 9.01 (d, J=2 Hz, 1H),9.06 (s, 1H), 10.62 (s, 1H), 13.96 (brs, 1H), 14.61 (s, 1H); ESIMS foundC₂₇H₁₉FN₈O m/z 491.2 (M+H).

N-(5-(3-(7-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide128.

Brown solid (42.6 mg, 0.08 mmol, 42.4% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 3.78 (s, 2H), 7.26 (t, J=7 Hz, 1H), 7.34 (t, J=8 Hz, 2H), 7.39 (d,J=7 Hz, 2H), 7.45 (t, J=8.5 Hz, 2H), 8.32 (brs, 2H), 8.60 (s, 1H), 8.74(brs, 1H), 8.75 (d, J=1.5 Hz, 1H), 8.78 (s, 1H), 9.00 (d, J=2 Hz, 1H),9.04 (d, J=2 Hz, 1H), 9.08 (brs, 1H), 10.67 (s, 1H), 14.76 (s, 1H);ESIMS found C₃₁H₂₁FN₈O m/z 541.4 (M+H).

1-Cyclopentyl-N-((5-(3-(7-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine142.

Tan solid (6.4 mg, 0.012 mmol, 7.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 1.13-1.26 (m, 2H), 1.39-1.55 (m, 4H), 1.58-1.76 (m, 2H), 2.56 (d,J=5.5 Hz, 2H), 2.03 (quin, J=7.5 Hz, 1H), 3.93 (brs, 2H), 7.40 (t, J=9Hz, 2H), 8.24 (s, 1H), 8.43 (brs, 2H), 8.64 (s, 2H), 8.88 (brs, 1H),8.96 (s, 1H), 9.08 (s, 1H), 9.11 (s, 1H); ESIMS found C₃₀H₂₇FN₈ m/z519.1 (M+H).

N-(5-(3-(7-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide158.

Brown solid (36.4 mg, 0.074 mmol, 40.8% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 0.92-1.02 (m, 3H), 1.69 (brs, 2H), 2.35-2.44 (m, 2H),7.33-7.45 (m, 2H), 7.45-7.59 (m, 1H), 8.52 (s, 1H), 8.73 (d, J=13 Hz,1H), 8.91 (t, J=6.5 Hz, 2H), 8.99 (s, 2H), 10.31 (s, 1H), 13.84 (s, 1H),14.48-14.63 (m, 1H); ESIMS found C₂₇H₂₁FN₈O m/z 493.4 (M+H).

N,N-Dimethyl-1-(5-(3-(7-(pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine176.

Dark brown solid (24.5 mg, 0.055 mmol, 28.7% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 2.26 (s, 6H), 3.60 (s, 2H), 7.59 (dd, J=5.5 Hz, J=8 Hz,1H), 8.11 (s, 1H), 8.58 (d, J=1.5 Hz, 1H), 8.66 (d, J=3.5 Hz, 1H), 8.73(brs, 2H), 8.91 (brs, 1H), 8.96 (d, J=2 Hz, 1H), 9.06 (brs, 2H), 9.49(brs, 1H), 13.91 (brs, 1H), 14.58 (brs, 1H); ESIMS found C₂₅H₂₁N₉ m/z448.1 (M+H).

5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-3-(7-(pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine178.

Brown solid (1.2 mg, 0.002 mmol, 0.9% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.36-1.79 (m, 6H), 2.42-251 (m, 4H), 3.62 (s, 2H), 7.60 (dd, J=7.5Hz, J=4.5 Hz, 2H), 8.66 (d, J=4.5 Hz, 1H), 8.70 (s, 1H), 8.72 (s, 1H),8.75 (s, 1H), 8.93 (s, 1H), 9.09 (brs, 3H), 9.58 (brs, 1H), 13.94 (s,1H), 14.64 (brs, 1H); ESIMS found C₂₈H₂₅N₉ m/z 488.3 (M+H).

3,3-Dimethyl-N-(5-(3-(7-(pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide179.

Brown solid (4.1 mg, 0.008 mmol, 4.7% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.07 (s, 9H), 2.30 (s, 2H), 7.65 (dd, J=5 Hz, J=8 Hz, 1H), 8.52(s, 1H), 8.66 (d, J=3.5 Hz, 1H), 8.70 (d, J=2 Hz, 1H), 8.77 (brs, 1H),8.81 (s, 2H), 8.99 (d, J=2 Hz, 1H), 9.01 (d, J=2 Hz, 1H), 9.05 (brs,1H), 9.39 (brs, 1H), 10.27 (s, 1H), 14.71 (s, 1H); ESIMS found C₂₈H₂₅N₉Om/z 504.3 (M+H).

N-(5-(3-(7-(Pyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide 185.

Brown solid (16.2 mg, 0.03 mmol, 18.6% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.20-1.38 (m, 3H), 1.47 (dq, J=2.5 Hz, J=12 Hz, 2H), 1.69 (d,J=12.5 Hz, 1H), 1.81 (d, J=12.5 Hz, 2H), 1.90 (d, J=10.5 Hz, 2H), 2.43(tt, J=3.5 Hz, J=11.5 Hz, 1H), 7.64 (dd, J=4.5 Hz, J=8 Hz, 1H), 8.56(brs, 1H), 8.63 (brs, 1H), 8.70 (d, J=2 Hz, 1H), 8.80 (brs, 3H), 8.96(brs, 1H), 9.00 (s, 2H), 9.41 (brs, 1H), 10.26 (s, 1H), 13.98 (brs, 1H),14.63 (s, 1H); ESIMS found C₂₉H₂₅N₉O m/z 516.3 (M+H).

5-(4-Methylpyridin-3-yl)-3-(7-(pyridin-4-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine192.

Beige solid (25.6 mg, 0.06 mmol, 71.1% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 2.42 (s, 3H), 7.49 (d, J=5 Hz, 1H), 8.34 (brs, 2H), 8.55 (d, J=5Hz, 1H), 8.60 (s, 1H), 8.69 (d, J=4.5 Hz, 2H), 8.78 (s, 2H), 8.87 (s,1H), 8.97 (s, 1H), 13.99 (brs, 1H), 14.63 (s, 1H); ESIMS found C₂₃H₁₆N₈m/z 405.2 (M+H).

N-Isopropyl-5-(3-(7-(pyridin-4-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine198.

Tan solid (1.3 mg, 0.003 mmol, 1.5% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 2.04 (d, J=6.5 Hz, 6H), 3.76 (sep, J=6.5 Hz, 1H), 6.06 (brs, 1H),7.34 (s, 1H), 8.06 (d, J=2 Hz, 1H), 8.21 b(s, 1H), 8.40 (brs, 2H), 8.69(d, J=6 Hz, 2H), 8.83 (brs, 1H), 8.97 (brs, 1H), 9.00 (s, 1H), 9.04 (s,1H), 14.03 (brs, 1H), 14.60 (s, 1H); ESIMS found C₂₅H₂₁N₉ m/z 448.0(M+H).

N-Benzyl-1-(5-(3-(7-(pyridin-4-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine209.

Beige solid (17.2 mg, 0.034 mmol, 33.8% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 4.01 (s, 2H), 4.09 (s, 2H), 7.30 (t, J=7 Hz, 1H), 7.37 (t,J=8 Hz, 2H), 7.45 (d, J=7.5 Hz, 2H), 8.31 (s, 1H), 8.33 (d, J=5 Hz, 2H),8.67 (s, 1H), 8.68 (dd, J=1.5 Hz, J=5 Hz, 1H), 8.73 (dd, J=1.5 Hz, J=4.5Hz, 2H), 8.76 (d, J=6 Hz, 2H), 9.15 (s, 2H), 14.65 (brs, 1H); ESIMSfound C₃₀H₂₃N₉ m/z 510.2 (M+H).

N-(5-(3-(7-(Pyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide 229.

Tan solid (8.5 mg, 0.017 mmol, 5.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 1.82-1.93 (m, 1H), 1.95-2.06 (m, 1H), 2.15-2.25 (m, 2H), 2.26-2.34(m, 2H), 7.40-7.47 (m, 2H), 7.95 (dt, J=2 Hz, J=8 Hz, 1H), 8.15 (d, J=8Hz, 1H), 8.42 (s, 1H), 8.75 (s, 1H), 8.77 (d, J=1 Hz, 1H), 8.78 (s, 1H),8.89 (s, 1H), 9.06 (s, 2H), 10.20 (s, 1H), 13.05 (brs, 1H), 14.65 (s,1H); ESIMS found C₂₇H₂₁N₉O m/z 488.2 (M+H).

5-(3-(7-(Piperidin-1-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b] pyridin-5-yl)pyridin-3-amine 238.

Tan solid (7.5 mg, 0.018 mmol, 8.9% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 1.61 (brs, 6H), 3.49 (brs, 4H), 5.65 (brs, 2H), 6.69 (s, 1H), 7.36(s, 1H), 8.02 (s, 1H), 8.19 (s, 1H), 8.65 (s, 1H), 8.89 (s, 1H), 8.92(d, J=2 Hz, 1H), 13.04 (s, 1H), 14.36 (s, 1H); ESIMS found C₂₂H₂₁N₉ m/z412.3 (M+H).

N-((5-(3-(7-(Piperidin-1-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine241.

Brown solid (9.9 mg, 0.022 mmol, 11.4% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.08 (t, J=7 Hz, 3H), 1.60 (brs, 6H), 2.61 (q, J=7 Hz, 2H), 3.48(brs, 4H), 3.85 (s, 2H), 6.67 (brs, 1H), 8.19 (s, 1H), 8.60 (d, J=1.5Hz, 1H), 8.64 (brs, 1H), 8.89 (d, J=2.5 Hz, 1H), 8.97 (d, J=2 Hz, 1H),9.00 (d, J=2.5 Hz, 1H), 12.95 (brs, 1H); ESIMS found C₂₅H₂₇N₉ m/z 454.2(M+H).

N-(5-(3-(7-(Piperidin-1-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide246.

Brown solid (33.1 mg, 0.064 mmol, 37.6% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.60 (brs, 6H), 3.49 (brs, 4H), 6.67 (s, 1H), 7.59 (t, J=7Hz, 2H), 7.65 (t, J=7 Hz, 1H), 8.05 (d, J=8 Hz, 2H), 8.58 (t, J=2 Hz,1H), 8.65 (s, 1H), 8.79 (d, J=2 Hz, 1H), 8.97 (d, J=2 Hz, 1H), 9.02 (d,J=2 Hz, 1H), 9.14 (d, J=2 Hz, 1H), 10.65 (s, 1H), 13.01 (s, 1H), 14.40(s, 1H); ESIMS found C₂₉H₂₅N₉O m/z 516.4 (M+H).

3-(7-(Piperidin-1-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine249.

Beige solid (26.5 mg, 0.055 mmol, 30.4% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.61 (brs, 6H), 1.74 (brs, 4H), 2.54 (brs, 4H), 3.49 (brs,4H), 3.76 (brs, 2H), 6.67 (s, 1H), 8.13 (s, 1H), 8.59 (d, J=1.5 Hz, 1H),8.65 (s, 1H), 8.91 (d, J=2 Hz, 1H), 8.95 (d, J=2 Hz, 1H), 9.00 (d, J=2.5Hz, 1H), 12.99 (s, 1H), 14.37 (brs, 1H); ESIMS found C₂₇H₂₉N₉ m/z 480.1(M+H).

N-(5-(3-(7-(Piperidin-1-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide254.

Yellow-white solid (8.6 mg, 0.018 mmol, 8.2% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 0.82-0.92 (m, 4H), 1.61 (brs, 6H), 1.81-1.88 (m, 1H),3.49 (brs, 4H), 6.67 (s, 1H), 8.40 (s, 1H), 8.65 (s, 1H), 8.71 (d, J=2Hz, 1H), 8.88 (d, J=2 Hz, 1H), 8.91 (d, J=1.5 Hz, 1H), 8.97 (d, J=2 Hz,1H), 10.63 (s, 1H), 13.00 (s, 1H), 14.38 (s, 1H); ESIMS found C₂₆H₂₅N₉Om/z 480.1 (M+H).

N-(5-(3-(7-(4-Methylpiperazin-1-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide305.

Brown solid (30.4 mg, 0.06 mmol, 33.7% yield). ¹H NMR (CD₃OD, 500 MHz) δppm 1.00 (t, J=7.5 Hz, 3H), 1.46 (sex, J=7.5 Hz, 2H), 1.74 (quin, J=7.5Hz, 2H), 2.48 (t, J=7.5 Hz, 2H), 2.79 (s, 3H), 3.19 (brs, 4H), 3.72(brs, 4H), 6.94 (brs, 1H), 8.54 (s, 1H), 8.65 (brs, 1H), 8.70 (d, J=2Hz, 1H), 8.79 (d, J=2 Hz, 1H), 8.91 (d, J=2 Hz, 1H), 9.10 (d, J=1.5 Hz,1H); ESIMS found C₂₇H₃₀N₁₀O m/z 511.5 (M+H).

N-(5-(3-(7-(4-Methylpiperazin-1-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide309.

Brown solid (25.9 mg, 0.05 mmol, 28.6% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.15-1.36 (m, 3H), 1.45 (dq, J=3 Hz, J=12 Hz, 2H), 1.67 (d, J=12.5Hz, 1H), 1.78 (d, J=12 Hz, 2H), 1.87 (d, J=12.5 Hz, 2H), 2.34-2.45 (m,4H), 2.66 (brs, 4H), 3.52 (brs, 4H), 6.73 (s, 1H), 8.42 (t, J=2 Hz, 1H),8.68 (s, 1H), 8.70 (d, J=2 Hz, 1H), 8.89 (d, J=2.5 Hz, 1H), 8.91 (d, J=2Hz, 1H), 8.97 (d, J=2 Hz, 1H), 10.24 (s, 1H), 13.13 (s, 1H), 14.42 (s,1H); ESIMS found C₂₉H₃₂N₁₀O m/z 537.4 (M+H).

5-(3-(3H-Imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine325.

Tan solid (11.8 mg, 0.032 mmol, 16.7% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.20 (d, J=6 Hz, 6H), 3.75 (sep, J=6.5 Hz, 1H), 5.91 (d, J=8 Hz,1H), 7.27 (t, J=2.5 Hz, 1H), 8.03 (d, J=2.5 Hz, 1H), 8.14 (d, J=1.5 Hz,1H), 8.35 (d, J=5.5 Hz, 1H), 8.93 (d, J=2 Hz, 1H), 8.95 (d, J=2.5 Hz,1H), 9.01 (brs, 1H), 13.63 (brs, 1H); ESIMS found C₂₀H₁₈N₈ m/z 370.9(M+H).

1-(5-(3-(3H-Imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N-benzylmethanamine336.

Beige solid (12.0 mg, 0.028 mmol, 27.7% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 3.77 (s, 2H), 3.85 (s, 2H), 7.23 (t, J=7.5 Hz, 1H), 7.33 (t,J=8 Hz, 2H), 7.40 (d, J=7 Hz, 2H), 7.61 (s, 1H), 8.21 (s, 1H), 8.35 (d,J=5.5 Hz, 1H), 8.61 (d, J=2 Hz, 1H), 8.90 (d, J=2.5 Hz, 1H), 9.02 (dd,J=2 Hz, J=6.5 Hz, 3H), 13.60 (brs, 1H); ESIMS found C₂₅H₂₀N₈ m/z 433.1(M+H).

N,N-Dimethyl-5-(3-(7-(thiophen-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine346.

Tan solid (5.8 mg, 0.013 mmol, 6.7% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 3.14 (s, 6H), 7.74 (s, 1H), 7.78 (dd, J=3 Hz, J=5 Hz, 1H), 8.15 (d,J=4.5 Hz, 1H), 8.25 (d, J=3 Hz, 1H), 8.46 (d, J=1.5 Hz, 1H), 8.92 (s,2H), 9.02 (s, 1H), 9.13 (d, J=2 Hz, 1H), 9.14 (d, J=2.5 Hz, 1H), 14.83(s, 1H); ESIMS found C₂₃H₁₈N₈S m/z 439.1 (M+H).

N,N-Dimethyl-1-(5-(3-(7-(thiophen-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine352.

Dark brown solid (24.4 mg, 0.054 mmol, 28.2% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 2.28 (s, 6H), 3.62 (brs, 2H), 7.74 (dd, J=3 Hz, J=5 Hz,1H), 8.12-8.18 (m, 2H), 8.59 (s, 1H), 8.78 (brs, 1H), 8.81 (s, 2H), 9.00(s, 1H), 9.09 (s, 1H), 9.13 (s, 1H), 13.80 (brs, 1H), 14.59 (brs, 1H);ESIMS found C₂₄H₂₀N₈S m/z 453.0 (M+H).

5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-3-(7-(thiophen-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine354.

Brown solid (17.8 mg, 0.04 mmol, 52.4% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.40 (brs, 2H), 1.52 (brs, 4H), 2.43 (brs, 4H), 3.63 (s, 2H), 7.74(dd, J=3 Hz, J=4.5 Hz, 1H), 8.11-8.18 (m, 2H), 8.60 (s, 1H), 8.78 (s,1H), 8.81 (s, 2H), 8.98 (s, 1H), 9.08 (s, 1H), 9.14 (s, 1H), 13.81 (brs,1H), 14.59 (brs, 1H); ESIMS found C₂₇H₂₄N₈S m/z 493.3 (M+H).

N-(5-(3-(7-(Furan-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide 373.

Tan solid (21.6 mg, 0.045 mmol, 25.5% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.30 (s, 9H), 7.43 (brs, 1H), 7.85 (s, 1H), 8.59 (brs, 1H), 8.71(s, 1H), 8.78 (d, J=1.5 Hz, 1H), 8.83 (brs, 2H), 8.95 (d, J=2 Hz, 1H),9.04 (d, J=2.5 Hz, 1H), 9.09 (s, 1H), 9.63 (s, 1H), 13.86 (brs, 1H),14.61 (s, 1H); ESIMS found C₂₆H₂₂N₈O₂ m/z 479.0 (M+H).

N-(5-(3-(7-(Furan-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide 376.

Brown solid (49.9 mg, 0.10 mmol, 58.6% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 7.47 (brs, 1H), 7.60 (t, J=7.5 Hz, 2H), 7.66 (t, J=7 Hz, 1H), 7.86(t, J=2 Hz, 1H), 8.06 (d, J=8 Hz, 2H), 8.76 (s, 1H), 8.78 (s, 1H), 8.85(d, J=2 Hz, 1H), 8.90 (brs, 1H), 8.93 (brs, 1H), 9.05 (d, J=2 Hz, 1H),9.08 (d, J=2 Hz, 1H), 9.13 (d, J=2 Hz, 1H), 10.68 (s, 1H), 14.74 (s,1H); ESIMS found C₂₈H₁₈N₈O₂ m/z 499.3 (M+H).

N-(5-(3-(7-(Furan-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide 382.

Brown solid (32.2 mg, 0.069 mmol, 38.3% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 0.96 (t, J=7 Hz, 3H), 1.67 (sex, J=7 Hz, 2H), 2.39 (t, J=7.5Hz, 2H), 7.44 (s, 1H), 7.86 (t, J=1.5 Hz, 1H), 8.58 (s, 1H), 8.72 (s,1H), 8.75 (d, J=2 Hz, 1H), 8.80 (d, J=2 Hz, 1H), 8.81 (s, 1H), 8.83 (s,1H), 9.01 (d, J=2.5 Hz, 1H), 9.07 (d, J=2 Hz, 1H), 10.32 (s, 1H), 13.92(brs, 1H), 14.62 (s, 1H); ESIMS found C₂₅H₂₀N₈O₂ m/z 465.0 (M+H).

N-(5-(3-(7-(Thiophen-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide440.

Dark brown solid (33.7 mg, 0.07 mmol, 38.8% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.17 (t, J=7.5 Hz, 3H), 2.48 (q, J=7.5 Hz, 2H), 7.29 (dd, J=4Hz, J=5 Hz, 1H), 7.69-7.76 (m, 2H), 8.21 (brs, 1H), 8.73 (s, 2H), 8.76(s, 1H), 8.82 (s, 1H), 8.84 (s, 1H), 9.07 (d, J=2 Hz, 1H), 9.21 (s, 1H),10.37 (s, 1H), 14.65 (s, 1H); ESIMS found C₂₄H₁₈N₈OS m/z 466.9 (M+H).

N,N-Dimethyl-1-(5-(3-(7-(thiophen-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine452.

Beige solid (100.3 mg, 0.22 mmol, 29.0% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.24 (s, 6H), 3.58 (s, 2H), 7.27 (dd, J=3.5 Hz, J=5 Hz, 1H),7.69 (d, J=5 Hz, 1H), 8.15 (s, 1H), 8.22 (brs, 1H), 8.59 (s, 1H), 8.79(s, 1H), 8.81 (s, 1H), 9.00 (d, J=2 Hz, 1H), 9.10 (d, J=2 Hz, 1H), 9.24(s, 1H), 13.87 (brs, 1H), 14.59 (brs, 1H); ESIMS found C₂₄H₂₀N₈S m/z453.1 (M+H

N-(5-(3-(7-(Thiophen-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide458.

Dark yellow solid (15 mg, 0.03 mmol, 36.0% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 0.90 (d, J=6 Hz, 4H), 1.90 (quin, J=6 Hz, 1H), 7.27 (t, J=5Hz, 1H), 7.66 (d, J=5 Hz, 1H), 8.22 (d, J=3 Hz, 1H), 8.67 (s, 1H), 8.73(s, 1H), 8.76 (s, 1H), 8.79 (s, 1H), 8.82 (s, 1H), 9.06 (s, 1H), 9.21(s, 1H), 10.67 (s, 1H), 13.88 (brs, 1H), 14.61 (s, 1H); ESIMS foundC₂₅H₁₈N₈OS m/z 479.1 (M+H).

1-Cyclopentyl-N-((5-(3-(7-(thiophen-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine463.

Tan solid (15.0 mg, 0.03 mmol, 17.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 1.12-1.21 (m, 2H), 1.40-1.55 (m, 4H), 1.65-1.74 (m, 2H), 2.01 (quin,J=7.5 Hz, 1H), 2.52 (d, J=5.5 Hz, 2H), 3.90 (s, 2H), 2.27 (dd, J=3.5 Hz,J=5 Hz, 1H), 7.71 (d, J=5 Hz, 1H), 8.22 (brs, 1H), 8.25 (s, 1H), 8.64(d, J=1.5 Hz, 1H), 8.79 (s, 1H), 8.80 (s, 1H), 8.97 (d, J=2 Hz, 1H),9.10 (d, J=2 Hz, 1H), 9.27 (d, J=1.5 Hz, 1H); ESIMS found C₂₈H₂₆N₈S m/z507.1 (M+H).

N-((5-(3-(4-(3-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine 547.

Tan solid (9.4 mg, 0.02 mmol, 10.6% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 1.06 (t, J=7.5 Hz, 3H), 2.60 (q, J=7.5 Hz, 2H), 3.85 (s, 2H), 7.23(dt, J=2.5 Hz, J=8.5 Hz, 1H), 7.38 (t, J=8 Hz, 1H), 7.53-7.65 (m, 3H),8.14 (d, J=8 Hz, 1H), 8.17 (s, 1H), 8.39 (d, J=11 Hz, 1H), 8.62 (d,J=1.5 Hz, 1H), 8.92 (d, J=2 Hz, 1H), 9.06 (d, J=2 Hz, 1H), 9.13 (s, 1H),13.43 (brs, 1H); ESIMS found C₂₇H₂₂FN₇ m/z 464.0 (M+H).

5-(3-(4-(3-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-isopropylpyridin-3-amine 551.

Dark yellow solid (15.6 mg, 0.03 mmol, 17.6% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 1.19 (d, J=6.5 Hz, 6H), 3.72 (sep, J=6.5 Hz, 1H), 5.87(d, J=8 Hz, 1H), 7.21 (dd, J=5 Hz, J=2.5 Hz, 2H), 7.37 (t, J=7.5 Hz,1H), 7.54 (q, J=8 Hz, 1H), 7.55-7.61 (m, 2H), 8.04 (d, J=2.5 Hz, 1H),8.12 (d, J=8 Hz, 1H), 8.14 (d, J=2 Hz, 1H), 8.32 (dd, J=2 Hz, J=8 Hz,1H), 8.95 (d, J=2.5 Hz, 1H), 9.02 (d, J=2.5 Hz, 1H), 13.41 (s, 1H),14.35 (s, 1H); ESIMS found C₂₇H₂₂FN₇ m/z 464.2 (M+H).

1-(5-(3-(4-(3-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 552.

Brown solid (23.6 mg, 0.051 mmol, 26.7% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.22 (s, 6H), 3.56 (s, 2H), 7.24 (dt, J=2.5 Hz, J=8.5 Hz,1H), 7.37 (t, J=8 Hz, 1H), 7.53-7.61 (m, 3H), 8.09 (s, 1H), 8.13 (d, J=8Hz, 1H), 8.36 (dd, J=2 Hz, J=11.5 Hz, 1H), 8.58 (d, J=1.5 Hz, 1H), 8.96(d, J=2.5 Hz, 1H), 9.06 (d, J=2 Hz, 1H), 9.11 (d, J=2.5 Hz, 1H), 13.43(brs, 1H), 14.39 (brs, 1H); ESIMS found C₂₇H₂₂FN₇ m/z 464.3 (M+H).

3-(4-(3-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine554.

Light brown solid (57.4 mg, 0.11 mmol, 43.7% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 1.39 (brs, 2H), 1.50 (brs, 4H), 2.40 (brs, 4H), 3.60 (s,2H), 7.22 (dt, J=3 Hz, J=8.5 Hz, 1H), 3.78 (t, J=8 Hz, 1H), 7.51-7.62(m, 3H), 8.09 (s, 1H), 8.11 (d, J=7.5 Hz, 1H), 8.40 (d, J=11 Hz, 1H),8.59 (s, 1H), 8.95 (s, 1H), 9.06 (d, J=2.5 Hz, 1H), 9.11 (d, J=2 Hz,1H), 13.44 (s, 1H), 14.40 (s, 1H); ESIMS found C₃₀H₂₆FN₇ m/z 504.1(M+H).

N-(5-(3-(4-(3-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide 557.

Brown solid (36.9 mg, 0.073 mmol, 41.3% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 0.93 (t, J=7.5 Hz, 3H), 1.38 (sex, J=7.5 Hz, 2H), 1.64 (quin,J=7.5 Hz, 2H), 2.42 (t, J=7.5 Hz, 2H), 7.17 (dt, J=2 Hz, J=8 Hz, 1H),7.38 (t, J=7.5 Hz, 1H), 7.51-7.63 (m, 3H), 8.16 (brs, 1H), 8.31 (brs,1H), 8.52 (s, 1H), 8.72 (d, J=2 Hz, 1H), 8.81 (d, J=1.5 Hz, 1H), 8.98(d, J=2 Hz, 1H), 9.08 (d, J=2 Hz, 1H), 10.30 (s, 1H), 13.44 (brs, 1H),14.41 (s, 1H); ESIMS found C₂₉H₂₄FN₇O m/z 506.3 (M+H).

N-(5-(3-(4-(3-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide 560.

Brown solid (14.8 mg, 0.029 mmol, 16.5% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.55-1.64 (m, 2H), 1.64-1.73 (m, 2H), 1.73-1.83 (m, 2H),1.86-1.96 (m, 2H), 2.88 (quin, J=8 Hz, 1H), 7.16 (dt, J=2.5 Hz, J=8.5Hz, 1H), 7.38 (t, J=8 Hz, 1H), 7.51-7.61 (m, 3H), 8.19 (d, J=8 Hz, 1H),8.32 (dd, J=2 Hz, J=10 Hz, 1H), 8.55 (t, J=2 Hz, 1H), 8.71 (d, J=2 Hz,1H), 8.80 (d, J=2 Hz, 1H), 8.98 (d, J=2 Hz, 1H), 9.08 (d, J=2 Hz, 1H),10.27 (s, 1H), 13.44 (s, 1H), 14.41 (s, 1H); ESIMS found C₃₀H₂₄FN₇O m/z518.0 (M+H).

N-(5-(3-(4-(3-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide 561.

Brown solid (14.0 mg, 0.026 mmol, 15.6% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.15-1.36 (m, 3H), 1.46 (dq, J=3 Hz, J=12.5 Hz, 2H), 1.68 (d,J=12.5 Hz, 1H), 1.80 (dd, J=2.5 Hz, J=11.5 Hz, 2H), 1.90 (d, J=12.5 Hz,2H), 2.42 (tt, J=3.5 Hz, J=11.5 Hz, 1H), 7.15 (t, J=7.5 Hz, 1H), 7.38(t, J=7.5 Hz, 1H), 7.53-7.65 (m, 3H), 8.19 (d, J=7 Hz, 1H), 8.32 (d,J=10.5 Hz, 1H), 8.54 (s, 1H), 8.70 (d, J=2 Hz, 1H), 8.82 (d, J=1.5 Hz,1H), 8.98 (d, J=2 Hz, 1H), 9.07 (s, 1H), 10.22 (s, 1H), 13.44 (s, 1H),14.41 (s, 1H); ESIMS found C₃₁H₂₆FN₇O m/z 532.2 (M+H).

N-(5-(3-(4-(4-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide 573.

Tan solid (37.9 mg, 0.072 mmol, 42.2% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 7.32-7.41 (m, 3H), 7.50 (brd, J=6.5 Hz, 1H), 7.55 (brd, J=7.5 Hz,1H), 7.60 (t, J=7.5 Hz, 2H), 7.66 (t, J=7.5 Hz, 1H), 8.07 (d, J=7.5 Hz,2H), 8.40 (brs, 2H), 8.79 (brs, 1H), 8.82 (d, J=2 Hz, 1H), 9.01 (s, 1H),9.05 (d, J=2 Hz, 1H), 9.11 (s, 1H), 10.71 (s, 1H), 13.39 (brs, 1H),14.41 (s, 1H); ESIMS found C₃₁H₂₀FN₇O m/z 526.1 (M+H).

N-(5-(3-(4-(4-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide 581.

Brown solid (34.5 mg, 0.07 mmol, 40.0% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 0.85-0.96 (m, 4H), 1.85-1.93 (m, 1H), 7.26-7.29 (m, 3H), 7.50 (d,J=7 Hz, 1H), 7.55 (d, J=7 Hz, 1H), 8.39 (brs, 2H), 8.66 (s, 1H), 8.73(d, J=2 Hz, 1H), 9.01 (d, J=2 Hz, 1H), 9.05 (d, J=1.5 Hz, 1H), 10.69 (s,1H), 13.38 (brs, 1H), 14.40 (s, 1H); ESIMS found C₂₈H₂₀FN₇O m/z 490.2(M+H).

1-Cyclopentyl-N-((5-(3-(4-(4-fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine586.

Tan solid (13.8 mg, 0.027 mmol, 15.4% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.11-1.23 (m, 2H), 1.40-1.58 (m, 4H), 1.65-1.74 (m, 2H), 2.04(quin, J=7.5 Hz, 1H), 2.58 (d, J=6.5 Hz, 2H), 3.94 (s, 2H), 7.36 (t,J=8.5 Hz, 2H), 7.50 (d, J=7 Hz, 1H), 7.54 (d, J=7.5 Hz, 1H), 8.24 (s,1H), 8.34-8.42 (m, 3H), 8.65 (s, 1H), 8.97 (d, J=1.5 Hz, 1H), 9.13 (d,J=2 Hz, 1H), 9.14 (d, J=2 Hz, 1H), 13.38 (brs, 1H), 14.36 (brs, 1H);ESIMS found C₃₁H₂₈FN₇ m/z 518.0 (M+H).

N-(5-(3-(4-(2-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide 594.

Tan solid (54.7 mg, 0.108 mmol, 61.2% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.32 (s, 9H), 7.32-7.40 (m, 3H), 7.51 (d, J=7.5 Hz, 1H), 7.54 (d,J=8 Hz, 1H), 8.41 (dd, 6 Hz, J=9 Hz, 2H), 8.67 (t, J=2 Hz, 1H), 8.74 (d,J=2 Hz, 1H), 8.92 (d, J=2 Hz, 1H), 9.02 (d, J=2.5 Hz, 1H), 9.05 (d, J=2Hz, 1H), 9.66 (s, 1H), 13.38 (s, 1H), 14.41 (s, 1H); ESIMS foundC₂₉H₂₄FN₇O m/z 506.0 (M+H).

N-(5-(3-(4-(2-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide 595.

Beige solid (15.5 mg, 0.029 mmol, 15.4% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 3.78 (s, 2H), 7.23-7.29 (m, 4H), 7.29-7.42 (m, 6H), 7.52-7.61(m, 1H), 8.00-8.07 (m, 1H), 8.51 (t, J=2 Hz, 1H), 8.66 (d, J=2 Hz, 1H),8.77 (d, J=2.5 Hz, 1H), ABq, J=2 Hz, J=11 Hz, 2H), 10.61 (s, 1H), 13.34(s, 1H), 14.36 (s, 1H); ESIMS found C₃₂H₂₂FN₇O m/z 540.3 (M+H).

3-(4-(2-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine599.

Beige solid (6.2 mg, 0.013 mmol, 7.0% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.73 (brs, 4H), 2.54 (brs, 4H), 3.75 (s, 2H), 7.30-7.41 (m, 4H),7.43-7.52 (m, 1H), 7.60 (dd, J=2.5 Hz, J=7 Hz, 1H), 8.05 (s, 1H), 8.08(t, J=7.5 Hz, 1H), 8.58 (s, 1H), 8.89 (d, J=1.5 Hz, 1H), 9.00 (d, J=2Hz, 1H), 9.03 (d, J=2 Hz, 1H), 13.35 (s, 1H), 14.59 (brs, 1H); ESIMSfound C₂₉H₂₄FN₇ m/z 490.0 (M+H).

N-(5-(3-(4-(2-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide 602.

Tan solid (31.9 mg, 0.065 mmol, 35.8% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 0.98 (t, J=7 Hz, 3H), 1.69 (sex, J=7 Hz, 2H), 2.42 (t, J=7.5 Hz,2H), 7.30-7.46 (m, 5H), 7.59 (d, J=7 Hz, 1H), 8.09 (t, J=7 Hz, 1H), 8.43(s, 1H), 8.64 (s, 1H), 8.76 (s, 1H), 8.95 (s, 2H), 10.30 (s, 1H), 13.35(s, 1H), 14.37 (s, 1H); ESIMS found C₂₈H₂₂FN₇O m/z 492.1 (M+H).

N-(5-(3-(4-(2-Fluorophenyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide 605.

Beige solid (60.3 mg, 0.12 mmol, 35.1% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.81-1.91 (m, 1H), 1.93-2.07 (m, 1H), 2.13-2.25 (m, 2H), 2.25-2.37(m, 2H), 7.31-7.45 (m, 5H), 7.59 (dd, J=1.5 Hz, J=7 Hz, 1H), 8.10 (dt,J=2 Hz, J=7.5 Hz, 1H), 8.53 (t, J=2 Hz, 1H), 8.64 (d, J=2 Hz, 1H), 8.76(d, J=2 Hz, 1H), 8.92-8.97 (m, 2H), 10.16 (s, 1H), 13.35 (s, 1H), 14.37(s, 1H); ESIMS found C₂₉H₂₂FN₇O m/z 504.2 (M+H).

N,N-Dimethyl-5-(3-(4-(pyridin-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine616.

Tan solid (11.4 mg, 0.026 mmol, 13.4% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 3.09 (s, 6H), 7.59 (d, J=4.58 Hz, 2H), 7.72 (dd, J=3 Hz, J=5 Hz,2H), 8.03 (brs, 2H), 8.32 (s, 2H), 8.48 (s, 2H), 8.81 (brs, 2H), 13.79(brs, 1H), 14.56 (brs, 1H); ESIMS found C₂₅H₂₀N₈ m/z 433.0 (M+H).

N,N-Dimethyl-1-(5-(3-(4-(pyridin-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine621.

Dark brown solid (19.6 mg, 0.044 mmol, 23.0% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 2.24 (s, 6H), 3.57 (s, 2H), 7.36 (t, J=8 Hz, 1H), 7.41(t, J=7.5 Hz, 1H), 7.51 (d, J=7 Hz, 1H), 7.55 (t, J=7.5 Hz, 2H), 8.11(d, J=2 Hz, 1H), 8.32 (d, J=7.5 Hz, 2H), 8.58 (d, 1.5 Hz, 1H), 8.98 (d,J=2.5 Hz, 1H), 9.07 (d, J=2.5 Hz, 1H), 9.14 (d, J=2 Hz, 1H), 13.36 (brs,1H), 14.33 (brs, 1H); ESIMS found C₂₆H₂₂N₈ m/z 447.2 (M+H).

5-(3-(4-(Pyridin-4-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine635.

Brown solid (3.3 mg, 0.008 mmol, 4.0% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 5.65 (brs, 2H), 7.38 (s, 1H), 7.42 (t, J=7.5 Hz, 1H), 7.66 (d, J=8Hz, 1H), 7.71 (d, J=7.5 Hz, 1H), 8.05 (s, 1H), 8.22 (s, 1H), 8.41 (d,J=5.5 Hz, 2H), 8.73 (d, J=5 Hz, 2H), 8.93 (d, J=1.5 Hz, 1H), 9.07 (s,1H), 13.51 (s, 1H), 14.39 (s, 1H); ESIMS found C₂₃H₁₆N₈ m/z 405.1 (M+H).

5-(4-Methylpyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridine637.

Tan solid (6.8 mg, 0.017 mmol, 18.9% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 2.43 (s, 3H), 7.42 (t, J=4.5 Hz, 1H), 7.49 (d, J=5 Hz, 1H), 7.65 (t,J=7.5 Hz, 3H), 8.30 (d, J=6 Hz, 2H), 8.55 (d, J=4.5 Hz, 1H), 8.62 (d,J=6.5 Hz, 2H), 8.76 (d, J=2 Hz, 1H), 8.89 (d, J=2 Hz, 1H), 13.49 (s,1H), 14.42 (s, 1H); ESIMS found C₂₄H₁₇N₇ m/z 404.2 (M+H).

N-Isopropyl-5-(3-(4-(pyridin-4-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine643.

Brown solid (2.9 mg, 0.06 mmol, 3.4% yield). ¹H NMR (DMSO-d₆, 500 MHz) δppm 1.20 (d, J=6 Hz, 6H), 3.74 (sep, J=6.5 Hz, 1H), 5.93 (d, J=8 Hz,1H), 7.26 (s, 1H), 7.41 (t, J=8 Hz, 1H), 7.63.74 (sep, J=6.5 Hz, 1H),5.93 (d, J=8 Hz, 1H), 7.26 (s, 1H), 7.41 (t, J=8 Hz, 1H), 7.6 (dd, J=15Hz, J=7.5 Hz, 2H), 8.05 (d, J=2 Hz, 1H), 8.17 (d, J=1.5 Hz, 1H), 8.36(d, J=6 Hz, 2H), 8.68 (d, J=6 Hz, 2H), 8.97 (d, J=2.5 Hz, 1H), 9.06 (d,J=2 Hz, 1H), 13.49 (s, 1H), 14.38 (s, 1H); ESIMS found C₂₆H₂₂N₈ m/z447.0 (M+H).

3,3-Dimethyl-N-(5-(3-(4-(pyridin-4-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butanamide647.

Beige solid (1.2 mg, 0.002 mmol, 1.4% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.08 (s, 9H), 2.32 (s, 2H), 7.42 (t, J=8.5 Hz, 1H), 7.66 (d, J=8Hz, 1H), 7.71 (d, J=7.5 Hz, 1H), 8.40 (d, J=5.5 Hz, 2H), 8.62 (s, 1H),8.72 (d, J=6 Hz, 2H), 8.74 (d, J=2 Hz, 1H), 8.77 (d, J=2.5 Hz, 1H), 9.00(d, J=2.5 Hz, 1H), 9.09 (d, J=2 Hz, 1H), 10.28 (s, 1H), 13.52 (s, 1H),14.45 (s, 1H); ESIMS found C₂₉H₂₆N₈O m/z 503.3 (M+H).

N-Benzyl-1-(5-(3-(4-(pyridin-4-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine654.

Beige solid (26.1 mg, 0.051 mmol, 51.3% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 3.77 (s, 2H), 3.85 (s, 2H), 7.23 (t, J=7 Hz, 1H), 7.32 (t,J=8 Hz, 2H), 7.37-7.46 (m, 3H), 7.65 (d, J=8 Hz, 1H), 7.69 (d, J=7.5 Hz,1H), 8.28 (s, 1H), 8.39 (dd, J=1.5 Hz, J=4.5 Hz, 2H), 8.64 (s, 1H), 8.73(dd, J=1.5 Hz, J=4.5 Hz, 2H), 8.99 (s, 1H), 9.08 (d, J=2 Hz, 1H), 9.18(d, J=2 Hz, 1H), 13.51 (s, 1H), 14.42 (brs, 1H); ESIMS found C₃₁H₂₄N₈m/z 509.6 (M+H).

5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridine680.

Beige solid (26.4 mg, 0.052 mmol, 30.4% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.30 (quin, J=7 Hz, J=8 Hz, 2H), 2.84 (brs, 2H), 3.03 (brs,2H), 3.87 (s, 2H), 7.35 (s, 1H), 7.41 (t, J=7.5 Hz, 2H), 7.72 (brs, 1H),7.97 (t, J=7.5 Hz, 1H), 8.13 (d, J=6 Hz, 1H), 8.22 (s, 1H), 8.63 (s,1H), 8.79 (brs, 1H), 9.01 (s, 1H), 9.06 (d, J=2 Hz, 1H), 9.14 (brs, 1H),14.47 (s, 1H); ESIMS found C₂₈H₂₂F₂N₈ m/z 509.4 (M+H).

N-(5-(3-(4-(Piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)benzamide 691.

Brown solid (14.8 mg, 0.029 mmol, 16.8% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.74 (brs, 6H), 3.56 (brs, 4H), 6.53 (brd, J=7 Hz, 1H), 7.02(brd, J=8 Hz, 1H), 7.09 (t, J=8 Hz, 1H), 7.59 (t, J=7.5 Hz, 2H), 7.66(t, J=7.5 Hz, 1H), 8.05 (d, J=8 Hz, 2H), 8.72 (s, 1H), 8.81 (d, J=2 Hz,1H), 8.98 (s, 1H), 9.06 (d, J=2 Hz, 1H), 9.14 (s, 1H), 10.64 (s, 1H),13.06 (s, 1H), 14.26 (s, 1H); ESIMS found C₃₀H₂₆N₈O m/z 515.2 (M+H).

N-(5-(3-(4-(Piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pentanamide 698.

Brown solid (47.0 mg, 0.095 mmol, 53.7% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 0.93 (t, J=7.5 Hz, 3H), 1.36 (sex, J=7.5 Hz, 2H), 1.55-167(m, 4H), 1.68-1.81 (m, 4H), 2.40 (t, J=7.5 Hz, 2H), 3.59 (brs, 4H), 6.56(brs, 1H), 7.04 (brs, 1H), 7.10 (t, J=7.5 Hz, 1H), 8.59 (s, 1H), 8.70(d, J=2 Hz, 1H), 8.72 (s, 1H), 8.99 (d, J=2 Hz, 1H), 9.06 (s, 1H), 10.29(s, 1H), 13.06 (brs, 1H), 14.27 (s, 1H); ESIMS found C₂₈H₃₀N₈O m/z 495.4(M+H).

N-(5-(3-(4-(Piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide 701.

Brown solid (3.9 mg, 0.008 mmol, 4.4% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.54-1.63 (m, 4H), 1.63-1.73 (m, 2H), 1.72-1.83 (m, 6H), 1.85-1.95(m, 2H), 2.87 (quin, J=6.5 Hz, 1H), 3.58 (t, J=5 Hz, 4H), 6.53 (d, J=8Hz, 1H), 7.01 (d, J=8 Hz, 1H), 7.09 (t, J=8 Hz, 1H), 8.64 (t, J=2 Hz,1H), 8.71 (dd, J=3.5 Hz, J=2 Hz, 2H), 9.00 (d, J=2.5 Hz, 1H), 9.06 (d,J=2 Hz, 1H), 10.28 (s, 1H), 13.03 (s, 1H), 14.25 (s, 1H); ESIMS foundC₂₉H₃₀N₈O m/z 507.1 (M+H).

1-Cyclopentyl-N-((5-(3-(4-(piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)methanamine704.

Brown solid (10.1 mg, 0.02 mmol, 11.5% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.15-1.25 (m, 2H), 1.43-1.83 (m, 12H), 2.04 (quin, J=7.5 Hz, 1H),2.63 (d, J=6 Hz, 2H), 3.55-3.62 (m, 4H), 3.97 (brs, 2H), 6.54 (d, J=8Hz, 1H), 7.02 (d, J=8 Hz, 1H), 7.09 (t, J=8 Hz, 1H), 8.24 (brs, 1H),8.65 (s, 1H), 8.96 (s, 1H), 9.05 (d, J=2 Hz, 1H), 9.13 (d, J=2 Hz, 1H),13.05 (s, 1H), 14.27 (brs, 1H); ESIMS found C₃₀H₃₄N₈ m/z 507.0 (M+H).

N,N-Dimethyl-1-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine719.

Light brown solid (12.3 mg, 0.027 mmol, 14.3% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 2.24 (s, 6H), 2.25 (s, 3H), 3.58 (s, 2H), 7.35 (t, J=8Hz, 1H), 7.48 (t, J=8.5 Hz, 2H), 7.96 (s, 1H), 8.13 (s, 1H), 8.59 (d,J=1.5 Hz, 1H), 8.74 (s, 1H), 8.96 (d, J=2 Hz, 1H), 9.04 (d, J=2 Hz, 1H),9.07 (d, J=2.5 Hz, 1H), 13.58 (brs, 1H), 14.44 (brs, 1H); ESIMS foundC₂₅H₂₃N₉ m/z 450.2 (M+H).

N-(5-(3-(4-(4-Methyl-1H-imidazol-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide728.

Brown solid (30.7 mg, 0.06 mmol, 35.1% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.15-1.36 (m, 3H), 1.45 (dq, J=2.5 Hz, J=12 Hz, 2H), 1.67 (d,J=12.5 Hz, 1H), 1.78 (d, J=12.5 Hz, 2H), 1.88 (d, J=11.5 Hz, 2H), 2.22(s, 3H), 2.41 (tt, J=3 Hz, J=11.5 Hz, 1H), 7.35 (t, J=7.5 Hz, 1H), 7.48(d, J=2 Hz, 1H), 7.49 (d, J=2.5 Hz, 1H), 8.01 (s, 1H), 8.47 (t, J=2 Hz,1H), 8.70 (d, J=1.5 Hz, 2H), 8.87 (d, J=2.5 Hz, 1H), 8.96 (d, J=2.5 Hz,1H), 9.02 (d, J=2.5 Hz, 1H), 10.23 (s, 1H), 13.59 (s, 1H), 14.46 (s,1H); ESIMS found C₂₉H₂₇N₉O m/z 518.4 (M+H).

N-((5-(3-(4-(4-Methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine738.

Brown solid (15.2 mg, 0.033 mmol, 17.0% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.07 (t, J=7.5 Hz, 3H), 2.28 (s, 3H), 2.54-2.66 (m, 6H), 3.63(brs, 4H), 3.86 (s, 2H), 6.54 (d, J=8 Hz, 1H), 7.05 (d, J=8 Hz, 1H),7.10 (t, J=8 Hz, 1H), 8.16 (s, 1H), 8.62 (d, J=1.5 Hz, 1H), 8.92 (d,J=2.5 Hz, 1H), 9.05 (d, J=2.5 Hz, 1H), 9.06 (d, J=2 Hz, 1H), 13.08 (brs,1H); ESIMS found C₂₆H₂₉N₉ m/z 468.2 (M+H).

N-(5-(3-(4-(4-Methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide752.

Dark yellow solid (4.1 mg, 0.008 mmol, 2.4% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.78-1.89 (m, 1H), 1.92-2.05 (m, 1H), 2.11-2.21 (m, 2H), 2.23(s, 3H), 2.23-2.34 (m, 2H), 2.58 (brs, 4H), 3.63 (brs, 4H), 6.54 (d, J=8Hz, 1H), 7.04 (d, J=8 Hz, 1H), 7.10 (t, J=8 Hz, 1H), 8.58 (s, 1H), 8.69(d, J=2 Hz, 1H), 8.76 (d, J=2.5 Hz, 1H), 8.98 (d, J=2 Hz, 1H), 9.01 (d,J=2 Hz, 1H), 10.15 (s, 1H), 13.08 (s, 1H), 14.27 (s, 1H); ESIMS foundC₂₈H₂₉N₉O m/z 507.9 (M+H).

5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridine758.

Beige solid (39.6 mg, 0.075 mmol, 43.8% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.27 (quin, J=8.5 Hz, 2H), 2.28 (s, 3H), 2.61 (brs, 4H), 2.78(t, J=7 Hz, 2H), 2.96 (t, J=13 Hz, 2H), 3.63 (brs, 4H), 3.81 (s, 2H),6.54 (d, J=8 Hz, 1H), 7.05 (d, J=8 Hz, 1H), 7.11 (t, J=8 Hz, 1H), 8.11(s, 1H), 8.61 (d, J=1.5 Hz, 1H), 8.95 (d, J=2 Hz, 1H), 9.05 (s, 2H),13.08 (s, 1H), 14.27 (brs, 1H); ESIMS found C₂₈H₂₉F₂N₉ m/z 530.4 (M+H).

5-(3-(1H-Benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-amine 761.

Brown solid (7.9 mg, 0.024 mmol, 11.8% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 6.01 (brs, 1H), 7.20-7.31 (m, 2H), 7.56 (s, 1H), 7.66 (brs, 2H),8.05 (d, J=1.5 Hz, 1H), 8.30 (s, 1H), 8.94 (d, J=1.5 Hz, 1H), 8.98 (s,1H), 13.24 (brs, 1H), 14.41 (s, 1H); ESIMS found C₁₈H₁₃N₇ m/z 327.6(M+H).

5-(3-(1H-Benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-N,N-dimethylpyridin-3-amine765.

Tan solid (19.6 mg, 0.055 mmol, 28.1% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 3.09 (s, 6H), 7.25 (dd, J=3 Hz, J=6 Hz, 2H), 7.65 (s, 1H), 7.67(d, J=3.5 Hz, 2H), 8.22 (d, J=3 Hz, 1H), 8.38 (d, J=1.5 Hz, 1H), 9.01(d, J=2 Hz, 1H), 9.03 (d, J=2 Hz, 1H), 14.40 (s, 1H); ESIMS foundC₂₀H₁₇N₇ m/z 356.0 (M+H).

N-(5-(3-(1H-Benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide 774.

Brown solid (22.3 mg, 0.05 mmol, 30.3% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.07 (s, 9H), 2.29 (s, 2H), 7.24-7.31 (m, 2H), 7.68 (brs, 2H),8.46 (t, J=2 Hz, 1H), 8.75 (d, J=2 Hz, 1H), 8.91 (d, J=2.5 Hz, 1H), 8.99(d, J=2 Hz, 1H), 9.01 (d, J=2.5 Hz, 1H), 10.29 (s, 1H), 14.47 (s, 1H);ESIMS found C₂₄H₂₃N₇O m/z 426.2 (M+H).

1-(5-(3-(1H-Benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-N-benzylmethanamine 781.

Beige solid (21.0 mg, 0.049 mmol, 48.7% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 3.77 (s, 2H), 3.85 (s, 2H), 7.18-7.29 (m, 3H), 7.33 (t, J=8Hz, 2H), 7.39 (d, J=7.5 Hz, 2H), 7.55 (d, J=8 Hz, 1H), 7.77 (d, J=7.5Hz, 1H), 8.20 (s, 1H), 8.60 (d, J=1.5 Hz, 1H), 8.89 (d, J=2 Hz, 1H),9.00 (d, J=2 Hz, 1H), 9.03 (d, J=2 Hz, 1H), 13.17 (s, 1H), 14.27 (brs,1H); ESIMS found C₂₆H₂₁N₇ m/z 432.1 (M+H).

N-(5-(3-(4-(Thiophen-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)propionamide 785.

Brown solid (33.5 mg, 0.072 mmol, 38.7% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.17 (t, J=7.5 Hz, 3H), 2.46 (q, J=7.5 Hz, 2H), 7.32 (t,J=7.5 Hz, 1H), 7.48 (d, J=8 Hz, 1H), 7.64 (d, J=7.5 Hz, 1H), 7.68 (dd,J=3.5 Hz, J=5 Hz, 1H), 8.12 (dd, J=1 Hz, J=5 Hz, 1H), 8.65 (t, J=2 Hz,1H), 8.68 (dd, J=1 Hz, J=3 Hz, 1H), 8.75 (d, J=2 Hz, 2H), 9.02 (d, J=2Hz, 1H), 9.12 (d, J=2.5 Hz, 1H), 10.32 (s, 1H), 13.35 (s, 1H), 14.40 (s,1H); ESIMS found C₂₅H₁₉N₇OS m/z 466.1 (M+H).

N-(5-(3-(4-(Thiophen-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)isobutyramide793.

Tan solid (17.0 mg, 0.035 mmol, 19.6% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.20 (d, J=6.5 Hz, 6H), 2.71 (sep, J=6.5 Hz, 1H), 7.32 (t, J=8 Hz,1H), 7.49 (d, J=8 Hz, 1H), 7.64 (d, J=7.5 Hz, 1H), 7.68 (dd, J=3.5 Hz,J=5 Hz, 1H), 8.14 (d, J=4.5 Hz, 1H), 8.66 (d, J=2 Hz, 1H), 8.68 (d, J=2Hz, 1H), 8.75 (d, J=2 Hz, 1H), 8.79 (d, J=2 Hz, 1H), 9.02 (d, J=2.5 Hz,1H), 9.12 (d, J=2 Hz, 1H), 10.28 (s, 1H), 13.35 (s, 1H), 14.40 (s, 1H);ESIMS found C₂₆H₂₁N₇OS m/z 479.8 (M+H).

N,N-Dimethyl-1-(5-(3-(4-(thiophen-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)methanamine797.

Brown solid (26.7 mg, 0.059 mmol, 31.0% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 2.25 (s, 6H), 3.59 (s, 2H), 7.32 (t, J=8 Hz, 1H), 7.49 (d,J=8 Hz, 1H), 7.63 (d, J=7.5 Hz, 1H), 7.68 (dd, J=3 Hz, J=5 Hz, 1H), 8.11(dd, J=1 Hz, J=5 Hz, 1H), 8.15 (s, 1H), 8.59 (d, J=1.5 Hz, 1H), 8.74(dd, J=1.5 Hz, J=3 Hz, 1H), 9.00 (d, J=2 Hz, 1H), 9.08 (d, J=2 Hz, 1H),9.16 (d, J=2.5 Hz, 1H), 13.35 (brs, 1H), 14.38 (brs, 1H); ESIMS foundC₂₅H₂₁N₇S m/z 452.1 (M+H).

5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridine799.

Beige solid (55.8 mg, 0.11 mmol, 43.5% yield). ¹H NMR (DMSO-d₆, 500 MHz)δ ppm 1.40 (brs, 2H), 1.47-1.56 (m, 4H), 2.42 (brs, 1H), 3.63 (s, 2H),7.32 (t, J=7.5 Hz, 1H), 7.49 (d; J=8 Hz, 1H), 7.63 (d, J=7 Hz, 1H), 7.68(dd, J=5 Hz, J=3 Hz, 1H), 8.11 (dd, J=1 Hz, J=5.5 Hz, 1H), 8.13 (s, 1H),8.59 (d, J=1 Hz, 1H), 8.74 (dd, J=1 Hz, J=3 Hz, 1H), 8.98 (d, J=2 Hz,1H), 9.07 (d, J=2 Hz, 1H), 9.16 (d, J=2 Hz, 1H), 13.35 (s, 1H), 14.38(s, 1H) ESIMS found C₂₈H₂₅N₇S m/z 492.2 (M+H).

N-(5-(3-(4-(Thiophen-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide803.

Yellow-white solid (20.2 mg, 0.04 mmol, 56.4% yield). ¹H NMR (DMSO-d₆,500 MHz) δ ppm 0.85-0.95 (m, 4H), 1.85-1.92 (m, 1H), 7.32 (t, J=8 Hz,1H), 7.49 (d, J=8 Hz, 1H), 7.60-7.69 (m, 2H), 8.11 (brs, 1H), 8.64 (s,1H), 8.67 (s, 1H), 8.75 (s, 1H), 9.01 (d, J=2 Hz, 1H), 9.11 (s, 1H),10.65 (s, 1H), 13.35 (brs, 1H), 14.40 (s, 1H); ESIMS found C₂₆H₁₉N₇OSm/z 478.1 (M+H).

N-(5-(3-(4-(Furan-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)pivalamide818.

Brown solid (36.0 mg, 0.075 mmol, 42.6% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.30 (s, 9H), 7.30 (t, J=7.5 Hz, 1H), 7.35 (d, J=1 Hz, 1H),7.45 (d, J=7.5 Hz, 1H), 7.53 (d, J=7.5 Hz, 1H), 7.78 (t, J=1.5 Hz, 1H),8.59 (t, J=2 Hz, 1H), 8.78 (d, J=2 Hz, 1H), 8.83 (s, 1H), 8.96 (d, J=2Hz, 1H), 9.02 (d, J=2.5 Hz, 1H), 9.11 (d, J=2 Hz, 1H), 9.62 (s, 1H),13.32 (s, 1H), 14.40 (s, 1H); ESIMS found C₂₇H₂₃N₇O₂ m/z 478.1 (M+H).

N-(5-(3-(4-(Furan-3-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)butyramide827.

Brown solid (29.6 mg, 0.064 mmol, 36.9% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 0.96 (t, J=7.5 Hz, 3H), 1.68 (sex, J=7.5 Hz, 2H), 2.39 (t,J=7 Hz, 1H), 7.29 (t, J=8 Hz, 1H), 7.36 (d, J=1.5 Hz, 1H), 7.45 (d,J=7.5 Hz, 1H), 7.53 (d, J=7.5 Hz, 1H), 7.79 (t, J=1.5 Hz, 1H), 8.57 (d,J=2 Hz, 1H), 8.75 (d, J=1.5 Hz, 1H), 8.80 (d, J=2 Hz, 1H), 8.81 (s, 1H),8.98 (d, J=2.5 Hz, 1H), 9.08 (d, J=2 Hz, 1H), 10.31 (s, 1H), 13.32 (s,1H), 14.40 (s, 1H); ESIMS found C₂₆H₂₁N₇O₂ m/z 464.2 (M+H).

5-(5-(Pyrrolidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[3,4-b]pyridine898.

Beige solid (15.4 mg, 0.032 mmol, 17.7% yield). ¹H NMR (DMSO-d₆, 500MHz) δ ppm 1.74 (brs, 4H), 2.52 (brs, 4H), 3.80 (brs, 2H), 7.23 (dd,J=3.5 Hz, J=5 Hz, 1H), 7.31 (t, J=8 Hz, 1H), 7.48 (d, J=7.5 Hz, 1H),7.61 (dd, J=1 Hz, J=5 Hz, 1H), 7.66 (d, J=7.5 Hz, 1H), 8.18 (dd, J=1 Hz,J=3.5 Hz, 1H), 8.19 (brs, 1H), 8.63 (brs, 1H), 9.01 (brs, 1H), 9.09 (d,J=2 Hz, 1H), 9.32 (d, J=2 Hz, 1H), 13.42 (s, 1H), 14.40 (s, 1H); ESIMSfound C₂₇H₂₃N₇S m/z 478.0 (M+H).

Example 3

The above synthesized compounds were screened using the assay procedurefor Wnt activity described below.

Reporter cell lines can be generated by stably transducing cells ofcancer cell lines (e.g., colon cancer) with a lentiviral construct thatinclude a wnt-responsive promoter driving expression of the fireflyluciferase gene.

Lentiviral constructs can be made in which the SP5 promoter, a promoterhaving eight TCF/LEF binding sites derived from the SP5 promoter, islinked upstream of the firefly luciferase gene. The lentiviralconstructs can also include a hygromycin resistance gene as a selectablemarker. The SP5 promoter construct can be used to transduce SW480 cells,a colon cancer cell line having a mutated APC gene that generates atruncated APC protein, leading to de-regulated accumulation ofβ-catenin. A control cell line can be generated using another lentiviralconstruct containing the luciferase gene under the control of the SV40promoter which does not require β-catenin for activation.

Cultured SW480 cells bearing a reporter construct can be distributed atapproximately 10,000 cells per well into 96 well or 384 well plates.Compounds from a small molecule compound library can then be added tothe wells in half-log dilutions using a ten micromolar topconcentration. A series of control wells for each cell type receive onlybuffer and compound solvent. Twenty-four to forty hours after theaddition of compound, reporter activity for luciferase can be assayed,for example, by addition of the BrightGlo luminescence reagent (Promega)and the Victor3 plate reader (Perkin Elmer). Readings can be normalizedto DMSO only treated cells, and normalized activities can then be usedin the IC₅₀ calculations. Table 2 shows the activity of selectedcompounds of the invention.

TABLE 2 Compound Wnt inhibition (μM) 1 0.006 2 0.038 2 0.006 4 0.333 50.0039 6 0.55 7 0.006 8 8.25 9 0.0012 10 0.263 11 0.099 12 0.021 130.172 14 0.138 15 0.326 16 0.384 17 0.55 18 0.013 19 0.499 20 10 210.167 22 0.032 23 10 24 0.021 25 10 27 1.78 28 0.72 114 0.011 128 0.09142 0.645 158 0.008 176 1.55 178 0.392 179 1.45 185 1.32 192 1.05 1981.13 209 9.8 229 0.012 238 0.35 241 0.19 246 1.27 249 10 254 0.235 3057.35 309 1.02 325 0.058 336 0.79 346 0.056 352 0.057 354 0.293 373 0.07376 0.051 382 0.003 440 0.004 443 0.001 452 0.048 458 0.022 463 0.098547 0.097 551 0.033 552 0.022 554 0.2 557 0.053 560 0.09 561 0.143 5730.082 581 0.048 586 0.42 590 0.02 594 0.12 595 0.354 599 0.22 602 0.018605 0.018 616 1.41 621 0.036 635 0.034 637 0.11 643 0.03 647 1.52 6541.5 680 0.17 691 0.187 698 0.3 701 0.625 704 0.81 719 0.2 728 0.039 7380.55 752 0.226 758 0.048 761 0.32 765 0.027 774 0.2 781 1.44 785 0.01793 0.016 797 0.032 799 0.082 803 0.017 818 0.05 827 0.063 888 0.012 8980.12

Example 3

Preparation of a parenteral suspension with a compound of Formulas (I)or (II) for the treatment of bone/cartilage diseases.

TABLE 3 Approximate solubility of a compound of Formulas (I) or (II)Sample mg/mL pH water 0.12 1 mM HCl 0.72 5.8 2 mM HCl 1.38 5.5 3 mM HCl1.84 5.4 EtOH 0.56 Propylene Glycol 2.17

Preparation of a 220 μg/mL suspension in 0.5% CMC/0.05% tween 80 beginsby dispensing 597 g+1 g of Gibco 1×PBS into the 1 L glass bottle. Usinga 1 mL sterile syringe, measure 0.3 mL of Tween 80. In a weigh boat,weigh out 3 g+0.1 g of Carboxymethyl Cellulose 7LXF PH (CMC). Mix withthe Tween80/PBS solution and slowly sprinkle the CMC into the 1 L bottlecontaining the PBS/Tween mixture (increase mixing speed as necessary).Once visually dispersed and the polymer is hydrated, start heating thecontainer on a heating plate to promote phase inversion (turbidity).Once the solution is cool to the touch, filter NLT 120 mL into the 250mL glass bottle. Weigh 27 mg of a compound of Formulas (I) or (II) andsuspend by mixing with the aid of 120 g of the sterile filteredCMC/tween solution. Fill 2 mL schott glass vials and 13 mm Fluroteccoated stoppers (West Pharma) and autoclave the vials at 260° F. for NLT25 minutes.

Example 4

Preparation of a parenteral preparation with a compound of Formulas (I)or (II).

10 mg of a compound of Formulas (I) or (II) (or its salt) is dissolvedwith the aid of 10 mL of propylene glycol (USP grade), using aseptictechniques, sterile filter the solution using a millex GP syringe filterinto a sterile glass (type II) container. Before parenteraladministration, add 10 mL of the above solution in propylene glycol to avial containing 90 mL of sterile water, mix well.

Example 5

Preparation of a suspension for intravitreal injection with a compoundof Formulas (I) or (II).

Weigh 10 mg of a micronized compound of Formulas (I) or (II) (medianparticle size of 5 μm) and add slowly while mixing to 100 mL of solutionof 0.5% carboxymethyl cellulose (Aqualon 7LXF) and 0.05% tween 80HP-LQ-MH (Croda) dissolved in PBS (Gibco, pH 7.4). The final suspensionis loaded into 2 mL glass vials and terminally sterilized byautoclaving.

It is also contemplated to heat sterilize a micronized compound ofFormulas (I) or (II) and aseptic mixing with the sterile filteredsolution of 0.5% carboxymethyl cellulose (Aqualon 7LXF) and 0.05% tween80 HP-LQ-MH (Croda) dissolved in PBS (Gibco, pH 7.4).

Administration is performed using a 30 G needle and a volume ofapproximately 50 μL for intravitreal injection in rabbits.

Example 6

Composition for intratympanic injection with a compound of Formulas (I)or (II).

10 mg of a compound of Formulas (I) or (II) is dissolved with the aid of100 mL of propylene glycol (USP grade), using aseptic techniques,sterile filter the solution using a millex GP syringe filter into asterile glass (type II) container. Before parenteral administration, add10 mL of the above solution in propylene glycol to a vial containing 90mL of sterile water, mix well.

Administration is performed using a 25 G needle and a volume ofapproximately 200 μL for intratympanic injection targeting the roundwindow membrane.

Example 7

Primary screening assay for idiopathic pulmonary fibrosis (IPF).

Compounds of Formulas (I) or (II) were screened in a β-catenin-basedreporter assay in a transformed human bronchial epithelial cell line(NL-20). The results shown in Table 4 demonstrated that compounds ofFormulas (I) or (II) are able to inhibit β-catenin activity in thesecells, supporting the drug's mechanism of action for the treatment ofidiopathic pulmonary fibrosis (IPF). Compounds of Formulas (I) or (II)are significantly more potent than ICG-001, a small molecule β-catenininhibitor [Proc. Natl. Acad. Sci. U.S.A (2010), 107(32), 14309-14314].

TABLE 4 NL-20 β-catenin reporter Compound assay (IC₅₀, μM) ICG-001(β-catenin 7 inhibitor) 5 0.175 7 1.9 9 0.067 10 0.247 11 0.21 12 0.3114 2.03 18 0.44 452 1.09

Example 8

Preparation of a composition for pulmonary delivery with a compound ofFormulas (I) or (II) for the treatment of pulmonary fibrosis.

Weigh 100 mg of a compound of Formulas (I) or (II) (or its salt) anadded slowly while mixing to 100 mL of solution of 1.5% dextrose (orlactose)+0.05% tyloxapol. The final solution is sterile filter thesolution using a millex GP syringe filter.

Administration is performed using a jet nebulizer (Pari LC plus) or anaerodose nebulizer.

C57Bl/6 mice were dosed for 30 minutes via a nose only chamber (CHTechnology) at a flow rate of 15 LPM, particle size distribution anddose was measured by a 7 stage impactor (1 LPM) placed in one of theports. A median aerosol particle size of 1.2 μm with a GSD of 1.8 μm wasobtained and a dosing rate of 1.5 M/min/mouse.

TABLE 5 Concentrations of a compound of Formulas (I) or (II) in Mice(C57Bl/6) Inhalation Conc. (ng/mL) Time Point (h) Plasma Lung Ratio 0.2521.9 467.2 21.3 2 0.8 400.1 500.1 6 8.8 392.5 44.6 23 0.03 260.7 8690

A diluted formulation of 0.5 mg/mL of compound of Formulas (I) or (II)was nebulized for 10 and 30 minutes to bleomycin-induced pulmonaryfibrotic C57Bl/6 mice. Bleomycin is a chemotherapeutic agent which usehas been shown to cause pulmonary fibrosis in humans. As a result, itbecame widely used as a research tool to induce and study pulmonaryfibrosis in animals [Walters, D. M. and Kleeberger, S. R., “Mouse modelsof bleomycin-induced pulmonary fibrosis” Current Protocols inPharmacology (2008) Chapter 5: Unit 5.46, 1-17]. Male C57Bl/6 mice wereanesthetized and 2 U/kg Bleomycin (Henry Schien) was orophrayngeallyadministered. After 7 days, the compound of Formulas (I) or (II) wasdelivered via a nose only chamber (CH Technology) at a flow rate of 20LPM daily for 30 minutes for 13 days. After the last dose, 13 days, theanimals were sacrificed, and their lungs were perfused and with 10%buffered formalin and processed for tissue histology. The plasma wasobtained and published biomarkers of disease, MMP-7, TIMP-1 and TGF-β, 1were evaluated by ELISA [British Journal of Pharmacology (2010), 160(7),1699-1713; American journal of respiratory and critical care medicine(2012), 185(1), 67-76]. H&E sections of the lungs and scored in ablinded fashion according to the Ashcroft system to evaluate pulmonaryfibrosis [Biotechniques (2008), 44(4), 507-517]. A reduction inpulmonary fibrosis and plasma biomarkers were demonstrated inCompound-treated animals (Table 6).

TABLE 6 Grade of MMP-7 TIMP-1 TGF-β Fibrosis- levels levels levelsTreatment Ashcroft Score (ng/mL) (ng/mL) (ng/mL) PBS/no dose 0.25 10.01203 10.0 Bleomycin/vehicle 3.04 13.6 2763 14.5 Bleomycin/10 min 3.5210.7 2023 14.2 aerosol of a compound of Formulas (I) or (II)Bleomycin/30 min 2.08* 9.4** 1958 9.7 aerosol of a compound of Formulas(I) or (II) *p < 0.05 vs Bleo/Vehicle, **p = 0.035 vs Bleo/Vehicle

Example 9

Preparation of a suspension of drug-eluting material with a compound ofFormulas (I) or (II).

Solution 1 (PLGA containing active): Weigh 425 mg of PLGA 50:50 (PLGA0.55-0.75, Lactel B6010-2P)+4.5 mg of a compound of Formulas (I) or(II)+4 mL of dichloromethane, mix well to dissolve.

Solution 2 (1% PVA solution): Add 40 mL of DI water, then add 413 mg ofpolyvinyl alcohol (Sigma 87-89% hydrolyzed, PN 363170-25), mix todissolve then sterile filter through a 0.22μ PES syringe filter(Millipore Millex GP).

PLGA microparticle formation: Add 20 mL of solution 2 into a cleansterile container, while mixing (high speed mixing) slowly add theentire 4 mL of solution 1 to solution 2.

The term “comprising” as used herein is synonymous with “including,”“containing,” or “characterized by,” and is inclusive or open-ended anddoes not exclude additional, unrecited elements or method steps.

1. (canceled)
 2. A compound or pharmaceutically acceptable salt orprodrug thereof having the structure of Formula I:

wherein: R¹ and R² are independently selected from the group consistingof H, lower alkyl, halide, —(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₉alkyl)_(n)heteroaryl(R⁷)_(q), —(C₁₋₉ alkyl)_(n)heterocyclyl(R⁸)_(q),—(C₁₋₉ alkyl)_(n)N(R⁹)₂, —OR¹⁰ and —NHC(═O)R¹¹; R³ is selected from thegroup consisting of H, halide and lower alkyl; with the proviso that atleast two of R¹, R² and R³ are H; R⁴ and R⁵ are independently selectedfrom the group consisting of H, —C(═O)N(R¹²)₂, -aryl(R¹³)_(q),-heterocyclyl(R¹⁴)_(q), and -heteroaryl(R¹⁵)_(q); with the proviso thatat least one of R⁴ and R⁵ is H; each R⁶ is a substituent attached to thearyl ring and independently selected from the group consisting of H,—C₁₋₉ alkyl, halide, CF₃ and CN; each R⁷ is a substituent attached tothe heteroaryl ring and independently selected from the group consistingof H, —C₁₋₉ alkyl, halide, CF₃ and CN; each R⁸ is a substituent attachedto the heterocyclyl ring and independently selected from the groupconsisting of H, halide, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₄ alkyl;each R⁹ is independently selected from the group consisting of H, —C₁₋₉alkyl, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃ alkyl)_(n)carbocyclyl and—(C₁₋₉ alkyl)N(R¹⁶)₂; alternatively, two adjacent R⁹ or two adjacentR¹², may be taken together with the atoms to which they are attached toform a heterocyclyl(R¹⁷)_(q); R¹⁰ is selected from the group consistingof H, —CF₃, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl; R¹¹ isselected from the group consisting of —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q),—(C₁₋₃ alkyl)_(n)carbocyclyl, —C₁₋₉ alkyl and —CF₃; each R¹² isindependently selected from the group consisting of H, —(C₁₋₉alkyl)_(n)aryl(R⁶)_(q) and —C₁₋₉ alkyl; each R¹³ is a substituentattached to the aryl ring and independently selected from the groupconsisting of H, halide, —CF₃, CN, —(C₁₋₃alkyl)_(n)heterocyclyl(R⁸)_(q), —(C₁₋₉ alkyl)_(n)N(R⁹)₂ and —(C₁₋₉alkyl)_(n)NHSO₂R¹⁸; each R¹⁴ is a substituent attached to theheterocyclyl ring and independently selected from the group consistingof H, lower alkyl, halide, —CF₃ and CN; each R¹⁵ is a substituentattached to the heteroaryl ring and independently selected from thegroup consisting of H, lower alkyl, halide, —CF₃, CN, —C(═O)(C₁₋₃alkyl), —(C₁₋₉ alkyl)_(n)N(R⁹)₂ and —(C₁₋₉ alkyl)_(n)NHSO₂R¹⁸; each R¹⁶is independently selected from the group consisting of H and loweralkyl; each R¹⁷ is a substituent attached to the heterocyclyl ring andindependently selected from the group consisting of H, —(C₁₋₉alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl; each R¹⁸ is a lower alkyl; A isN or C; with the proviso that if A is N then R² is nil; each q is aninteger of 1 to 5; each n is an integer of 0 or 1; and with the provisothat Formula I is not a structure selected from the group consisting of:


3. The compound of claim 2, wherein aryl is phenyl.
 4. The compound ofclaim 2, wherein heteroaryl is pyridinyl.
 5. A compound orpharmaceutically acceptable salt or prodrug thereof having the structureof Formula II:

wherein: R¹ and R² are independently selected from the group consistingof H, lower alkyl, halide, —(C₁₋₉ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₉alkyl)_(n)heteroaryl(R⁷)_(q), —(C₁₋₉ alkyl)_(n)heterocyclyl(R⁸)_(q),—(C₁₋₉ alkyl)_(n)N(R⁹)₂, —OR¹⁰ and —NHC(═O)R¹¹; R³ is selected from thegroup consisting of H, halide and lower alkyl; with the proviso that atleast two of R¹, R² and R³ are H; R⁴ and R⁵ are independently selectedfrom the group consisting of H, —C(═O)N(R¹²)₂, -aryl(R¹³)_(q),-heterocyclyl(R¹⁴)_(q), and -heteroaryl(R¹⁵)_(q); with the proviso thatat least one of R⁴ and R⁵ is H; each R⁶ is a substituent attached to thearyl ring and independently selected from the group consisting of H,—C₁₋₉ alkyl, halide, CF₃ and CN; each R⁷ is a substituent attached tothe heteroaryl ring and independently selected from the group consistingof H, —C₁₋₉ alkyl, halide, CF₃ and CN; each R⁸ is a substituent attachedto the heterocyclyl ring and independently selected from the groupconsisting of H, halide, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₄ alkyl;each R⁹ is independently selected from the group consisting of H, —C₁₋₉alkyl, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), —(C₁₋₃ alkyl)_(n)carbocyclyl and—(C₁₋₉ alkyl)N(R¹⁶)₂; alternatively, two adjacent R⁹ or two adjacentR¹², may be taken together with the atoms to which they are attached toform a heterocyclyl(R¹⁷)_(q); R¹⁰ is selected from the group consistingof H, —CF₃, —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl; R¹¹ isselected from the group consisting of —(C₁₋₃ alkyl)_(n)aryl(R⁶)_(q),—(C₁₋₃ alkyl)_(n)carbocyclyl, —C₁₋₉ alkyl and —CF₃; each R¹² isindependently selected from the group consisting of H, —(C₁₋₉alkyl)_(n)aryl(R⁶)_(q) and —C₁₋₉ alkyl; each R¹³ is a substituentattached to the aryl ring and independently selected from the groupconsisting of H, halide, —CF₃, CN, —(C₁₋₃alkyl)_(n)heterocyclyl(R⁸)_(q), —(C₁₋₉ alkyl)_(n)N(R⁹)₂ and —(C₁₋₉alkyl)_(n)NHSO₂R¹⁸; each R¹⁴ is a substituent attached to theheterocyclyl ring and independently selected from the group consistingof H, lower alkyl, halide, —CF₃ and CN; each R¹⁵ is a substituentattached to the heteroaryl ring and independently selected from thegroup consisting of H, lower alkyl, halide, —CF₃, CN, —C(═O)(C₁₋₃alkyl), —(C₁₋₉ alkyl)_(n)N(R⁹)₂ and —(C₁₋₉ alkyl)_(n)NHSO₂R¹⁸; each R¹⁶is independently selected from the group consisting of H and loweralkyl; each R¹⁷ is a substituent attached to the heterocyclyl ring andindependently selected from the group consisting of H, —(C₁₋₉alkyl)_(n)aryl(R⁶)_(q), and —C₁₋₉ alkyl; each R¹⁸ is a lower alkyl; A isN or C; with the proviso that if A is N then R² is nil; each q is aninteger of 1 to 5; each n is an integer of 0 or 1; and with the provisothat Formula II is not a structure selected from the group consistingof:


6. The compound of claim 5, wherein aryl is phenyl.
 7. The compound ofclaim 5, wherein heteroaryl is pyridinyl.
 8. A pharmaceuticalcomposition comprising a therapeutically effective amount of at leastone compound according to any of the claims 2 or 5, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient.
 9. A method of treating a disorder or disease inwhich aberrant Wnt signaling is implicated in a patient, wherein thedisorder or disease is cancer, diabetic retinopathy, pulmonary fibrosis,idiopathic pulmonary fibrosis (IPF), rheumatoid arthritis, scleroderma,mycotic or viral infection, bone or cartilage disease, Alzheimer'sdisease, dementia, Parkinson's disease, lung disease, osteoarthritis,and a genetic disease caused by mutations in Wnt signaling components,the method comprising administering to the patient a therapeuticallyeffective amount of at least one compound according to any of the claims2 or 5, or a pharmaceutically acceptable salt thereof, wherein thepatient is a human.
 10. A method of claim 9, wherein the disorder ordisease is a genetic disease caused by mutations in Wnt signalingcomponents, wherein the genetic disease is selected from: polyposiscoli, osteoporosis-pseudoglioma syndrome, familial exudativevitreoretinopathy, retinal angiogenesis, early coronary disease,tetra-amelia syndrome, Müllerian-duct regression and virilization,SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome,Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation,caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletaldysplasia, focal dermal hypoplasia, autosomal recessive anonychia,neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile Xsyndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome,Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.
 11. Themethod of claim 9, wherein the cancer is chosen from: hepatocellularcarcinoma, colon cancer, breast cancer, pancreatic cancer leukemia,lymphoma, sarcoma and ovarian cancer.
 12. The method of claim 9, whereinthe compound inhibits one or more proteins in the Wnt pathway.
 13. Themethod of claim 9, wherein the compound inhibits signaling induced byone or more Wnt proteins.
 14. The method of claim 13, wherein the Wntproteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4. WNT5A,WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B,WNT11, and WNT16.
 15. The method of claim 9, wherein the compoundinhibits a kinase activity.